Bioorganic & Medicinal Chemistry Letters

A Tetrahedron Publication for Rapid Dissemination of Preliminary Communications on all Aspects of Bioorganic Chemistry, Medicinal Chemistry and Related Disciplines

Editor-in-Chief: **DALE L. BOGER**, *The Scripps Research Institute, La Jolla, CA 92037, USA*
Chairman of the Executive Board of Editors for Tetrahedron Publications: Sir Derek Barton, *Texas A&M University, USA*

SUBJECT INDEX AND AUTHOR INDEX

Volume 3 (1993)

Pergamon

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Editor-in-Chief: **PROFESSOR D. L. BOGER**
Managing Editor: A. Crown
Department of Chemistry, The Scripps Research Institute, 10666 North Torrey Pines Road
La Jolla, California 92037, USA
Fax: (1) 619 554 6401

European Regional Editor: **Professor L. Ghosez**, Laboratoire de Chimie Organique de Synthèse, Université Catholique de Louvain, B-1348 Louvain-la-Neuve, Belgium
Fax: (32) 10 47 41 68

Japanese Regional Editor: **Professor M. Shibasaki**, Faculty of Pharmaceutical Sciences, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113, Japan
Fax: (81) 3 5684 5206

EXECUTIVE BOARD OF EDITORS FOR TETRAHEDRON PUBLICATIONS

Chairman: **Professor Sir Derek Barton, FRS,** Department of Chemistry, Texas A & M University, College Station, Texas 77843-3255, USA

Professor J. E. Baldwin, FRS, Dyson Perrins Laboratory, Oxford, OX1 3QY, UK

Dr S. G. Davies, Dyson Perrins Laboratory, Oxford, OX1 3QY, UK

Professor S. Ito, Faculty of Pharmaceutical Sciences, Tokushima Bunri University, Yamashiro-cho, Tokushima 770, Japan
(Associate Editor, Professor Y. Shizuri)

Professor A. R. Katritzky, FRS, Department of Chemistry, University of Florida, Gainesville, FL 32611, USA

Professor N. K. Kochetkov, N. D. Zelinsky Institute of Organic Chemistry, Academy of Sciences, Moscow B-334, Russia

Professor Lin Guo-Qiang, Shanghai Institute of Organic Chemistry, Academia Sinica, Shanghai 200032, China

Professor S. F. Martin, Department of Chemistry and Biochemistry, University of Texas, Austin, TX 78712, USA

Professor A. McKillop, University of East Anglia, School of Chemical Sciences, University Plain, Norwich, NR4 7TJ, UK

Professor W. B. Motherwell, Department of Chemistry, University College, 20 Gordon Street, London WC1H 0AJ, UK

Professor A. Nickon, Department of Chemistry, The Johns Hopkins University, Baltimore, MD 21218, USA

Professor G. Ourisson, Centre National de la Recherche Scientifique, Centre de Neurochimie, 67084 Strasbourg, Cedex, France
(Associate Editor, Professor G. Solladié)

Professor T. Shioiri, Faculty of Pharmaceutical Sciences, Nagoya City University, Tanabe-dori, Mizuho-ku, Nagoya 467, Japan

Professor W. Steglich, Institut für Organische Chemie der Universität München, Karlstr. 23, D-80333 München, Germany

Professor H. H. Wasserman, Department of Chemistry, Yale University, PO Box 208107, New Haven, CT 06520-8107, USA

Professor C.-H. Wong, Department of Chemistry, The Scripps Research Institute, La Jolla, CA 92037, USA

BOARD OF CONSULTING EDITORS

R. Abeles, Waltham, MA
P. S. Anderson, Lansdale, PA
M. J. Ashton, Dagenham
J. K. Barton, Pasadena, CA
S. Bell, Raritan, NJ
S. J. Benkovic, Pennsylvania, PA
R. C. Breslow, New York, NY
J. P. Collman, Stanford, CA
P. N. Confalone, Wilmington, DE
E. J. Corey, Cambridge, MA
S. J. Danishefsky, New York, NY
P. B. Dervan, Pasadena, CA
T. W. Doyle, Wallingford, CT
A. Eschenmoser, Zürich
D. M. Floyd, Princeton, NJ
A. K. Ganguly, Bloomfield, NJ
D. Gani, St Andrews
H. B. Gray, Pasadena, CA
J. T. Groves, Princeton, NJ
G. L. Grunewald, Lawrence, KS
H.-J. Hess, Groton, CT
M. Hirobe, Tokyo
R. H. Holm, Cambridge, MA
D. C. Horwell, Cambridge
W. L. Jorgensen, New Haven, CT
D. D. Keith, Nutley, NJ
R. A. Lerner, La Jolla, CA
S. J. Lippard, Cambridge, MA
D. Mansuy, Paris
B. W. Metcalf, King of Prussia, PA
L. A. Mitscher, Lawrence, KS
W. H. Moos, Emeryville, CA
K. Mori, Tokyo
K. Nakanishi, New York, NY
K. C. Nicolaou, La Jolla, CA
T. Ogawa, Saitama
M. Ohno, Ibaragi
H. L. Pearce, Indianapolis, IN
P. Potier, Gif-sur-Yvette
C. D. Poulter, Salt Lake City, UT
A. V. Rama Rao, Hyderabad
J. Rebek, Jr, Cambridge, MA
R. L. Schowen, Lawrence, KS
S. L. Schreiber, Cambridge, MA
P. G. Schultz, Berkeley, CA
A. I. Scott, College Station, TX
I. Shinkai, Rahway, NJ
T. J. Simpson, Bristol
J. Stubbe, Cambridge, MA
C. T. Walsh, Boston, MA
G. Whitesides, Cambridge, MA
R. V. Wolfenden, Chapel Hill, NC

PUBLISHED TWICE MONTHLY

Publishing, Subscription and Advertising Office:
Elsevier Science Ltd, The Boulevard, Langford Lane, Kidlington, Oxford, OX5 1GB, UK (Tel: (0865) 843000; Fax: (0865) 843010)

Subscription Rates
Annual Institutional Subscription Rates 1994: North, Central and South America, U.S.$ 745.00, Rest of World £ 485.00. Associated Personal Subscription Rates are available on request for those whose institutions are library subscribers. Sterling prices exclude VAT. Non-Vat registered customers in the European Community will be charged the appropriate VAT in addition to the price listed. Prices include postage and insurance and are subject to change without notice. Subscription enquiries from customers in North America should be sent to: Elsevier Science Inc., 660 White Plains Road, Tarrytown, New York 10591-5153, USA, and for the remainder of the world to: Elsevier Science Ltd, The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, UK.
Second Class Postage paid at Newark, NJ. Postmaster send address corrections to Elsevier Science Inc., 660 White Plains Road, Tarrytown, New York 10591-5153, USA.

Copyright © 1994 Elsevier Science Ltd

Subject Index 1993

Abbeymycin
analog, prep hydroxy [1,2,3,11a]-tetrahydro[2,1-*c*][1,4]benzodiazepine-5-thione 74
ACAT
conformationally restricted inhibitors, *N*-oleoyl 1,2,3,4-tetrahydroisoquinolines 571
inhibitors, *N,N*-diphenyl ureas 259
Acceptors
α-1,2-L-fucosyltransferase family, synthesis Galβ1→3(Fucα) GlcNAcβ-OR 1333
macromolecular, screening ligands, large random peptide libraries 419
Acetamides
p-hydroxyphenyl, kinetic resolution, hydrolysis with Pen-G acylase 1041
Acetamidines
N,N'-disubstit, high affinity sigma receptor ligands 2113
Acetogenins
giganin from *Goniothalamus giganteus*, cytotoxicity 1153
Acetylation
primary amines by *Cylindrocarpon radicicola*, enantioselectivity 681
Acetylcholinesterase
inhibition:
activity of velnacrine 1-substit analogs 2789
by N-2 methylated quaternary derivs β-carboline-3-carboxylates 2831
transition state analog, *m*-alkyl-α,α,α-trifluoroacetophenones 2619
Acetyl esters
sec, deacetylation in peracetylated methyl glycopyranosides by *Aspergillus niger* lipase 2125
Acosamine
ristosamine, synthesis trehalosamine non-reducing disaccharide analogs 235
Acyclonucleotides
synthesis, antiviral activity 9-(phosphonoalkynyloxy) purines 2611
Acyl-CoA:Cholesterol acyltransferase
see **ACAT**
Acylation
cysteine peptide with palmitoyl chloride 1025
Acyl transfer
O to N, intramolecular synthesis amide-linked *N*-hydroxyurea 5-lipoxygenase inhibitors 305
Addition reactions
amines to methyl 3-dehydroquinate and 3-dehydroshikimate 1447
Adenosine
2'-monophosphate derivs, structural requirements as substrates for inositol monophosphate 1925
selective receptor agonist with 6-hydrazinopurine moiety, synthesis, biochemical evaluation 2661
Adenosyl-L-homocysteine hydroxylase
inhibitors, prep carbocyclic tubercidin deriv 663
Adenosylmethionine
decarboxylase, inhibition by enzyme activated irreversible α-cyano analogs of carboxylated S-adenosylmethionine 2811
restricted rotation analogs antitrypanosomal agents, inhibitors S-adenosylmethionine decarboxylase 147
α1-Adrenoreceptor
Ca antagonist, prep, evaluation dihydropyridine amide BMY 20014 enantiomers 561
Affinity probes
dithiane inhibitors GABA-gated chloride channel 2671
Aflotoxin B_1
biosynthesis, bisfuran ring formation, Baeyer–Villiger oxidation and course of cyclization 653
Agonists
AMPA receptor, synthesis, pharmacology LY300020 95
autoreceptor dopamine enantiomers, PD135385, synthesis, evaluation 639
CCK-B systemically active selective peptidomimetics structure-based design and pharmacology 847
δ-opioid, conjugation to β-cyclodextrin, bioavailability active peptides improved 831
dopamine autoreceptor computer, synthetic, biological studies 1477
GABA with CNS activity, 3-aminopropyl (methyl) phosphinic acid activity 515
glutamate conformationally restricted, synthesis DCG-1/4, DCG-2/3 15
5-HT_3, receptor activity, histamine derived arylureas 205
kappa opiate, phenalene analogs 2641
kappa opioid receptor binding model, design, synthesis kappa opioid ligands 841
neuropeptide Y, reduced size Y_2-selective 937
partial, NMDA receptor glycine-site, HA-966 71
receptor, 5-HT_4 *N*-(quinuclidin-3-yl)-1,8-naphthylimides, properties 1375
selective adenosine receptor, with 6-hydrazinopurine moiety, synthesis, biochemical evaluation 2661
selective 5-HT_4 receptor, quaternised renzapride 633
tetrapeptide-based receptor, CCK-A backbone amide bond replaced by methylene amino isostere 855
thiadiazolyl-tryptamine $5HT_{1D}$ receptor, synthesis, activity, electrostatic properties 993
Alcalase
catalysed incorporation D-amino acid esters into peptides in *t*-BuOH 539
catalysed S-1' subsite peptide bond formation, selectivity in anhydrous BuOH 727
Alcohols
long-chain, antibacterial activity, role hydrophobic alkyl groups 1305
secondary, diastereoselective addition to acyloxyazetidinones 2393
Aldehydes
4-benzoyloxycrotonaldehyde, baker's yeast pH dependent conversion into benzoate of (2*R*) 1,2,4-butenetriol 2785
Aldol reactions
boron mediated, chiral imines and silyl ketene acetals derived from 3-hydroxybutyrate 2337
***E*-Alkene dipeptide isosteres**
stereoselective synthesis 2879

α-Alkyl-γ-lactones
interaction with protein kinase C 1101
α-Alkylidene-γ-lactones
interaction with protein kinase C 1107
Alkylpiperidines
inhibition oxidosqualene cyclase 1175
Amide-linked
N-hydroxyurea 5-lipoxygenase inhibitors, synthesis intramolecular O to N acyl transfer 305
Amides
unsat and β-lactams, prep via *N*-[(chlorosulfinyl)-oxy]methylene]-*N*-methylmethanaminium chloride 2419
Amines
addition to methyl 3-dehydroquinate and 3-dehydroshikimate 1447
primary, acetylation by *Cylindrocarpon radicicola*, enantioselectivity 681
Amino (2-aminoethyl)-2'-deoxyadenosine incorporation into DNA by solid phase synthesis 689
Amino acid esters
Zn-mediated condensation with imines to β-lactams 2351
Amino acids
bioisosteres, 2-quinolone derivs as glycine site NMDA receptor antagonists 299
excitatory related agents 9
neurotensin side-chains structure–affinity, N and C terminal deletions and Ala-scan 949
pharmacology N-substit quinoxalinediones 2801
prep 4 monothiothymopentin analogs, biological activity 619
receptor antagonists, pharmacology 3-(carboxymethoxy)isoxazoles derived from AMPA 1649
replacement endothelin receptor ligands 1253
synthesis aminoazalactams collagenase inhibitors 2537
tetrazole acyclic, piperazine-2-carboxylic, NMDA competitive antagonists 43
Aminoazalactams
synthesis as cyclic mimetics of basic alkyl amino acids 2537
Aminobenzyl derivs
NOTA, DOTA, macrocyclic bifunctional chelating agents for antibodies labeling 1067
Aminobutyric acid
gated chloride channel, dithiane inhibitors and candidate affinity probes 2671
Aminocyclopropane-1-carboxylic acid
containing β-lactams, synthesis 2423
Aminoethyl 3-chlorobenzyl ether
selective inactivation monoamine oxidase B 2077
Aminopeptidase B
angiotensin I converting enzyme, inhibition by OF4949, K-13 key analogs 245
Aminopropylbenzimidazoles
R82150 related TIBO anti-HIV agent 543
Aminopropyl(methyl)phosphinic acid
selective $GABA_B$ agonist 515
Aminopyrrolidin-2-one
1-hydroxy-3- deriv, NMDA receptor glycine site antagonist 71
AMI–SCRF calculations
carbocyclic equivalent tautomers quinolone antibiotics 2631
Ammonium
quaternary derivs chlorpromazine, binding dopamine D-2 receptors by addition H-bonding group 1241
AMPA
derived 3-(carboxymethoxy)isoxazoles, pharmacology, excitatory amino acid receptor antagonists 1649
enzymatic resolution by α-chymotrypsin 107
glycine-site antagonists, sulfonyl derivs 6,7-dichloro-3,4-dihydro-3-oxoquinoxaline-carboxylate 77
receptor agonist, synthesis, pharmacology LY300020 95
AMPA/glycine
antagonist N-substit quinoxalinediones 2801
Analgesics
activity epibatidine and isomers 2759
E-3710, prep enantiomers 269
neurotensin C-terminal pentapeptides, amide bond modified stable isosteres 1035
Analysis
tool, evaluation solid phase oligonucleotide synthesis by gel-phase ^{31}P-NMR 2793
Angiotensin
antagonists:
activity, synthesis hetero-substit benzimidazole derivs 1019
benzofuran based related to GR117289 2043
benzofuran-based related to GR117289, potency enhancement, *in vitro* oral activity 2043
GR138950, triflamide with oral bioavailability 2047
in vivo active non-tetrazole, application carboxylic acid bioisostere 757
nonpeptide, refinement molecular model 909
receptors:
1,3- and 1,5-bisbiphenyl substit 3-mercapto-triazoles 375
AT_2, synthesis, study binding affinities of tools 905
containing phenylthiophenes and phenyl furans in place of biphenyl moiety 1119
N_1-sterically hindered 2*H*-imidazole-2-one, conversion surmountable to insurmountable antagonists 1055
nonpeptide 1,5-naphthyridine, pyridine and quinoline derivs 899
nonpeptide 4,5,6,7-tetrahydro-8-oxocyclo-heptimidazoles 1559
nonpeptide AT_2-selective, synthesis, SAR relationships 2023
orally active RWJ 47639 synthesis 1523
prep perfluoroalkylimidazoles 899
substit pyrrolidin-2-one biphenyltetrazoles 369
synthesis, properties and SAR of quinoxaline 2667
substit pyrrolidin-2-one biphenyltetrazoles 369

subtype AT_1, prep [^{3}H]-losartan, [^{3}H]-L-158,641 and [^{3}H]-L-158,809 557
converting enzyme, aminopeptidase B inhibitory properties, key analogs OP4949, pharmacophore delineation 245
containing phenylpyridine element 1693
Anilide
tertiary carbinols, potassium channel openers 2723
Antagonists
AMPA/glycine, N-substit quinoxalinediones 2801
angiotensin II, activity, synthesis hetero-substit benzimidazole derivs 1019
angiotensin II, receptors:
1,3- and 1,5-bisbiphenyl substit 3-mercapto-triazoles 375
4,5,6,7-tetrahydro-8-oxo-cycloheptimidazoles 1559
containing phenylpyridine element 1693
containing phenylthiophenes and phenyl-furans in place biphenyl moiety 1119
prep (perfluoroalkyl) imidazoles 895
quinazolinone containing AT_1, design and synthesis 1293
quinoxaline, synthesis, properties, SAR 2667
synthesis orally active RWJ 46739 1523
application carboxylic acid bioisostere synthesis non-peptide, non-tetrazole compd 757
AT_1, quinazolinones, SAR, *in vivo* characterization 1299
benzofuran based:
angiotensin, related to GR117289, amino acid amides 2043
related to GR117289 potency enhancement, *in vitro* oral activity 589
triflamide GR138950 high oral bioavailability 2047
bicyclic thiazolidine PAF 2729
C21 derivs FK-506-mediated immunosuppression 657
Ca-channel, isosteric replacement in β-substit monophosphate series 281
CCK, properties (*R*)-4-benzamido-5-oxopentanoic basic derivs 861
CCK-A, with 10^{-8} receptor affinities 867
CCK-B, active selective peptidomimetics, structure based on design, pharmacology 847
CCK-B, synthesis, SAR study 2805
C-terminal peptide of endothelin SAR of ET-1[16-21, D-His^{16}] 497
diphenylpyrazolidinone and benzodiazepine-cholecystokinin 875
discovery non-peptide, refinement molecular model angiotensin 909
dual, platelet activating factor and histamine 1073
glutamate, 2,3-benzodiazepine compds, SAR relationships 99
glycine, related to 5,7-dichlorokynurenic acid and 3-(2-carboxy-6-chloroindol-3-yl) acetic acid 81
glycine-site NMDA and AMPA, *N*-sulfonyl derivs 6,7-dichloro-3,4-dihydro-3-oxo-quinoxaline carboxylate 77
glycine-site NMDA, anticonvulsant activity 61, 65
LHRH, progress towards non-peptide leads 943
LDT_4, in styrylquinoline class 1125
NK-1, quinuclidine-based 1361, 1703
NK-2, low mol wt 931
NMDA, competitive:
anticonvulsant activity enantiomers 1,2,3,4-tetrahydro-5(2-phosphonoethyl)-3-isoquinoline carboxylic acid 39
pharmacology NPC 17742 33
synthesis (2*R*,4*R*,5*S*)-2-amino-4,5-(1,2-cyclohexyl)-7-phosphonoheptanoic acid 27
tetrazole amino acids 43
NMDA:
decahydroisoquinoline-3-carboxylic acid competitive, stereochemical preferences 2067
4a-phenanthreneamine derivs 49
non-NMDA, bioavailable isatin oximes 105
oxindole *N*-methyl-D-aspartate 91
non-competitive, neurokinin A, synthesis 319
receptors:
1,5-naphthyridine and pyridine quinoline derivs 899
5-HT_3, *N*-(quinuclidin-3-yl)-1,8-naphthalimides 1375
5-HT_3, quinuclidin derivs 1555
AT_2 selective, synthesis and QSAR 2023
Ca and α1-adrenoreceptor, prep, evaluation dihydropyridine amide BMY 20014 enantiomers 561
CCK_A, 2-NAP hydrophilic nonpeptide derived from cholecystokinin C-terminal dipeptide 1511
CCK_B, prep L-365,260 1919
competitive NMDA, (*R*)-4-oxo-5-phosphono-norvaline, SAR relationships 23
competitive NMDA, synthesis β-ketophosphonate substit piperidine carboxylic acid derivs 19
cyclic ether acetal PAF, 3-pyridyl derivs 1493
cyclic ether acetal PAF, imidazo[4,5-*c*]-pyridyl derivs 1499
excitatory amino acid, synthesis, pharmacology 3-(carboxymethoxy)-isoxazole derived from AMPA 1649
fibrinogen, containing Arg-Asp sequence and nitroxide radicals 1179
fibrinogen, containing γ-lactam Gly–Asp isostere 1675
glycine-site NMDA, design 2-quinolone derivs 299
hydroxyacetophenone substit benzophenone/xanthone leukotriene B_4 1981
LTB_4, effect of 1,2,4,5-substit hydroxy-acetophenones, acid modifications 1147
LY255283 diaryl ether/carboxylic acid derivs of leukotriene B_4 1985
N_1-sterically hindered 2*H*-imidazole-2-one, conversion surmountable to insurmountable antagonists 1055
nonpeptide endothelin, CGS27830 2099
NK_2-nonpeptide synthesis, pharmacology SR 48968 925

non-prostanoid TXA_2, KT2-962, role of sulfonamide, modification and resulting activity 1687
oxytocin nonpeptide from natural sources 337
substance P, 1,4-diacylpiperazine-2-(*S*)-[(*N*-aminoalkyl)carboxamides] 2707
TXA_2/endoperoxide:
1,3-dioxane and 1,3-dioxolane analogs 1271
synthesis cyclopentane, cyclohexene and olefin oxazoles 1267
synthesis pyrrolidine oxazoles 1263
TXA_2/PGH_2, based on carbocyclin skeleton 199
vasopressin, synthesis *N*-acetylhemiaminal metabolites of OPC-21268 1633
subtance P, restricted spirocyclic analog 2083
structural analog of peptido-leukotrienes, BAY x7195 1517
Anthelmintic agents
4"-deoxy-4"-thio-substit avermectin derivs 2675
Anthramycin
antitumor activity pyrazolo[4,3-*e*]pyrrolo[1,2-*a*][1,4]diazepinone analogs of pyrrolo[1,4]benzodiazepines 2511
Anti-aggregation agents
vasodilating activities, prep, evaluation 3-nitro-4(3*H*)-quinazolinone derivs 611
Anti-arthritic agents
1-aryl-3-dimethylamino-1,4-dihydroisoquinolines derivs 2571
Antibacterials
2-functionalized-vinyl deriv 1β-methylcarbapenems 2199
2-*para*-quaternary ammonio-methylphenylcarbapenems 2187
3-phosphono-1-carba-1-dethiacephalosporins 2237
5-thioabbeymycin synthesis 743
(1'*R*,5*R*,6*R*)-2-*t*-butyl-6-(1'-hydroxyethyl)-oxapenem-3-carboxylic acid 2211
aryl analogs hygromycin A 289
C-3-lactonyl substit cephalosporins 2219
catechol bearing penems 2183 flavanones 225
hygromycin A analogs modified at C4' aryl position 1531
in vitro activity penems with amino acid derived substituents at C-2 2177
long-chain alcohols, role hydrophobic alkyl groups 1305
mechanism tetrazole-tethered cephalosporin–quinolone hybrid 209
oral 3-[(*Z*)-2-(1,2,3-thiadiazolyl)ethenyl] substit cephalosporins 2225
QSARs of heteroatom substit 3-isopropylidene and 3-isopropyl analogs of N-acyl, 3-alkylidenyl- and 3-alkyl-azetidin-2-ones 2241
quinolone, U-87947E incorporating bicyclo-[1.1.1]pent-1-yl subunit 671
synthesis penem dithiocarbamates 2159
Antibiotics
A201A, application structure–activity of hygromycin A 295
azalide, semisynthesis linear fragments of eastern portion 1757
β-lactam 1,3,4-trisubstit and 3,4-disubstit, anti-elastase activity 2547
β-lactams, enantiomerically pure, precursors via Pd-catalysed osmylation rac 4-(2-styryl)-azetidin-2-ones 2397
biological value 11-hydroxy group azalides 1999
carbapenem, synthesis biological activity 2193
penam, penem, synthesis γ-lactam analogs, conversion β-lactams to γ-lactams 2299
penem, stereoselective synthesis and Sch 34343 syntheses 2171
vancomycin, binding peptide analogs, free energy cost restricting bond rotation 803
Antibodies
48G7, active site via spin-labelled haptens 285
catalytic, phenylphosphonate monoester analogs of cocaine potential haptens 309
labeling, macrocyclic bifunctional chelating agents aminobenzyl derivs NOTA, DOTA 1067
mimotopes with non-natural amino acids, identification by recombinant peptide library affinity selection 463
monoclonal, selective enhancement necrosis factor activity tumours 457
Anticancer agents
3',4',5'-trihydroxy-etoposide, synthesis, activity 1619
Anticonvulsant agents
1,2,3,4-tetrahydro-5-(2-phosphonoethyl)-3-isoquinoline carboxylic acid 39
3',4',5'-trihydroxyetoposide, synthesis activity 1619
activity 3-arylamino-4-aryl-5-(*N*-4-chlorophenyl-thiocarbamido)-1,2,4-thiadiazoles 547
glycine-site NMDA antagonists 61, 65
non-NMDA bioavailable antagonists, isatin oximes 105
sugar sulfamates, cyclic sulfate and sulfite analogs of topiramate 2653
Anti-diabetic agents
synthesis biotin conjugate darglitazone, protocol for reversible biotinylation of ketones 703
Anti-elastase activity
1,3,4-trisubstit and 3,4-disubstit β-lactam antibiotics 2547
Anti-fungal agents
α-aminoacyl derivs UPOC, access key intermediate, synthesis 1079
pneumocandin lipopeptides, inhibition of 1,3-β-glucan synthesis, phenolic OH required 2039
Antigene therapy
antisense agents 193
Anti-glaucoma activity
phenyl substit $PGF_{2\alpha}$ analogs 241
Anti-glutamate activity
optical isomers RP 64406 983
Anti-hepatitis B
anti-immunodeficiency viruses, pyrimidine oxathiolane nucleoside activity 693
Anti-herpes activity
optically active fluorinated cyclobutane nucleoside analog 1215
Anti-histamine activity
synthesis 4-(2-benzothiazoyl)piperidines 753

Anti-HIV agents
5-glycosylamino pyrimidines 601
1,3-oxathiolane nucleoside analogs 1723
analog d4T, phosphate derivs, prep as prodrugs 1203
cosalane, design, synthesis 1739
drug design, kinase bypass strategy 1207
myristic acid activity resistant to metabolic processing by β-oxidation 779
penicillin dimers 503
pyrimidine dioxolanyl nucleosides 169
physicochemical properties phosphorothioate analogs complementary to HIV sequences 1223
R82150 related 1-(2-aminopropyl)benzimidazoles 543
synthetic pterocarpans 1229
Anti-hypertension activity
benzopyran K^+ channel activators related to cromakalim-amide replacements at position 4 999
KC-399, benzopyran K^+ channel opener long duration, less tachycardia 2005
synthesis 7-(substit benzamido)-6-hydroxythieno-[3,2-*b*]pyrans 1385
synthesis rigid, water soluble analogs coleonol 677
Anti-immunodeficiency agents
anti-hepatitis B viruses, pyrimidine oxathiolane nucleoside activity 693
Anti-inflammatory agents
β-benzeneethanamines synthesis 711
3-heterocyclyl-1,2-benzoisothiazoles 1551
β-benzeneethanamines synthesis 711
dehydroabietylamine derivs 2087
Anti-malarial agents
2,3,5-trioxabicyclo[2.2.3]nonane, model for putative pharmacophore of artemisinin 1707
Anti-microbial agents
quinolone carbocyclic equivalent tautomers, AMI–SCRF calculations 2631
Antinociceptive activity
lipophilic N_α-amido neurotensin analogs, neurotensin receptor binding 2055
simpler analogs of neurotensin 1767
Anti-*Pneumocystis carinii*
pneumonia agents, *cis* and *trans*-butamidine analogs 1137
Anti-proliferative compds
non-phototoxic, double-headed mols based on linear, angular psoralen and α-methylene-γ-butyrolactone 1283
Anti-psychotic agents
4-aryltetrahydropyridines, selective σ ligands 277
Anti-sense applications
introduction lipophilic thioether tether into minor groove nucleic acids 2765
Anti-sense oligonucleotides
modification O-PO_2-linkage by CH_2-CH_2-NH or NH-CH_2-CH_2 linkages 2771
Anti-trypanosomal activity
restricted rotation analogs S-adenosylmethionine 147
Anti-tumor agents
biselectrostatic interaction with DNA, 2,11-diamino-5,8-dithiaundecane derivs 607
acid cleavable linker stable at neutral pH, releases doxorubicin at lysosomal pH 2843
activity γ-fluoromethyl-α–methylene-γ-butyrolactone 2685
activity pyrazolo[4,3-*e*]pyrrolo[1,2-*a*][1,4]diazepinone analogs of pyrrolo[1,4]-benzodiazepines 2511
evaluation water soluble taxol phosphates 1357
netropsin, distamycin containing nitroarenes, synthesis 1697
selective daunomycin deriv 1051
in vivo activity of phosphate water soluble taxol prodrugs 1761
Anti-viral agents
4'-hydroxy and 4'-fluorocarbocyclic-2'-deoxy-guanosines 2577
9-(phosphonoalkynyloxy)purines 2611
AZT phosphodiester, triester derivs with tethered *N*-methyl and *N,N,N*-trimethylethylenediamine 1547
composition sulfated polysaccharide from *Schizymenia dubyi* 1141
differences isomers of fluorinated cyclobutane nucleoside analog 1211
HIV-1 protease inhibitors 2837
nucleosides analogs with 1,5-anhydrohexitol moiety 1013
optically pure dioxolane purine nucleotide analogs 1543
oxetane nucleoside 1061
photochemically activatable 4-alkylamino-3-bromo-*N*-1,8-naphthalimides 555
Anxiolytic activity
4-amino-pyrido[2,3-*b*]indoles 1941
Aromatic and heteroaromatic compds
quantitative structure–activity study using neural network 329
Aromatic–aromatic ring
interactions tested in cyclophanes 263
Artemisinin
putative pharmacophore, 2,3,5-trioxabicyclo-[2.2.3]nonane model 1707
Arylureas
histamine derived, 5-HT_3 receptor agonist activity 205
Ascaricidal agents
4"-deoxy-4"-thio-substit avermectin derivs 2675
Aspartates
α,β-disubstit-, 3,4-dialkyl substit β-lactams, stereoselective synthesis 2461
catalytic, interaction with HIV proteinase dimeric penicillin derived inhibitors 503
Aspartic protease
HIV-1 and hexapeptide inhibitors, complexation energy including effect of solvation 2105
Aspergillus niger
lipase, deacetylation sec acetyl esters in peracetylated methyl glycopyranosides 2125
Assays
radio-receptor, detn peptide ligands from combinatorial libraries synthetic peptides 405
Asymmetric synthesis
β-lactams with 3-(1'-hydroxyethyl) substituents 2337

cis-3-hydroxy-4-aryl azetidin-2-ones 2475
cis-3-phthalimido-4-styryl-2-azetidinones, N-protected derivs via chiral group new in monobactam chemistry 2379
AT_2
selective angiotensin II receptor antagonists, synthesis and QSAR 2023
Auxotroph
Escherichia coli proline growth on Δ^1-pyrroline-2-carboxylic acid 1185
Avermectin
4"-deoxy-4"-thio-substit derivs, anthelmintic, acaricidal agents 2675
B_1-8,9-oxide, reactivity, bioactivity, stereochemistry 2093
Azabicyclo[3.2.2]nonan-3-amines
2-diphenylmethyl-deriv, substance P antagonists 921
Azabicyclo[2.2.2]octanes
3-benzyloxy deriv, antagonists quinuclidine-based NK-1 1361
Azalides
11-hydroxy group, biological value 1999
antibiotics, semisynthesis linear fragments of eastern portion 1757
Azasugars
α-homofuconojirimycin, synthesis glycosidase inhibition 2533
Azetidinones
3-hydroxy-4-aryl-deriv via asymmetric ester enolate-iminecyclocondensation with glycolates 2467
3-(1'-hydroxyethyl) deriv, (+)-thienamycin intermediate, stereoselective synthesis 2337
1,3,4-trisubstit and 3,4-disubstit deriv, antielastase activity 2547
3,4-disubstit derivs, activity, stereospecific synthesis 2295
acyloxy-deriv, diastereoselective addition of secondary alcohols 2393
cis-3-hydroxy-4-aryl deriv, asymmetric synthesis 2475
cis-3-phthalimido-4-styryl-2-deriv, asymmetric synthesis, N-protected derivs via chiral group new in monobactam chemistry 2379
N-acyl 3-alkylidenyl- and 3-alkyl azetidinones antibacterial agents, synthesis, SAR relationships
heteroatom substit 3-isopropylidene and 3-isopropyl analogs 2241
N-(tetrazol-5-yl)-deriv, synthesis from L-tartaric acid 2429
substit, ring closure, route to [4.2.0] fused β-lactams 2443
unsymmetrical disulfides, rearrangement to 2β-(heterocyclylthiomethyl)penams, approach to β-lactamase inhibitors 2247
Azides
transfer and cyclization of diazo/azide to carbacephem nucleus 2431
Azido functionalized thiourea
analogs, photoaffinity probes for urea channel 2587
Azole peptide
biologically active dipeptide mimetics 915
AZT
phosphodiester, triester derivs with tethered *N*-methyl and *N,N,N*-trimethylethylenediamine 1547

Bacteriophage
photoirradiated ϕx 174 DNA, transfecting activity in presence hydroperoxynaphthalimides 1671
Baeyer–Villiger
oxidation, cyclization bisfuran ring formation, aflatoxin B_1 biosynthesis 653
Baker's yeast
pH dependent conversion 4-benzoyloxycrotonaldehyde into benzoate of (2*R*) 1,2,4-butenetriol 2785
reduction α-haloacetophenones, hydride transfer versus electron transfer 1637
BAY X7195
peptido-leukotriene antagonist 1517
Benzamido-5-oxopentanoic acid
basic derivs, CCK antagonists 861
Benzazepine
ring system, 4-aryl-1-hydroxy-2,3,4,5-tetrahydro-1*H*-3-deriv via monocyclization *N*-(2,2-diethoxyethyl)-1,2-diphenylethylamines 251
Benzeneethanamines
synthesis anti-PLA_2, antiinflammatory agents 711
Benzimidazole
hetero-substit derivs, angiotensin II antagonist activity 1019
Benzodiazepines
CCK antagonist 875
with glutamate antagonism, structure–activity 99
Benzofurans
based angiotensin II antagonists related to GR117289, potency enhancement, *in vitro* oral activity 589
Benzoisothiazole nucleus
derivs with 5 and 6 N, S and or O-heterocyclic systems attached to 3-position, antiinflammatory activity 1551
Benzolactams
non-peptide CCK receptor ligands 871
Benzophenone/xanthone
hydroxyacetophenone substit, leukotriene receptor antagonists 1981
Benzoporphyrin
derivs regiochemical purity 2615
Benzopyran-4-carbothioamide
2-substit 6-nitro-2*H*-1-derivs, as muscle relaxants 2627
Benzopyrans
4-carbothioamide-deriv, SAR 6-substit, potassium channel openers 1659
4-carboxamide-deriv, K^+ channel openers 1115
4-(*N'*-cyano)carboxamidine-deriv, *N,N*-disubstit derivs, selective guinea pig trachealis activity 1111
derivs of rolipram, phosphodiesterase IV inhibition 1743
K^+ channel opener, KC-399 action duration with less tachycardia 2005
K^+-channel activators, related to cromakalim-amide replacements at position 4 999

Benzoquinolines
QSARs, inhibitors human type 1 5-α-reductase 1157
Benzothiazepine-4-one
cis-3-methyl analogs, diltiazem Ca channel blocker 2797
Benzothiazoylpiperidines
antihistaminic activity, synthesis 753
Benzoxazine
fluoroalkyl, pyridine-N-oxide, potassium channel openers 2727
Benzoyloxycrotonaldehyde
Baker's yeast pH dependent conversion into benzoate of (2*R*) 1,2,4-butenetriol 2785
Benzyl-3-mercaptopropanoic acid
optically active, inhibition against carboxypeptidase A 2681
Bicyclo[3.2.0]heptane
derivs, enantioselective prep using ester hydrolysis catalysed by novo lipolase 359
Bicyclo[3.2.0]hept-2-en-6-ols
esters, porcine pancreatic lipase catalysed hydrolysis 357
Bicyclo[1.1.1]pent-1-yl subunit
incorporation quinolone antibacterial agents 671
Binding
peptide analogs to vancomycin antibiotics, free energy cost restricting bond rotation 803
Bioavailability
active peptides, improved by conjugation δ opioid agonist to β-cyclodextrin 831
Biocyclization
[2,3]-oxidosqualene analogs by sterol cyclase 365
Biogeneration
(*R*) γ-jasmolactone by *Pichia stipitis* 2777
Bioisosteres
carboxylic acid, application synthesis non-tetrazole non-peptide angiotensin II antagonists 757
Biological activity
hydroxylation vit D side chain 1789
molecules, screening synthesized peptide libraries 397
Biosynthesis
β-glucan inhibitors isolated from fungi, hyphal malformation inducer 1219
pathways, *Escherichia coli* proline auxotroph growth on Δ^1 pyrroline-2-carboxylic acid 1185
shared pathway for clavam metabolites and clavulanic acid 2313
Biotin
conjugate darglitazone, antidiabetic agent, protocol for reversible biotinylation of ketones 703
Biotinylation
ketones, darglitazone biotin conjugate protocol 703
Biphenyltetrazolopyrrolidin-2-ones
angiotensin II antagonists 369
Bisalkylating agents
cytotoxic, spiroepoxycyclohexadienone dimers 735
Bisbiphenylyl
substit 3-mercaptotriazoles, angiotensin II receptor antagonists 375
Biselectrostatic interaction
DNA, 2,11-diamino-5,8-dithiaundecane derivs, anti-tumor agents 607
Bisfuran ring formation
aflatoxin B_1 biosynthesis, Baeyer–Villiger oxidation and course of cyclization 653
Bisphosphonic acid
4-hydroxyphenoxymethylene derivs, non-hydrolysable *myo*-inositol monophosphatase inhibitors 141
Bleomycin
lexitropsin carriers incorporating metal-complexing moiety, design DNA-cleaving mols 1751
Blood platelets
aggregation, inhibition by 3-oxa-methano-PGI_1 2821
Bonds
peptide, cleavage protection against α-chymotrypsin by prodrugs 809
Bone mineralization loss
prevention, therapy with 2β-(3-hydroxypropoxy)-1α,25-dihydroxy vit D_3, ovariectomized rats 1815
Boric acid
effect hydrolysis 4-nitrophenyl 2,3-dihydroxybenzoate, serine proteases borate inhibition mimic 635
Boron
neutron capture therapy, potential of boronated porphyrins 2017
Brevifoliol
13-[*N*-benzoyl-(2'*R*,3'*S*)-3'-phenylisoserinate], semisynthesis, biological evaluation 1349
structure revision, reinvestigation taxol content *Taxus wallichiana* Zucc. 1345
Bronchospasmolytic activity
pyridazinone derivs 2713
Butamidine
cis- and *trans*-analogs, anti-*Pneumocystis carinii* pneumonia agents 1137
Butanol
anhydrous, industrial alkaline protease, probing S-1' subsite selectivity 727
γ-Butyrolactam
γ-fluoromethyl-α-methylene-γ-butyrolactone, prep, biological evaluation 2685
BW315C
synthesis and pharmacology 509

Calcipotriol
side chain triple bond analog MC 903, 1α,24*S*-dihydroxy-26,27-cyclo-22-yne vit D_3 1841
Calcitriol
18-substit analogs, synthesis, evaluation 1855
1-(hydroxyalkyl)-25-hydroxy vit D_3 analogs synthesis 1829
20-*epi*-23-oxa-analog, synthesis evaluation MC 1357 1845
23-oxa-, 23-thia-and 23-oxa-24-oxo derivs, synthesis, evaluation 1859

2β-(3-hydroxypropoxy)-deriv, prevention, therapy bone mineral loss ovariectomized rats 1815
biological evaluation:
1-(hydroxyalkyl)-25-hydroxyvitamin D_3 analogs of calcitriol 1835
18-substit analogs of 1α,25-dihydroxyvitamin D_3 1855
23-oxa-, 23-thia- and 23-oxa-24-oxo-1α,25–dihydroxy vit D_3 1859
vit D analog regulators cancer cell growth and differentiation 1891
Calcium
α1-adrenoreceptor antagonist, prep, evaluation dihydropyridine amide BMY 20014 enantiomers 561
channel, antagonists, isosteric replacement in β-substit monophosphates series 2817
channel blocker diltiazem, *cis*-3-methyl-[1,5]-benzothiazepine-4-one analogs 2797
synthetic Ca^{2+}-mobilizing inositol phosphate 2599
Cancer
cell growth, differentiation, vit D analog regulators 1891
Carbacephams
3,4,7-trisubstit, via vicinal tricarbonyls 2437
Carbacephem-4-carboxylic
$\Delta^{1,6}$-deriv, prototype for fused bicyclic β-lactams 2439
Carbacephems
precursor via *N*-hydroxy-β-lactams 2431
Carba-1-dethiacephalosporins
3-phosphono deriv, antibacterial activity 2237
Carbapenem(+)-PS-5
via transformation chiral vinylaziridine to β-lactams 2415
Carbapenems
2-*para*-quaternary ammoniomethylphenyl-, synthesis, antibacterial activity 2187
bioisosteres from penam and cephem nuclei 2329
intermediates, stereocontrolled synthesis using 1,3-iminoketone synthons 2369
synthesis via metalloimines-ester enolates condensation, prep (+)-1β-methyl PS-5 2347
synthons via microwave induced rapid reaction 2363
tetracyclic, synthesis, biological activity 2193
Carbinols
tertiary anilide, potassium channel openers 2723
Carbocyclin
skeleton basis for TXA_2/PGH_2 receptor antagonists 199
β-Carboline-3-carboxylates
N-2 methylated quaternary derivs, acetylcholin-esterase inhibition 2831
Carbon–carbon bond
formation, thiazolium salt modified papain 531
Carboxylic acids
GABA bioisosteres and $GABA_B$ binding affinity 515
Carboxypeptidase A
inhibition by optically active 2-benzyl-3-mercaptopropanoic acid 2681
Carcinoma KB
A-549 cells, cytotoxicity *ent*-udoteatrial diacetate and analogs 1085
Catalysis
diketopiperazine, synthesis cyclo[(*S*)-His-(*S*)-Phe] 2061
mechanism serine β-lactamase catalysed reactions 2317
Catechols
bearing penems, synthesis, antibacterial activity 2183
Cations
divalent and trivalent, binding K^+ to *trans*-isohumulone 769
CCK
antagonists:
β-carboline, multipurpose receptor ligands 867
biological properties (*R*)-4-benzamido-5-oxopentanoic basic derivs 861
diphenylpyrazolidinone and benzodiazepine 875
dipeptoid analogs, synthesis and incorporation cyclopropyl phenylalanines 667
functional role C-terminal carboxamide moiety 851
peripheral biological activity, significance of tryptophan residue 851
receptor ligands, non-peptide benzolactams 871
receptor subtypes CCK-A and CCK-B in single structural class 881
significance C-terminal primary amide 851
subtype A:
receptor antagonist, non-peptide selective hydrophilic, derived from CCK C-terminal dipeptide 1511
receptors
amides and ureas of 3-amino-β-carboline 867
selective ligands, design, synthesis non-peptide rhegnylogues of CCK-26-33 889
tetrapeptide-based receptor agonists, backbone amide bond replaced by methylene amino isostere 855
subtype B:
antagonists, synthesis and SAR study 2805
gastrin receptor, C5-cyclohexyl analog of L-365,260 selective high affinity ligand 1919
non-peptide gastrin receptor antagonist in tritiated form 885
receptor, bioactive conformation of potent, selective peptide 2011
systemically active, selective peptido-mimetics, structure-based design and pharmacology 847
CD
crystal structure, FCE 22891 2333
Cells
cancer, growth differentiation, vit D analog regulators 1891
growth, developmental control, tissue-specific gene expression osteoblast differentiation, effect of vit D analogs and $[1,25](OH)_2D_3$ 1885
Centaureidin
cytotoxic flavone from *Polymnia fruticosa*, inhibitor tubulin polymerization 581

Cephalosporinase
inhibitors, 2-substit penems a possibility 2253
Cephalosporins
3-thiazoliomethyl-deriv, intramolecular Michael addition to 3-spirocephalosporin 2447
-quinolone, tetrazole-tethered hybrid, mechanistic study 209
based prodrug, synthesis, release of doxorubicin by β-lactamase-immunoconjugate 323
C-3-lactonyl substit, synthesis, antibacterial activity 2219
oral, synthesis 3-[(*Z*)-2-(1,2,3-thiadiazolyl)-ethenyl] substit derivs 2225
tricyclic via cephem P-ylides and ketoaldehydes 2451
Cephems
3α,β-unsat ketones, via ketoaldehydes and cephalosporin P-ylides 2451
sulfones, mechanism-based inactivators of human leukocyte elastase, chemical and enzymatic β-lactam cleavage 2259, 2265
CGS 27830
endothelin nonpeptide receptor antagonist 2099
Channel blockers
Ca, diltiazem, *cis*-3-methyl-1,5-benzothiazepine-4-one analogs 2797
GABA-gated chloride, dithiane inhibitors and candidate affinity probes 2671
Channel openers
potassium:
anilide tertiary carbinols 2723
dihydropyridine K_{ATP} 2725
fluoroalkyl benzoxazine pyridine-*N*-oxide 2727
SAR 6-substit benzopyran-4-carbothioamide 1659
Chelating agents
antibodies labelling, macrocyclic bifunctional aminobenzyl derivs NOTA, DOTA 1067
macrocyclic bifunctional precursors via dicarboxymethylated triazacyclononane, tetraazacyclododecane 1071
Chemical delivery system
dihydropyridine-derived, covalent hydration as side reaction 1309
Chlorpromazine
quaternary ammonium derivs, binding dopamine D-2 receptors by addition H-bonding group 1241
Cholecystokinin
see CCK
Cholesta-5,7-diene
3β-acetoxy-1β,2β-hydroxy deriv, synthesis 1849
Chorismate
2,6,9^{13}C and 1,3,5,8^{13}C, microbial production and NMR characterization 1453
Chromans
4-aminomethyl deriv, serotonin, dopamine binding dependence on aromatic ring substit 1131
Chromogenic substrate
β-galactosidase, based on methyl purple 175
Chromophore
photoprotein *Symplectoteuthis* bioluminescence, structure, binding form 2647
α-Chymotrypsin
3-dimensional representation S_1 subsite 1313
AMPA enzymatic resolution 107
peptide bond cleavage, protection by prodrugs 809
Clavulanic acid
clavam metabolites shared biosynthetic pathway 2313
Cocaine
phenylphosphonate monoester analogs, potential haptens, generation catalytic antibodies 309
SAR, structural variations C-2 center, compds of subnanomolar binding potency 1327
Codlemone
synthesis biologically active chlorinated analog 1629
Colchicine
analogs, formation intracellular protein-linked DNA breaks, inhibition DNA topoisomerase
absence cross-resistance colchicine resistant subclone 1045
combretastatin hybrids, synthesis, evaluation combretatropones 565
derivs, dose dependent cytocidal effects osteogenic sarcoma cells 1045
Coleonol
synthesis rigid, water soluble analogs 677
Combretastatin
colchicine hybrids, synthesis, evaluation combretatropones 565
Complexation energy
between aspartic protease of HIV-1 and hexapeptide inhibitors including effect of solvation 2105
Conformation
active, 6-amino-α-[(4-diphenylmethyl-1-piperazinyl)methyl-9*H*-purine]-9-ethanol, inotropic agent 1233
analysis disubstit analogs vit D_3 side chain, molecular modeling semiempirical calculations 1795
analysis N-acyl urea containing valine residue in DMSO d_6 153
CYP2D6 model substrate sparteine under physiological conditions 1667
isoprenyl subunit squalene synthase inhibitors 595
selectivity alkaline proteases in anhydrous alcohols 1643
side chains vit D analogs, effect of C20 stereochemistry 1799
Copper
catalysis, reduction *N,O*-dibenzoylhydroxylamine by tertiary amine 1245
Corrigenda
Hamilton H., Steinbaugh B., Blankley J., Taylor M., Chan O. H., Stewart B., Schroeder R., Ryan M., Rapundalo S., Cook J., Bernabei A. and Stewart C. 813 (1993): page 3, legend for Fig 1 corrected 1773
Lawson J. E., Poindexter G. S., Owens D. A., Cavanagh R. L., Goggins G. D., Sarmiento J. G., Bleiberg B. B. and Weselcough E. O. 561 (1993): page 2, bottom paragraph corrected; page 3, in Table, values for imidazoles corrected; page 4, Note 12 corrected 1389

Mehta V. D., Kulkarni P. V., Mason R. P., Babcock E. E., Constantinescu A. and Antich P. P. 527 (1992): Dr S. B. Rajur unfortunately omitted as co-author 785
Murray W. V., Lalan P., Gill A., Ado M. F., Lewis J. M., Lee D. K. H., Wacher M. P., Rampulla R. and Underwood D. C. 369 (1993): regiochemistry and structures of **2** and **11** corrected 785
Cosalane
design, synthesis anti-HIV agents 1739
CP-99,994
conformationally restricted analogs synthesis spirocyclic amine 2083
Cromakalim
analog *N,N*-disubstit benzopyran-4-(*N'*-cyano)-carboxamidines selective guinea pig trachealis activity 1111
Crosslinking
proteins, peptides, synthesis cysteine homologs 739
Cyclase
sterol, biocyclisation 2,3-oxidosqualene analogs 365
Cyclization
peptides on TFA labile resin using trimethylsilyl ester as orthogonal protection 437
Cycloaddition
monoalkylketenes to 2-oxoalkanoic ester derived imines, stereoselective synthesis α,β-disubstit aspartates, 3,4-dialkyl substit β-lactams 2461
trichloroacetyl isocyanate to furanoid glycals 2403
Cyclobutane
fluorinated nucleoside analog: differences anti-viral activity of isomers 1211
optically active analogs, anti-herpes activity 1215
Cyclobutyl group
achiral, design, synthesis as inhibitors 5-lipoxygenase 2565
Cyclodextrin
conjugation δ opioid agonists, bioavailability active peptides improved 831
Cycloheptimidazoles
4,5,6,7-tetrahydro-8-oxo-deriv, angiotensin II receptor antagonists 1559
Cyclohexene
oxazoles, synthesis thromboxane A_2/ endo-peroxide antagonists 1267
Cyclohexyl C5
gastrin receptor, analog of L-365,260 selective high affinity ligand 1919
Cyclo[(*S*)-His-(*S*)-Phe]
diketopiperazine catalyst, synthesis 2061
Cyclooxygenase
5-lipoxygenase inhibition activity of 2,6-di-*t*-butylphenols linked by S-atom to 1,3,4-thiadiazoles and 1,3,4-oxadiazoles 2827
lipoxygenase dual inhibitors, oxazole, thiazole and imidazole derivs of [2,6]-di-*t*-butylphenol 1729
Cyclopentane
oxazoles, synthesis thromboxane A_2/ endo-peroxide antagonists 1267
Cyclopentenones
potential inhibitors penicillin sensitive enzymes 2309
Cyclophanes
tested aromatic–aromatic ring interactions 263
Cyclophilin
cyclosporin position 2 derivs as probes 2559
Cyclopropyl phenylalanines
synthesis and incorporation into dipeptides 667
Cyclosporin
position 2 derivs as cyclophilin probes 2559
Cylindrocarpon radicicola
enantioselective acetylation primary amines 681
CYP2D6
model substrate sparteine, conformation under physiological conditions 1667
Cysteine
homologs synthesis, proteins, peptides cross-linking 739
Cytochrome P-450
deethylase, fluorinated analogs, metabolism resistance rat liver microsomes with NADPH 179
Cytosolic delivery
nucleoside monophosphates, SATE and DTE enzyme-labile phosphate protecting groups 2521
Cytotoxicity
(±)-octadecylphosphodithionyl-1-*myo*-inositol 1931
annonaceous acetogenin giganin from *Goniothalamus giganteus* 1153
bisalkylating agents, spiroepoxycyclohexadienone dimers 735
ent-udoteatrial diacetate and analogs 1085

DAHP
Potato synthase, expression in *Escherichia coli* 1421
Darglitazone
biotin conjugate, antidiabetic agent, protocol for reversible biotinylation of ketones 703
Daunomycin
designed tumor selective deriv 1051
DCHQC
6,7-dichloro-3,4-dihydro-3-oxo-2-quinoxaline-carboxylic acid glycine-site NMDA, AMPA antagonists 77
Deacetylation
enzyme catalysed, benzyl phenyl ketone per-acetates in organic solvents 585
secondary acetyl esters in peracetylated methyl glycopyranosides by *Aspergillus niger* lipase 2125
Deazaaristeromycin
lacking hydroxymethyl side-chain, adenosyl-L-homocysteine hydroxylase inhibitors 663
Decahydroisoquinoline-3-carboxylic acid
stereochemical preferences as NMDA competitive antagonists 2067
Dehydroabietylamine
derivs, antiinflammatory agents 2087
Dehydroquinase
hybrid formation in shikimate pathway 1429

Dehydroquinate
methyl ester, addition of amines 1447
synthase, inhibitors, structural simplicity versus inhibitory potency 1403
Dehydroshikimate
methyl ester, addition of amines 1447
Deoxyguanosines
4'-hydroxy and 4'-fluorocarbocyclic-derivs, antiviral agents 2577
Deoxyshowdomycin
short convenient synthesis 2847
Deoxyuridine
5-formyl-2'-mutagenic deriv, incorporation into oligodeoxyribonucleotide 2751
5-NH_2-2'-deriv, incorporation into DNA 347
analog, with aminoalkyl tether at 1'-position sugar moiety incorporated into oligonucleotides, duplex formation, intercalating group attached to amino group 615
Diabetes mellitus
non-insulin dependent, therapy agents 1007
Diacylglycerol
conformationally constrained analogs, PK-C binding affinity 1993
rigid, interaction α-alkylidene-γ-lactones with protein kinase C 1107
rigid analogs, interaction α-alkyl-γ-lactones with protein kinase C 1101
Diacylpiperazine-2-(*S*)-(*N*-aminoalkyl) carboxamides
substance P receptor antagonist 2707
Diamine oxidase
inhibitors, synthesis 4(5)-imidazoyl allylamines and propargylamines 353
Diamino-2-hydroxypropane derivs
pseudosymmetric HIV proteinase inhibitors 535
Diastereomers
substance P, synthesis using cellulose-based carriers 441
Diastereoselective reactions
addition, secondary alcohols to acyloxy-azetidinones 2393
synthesis cyclopropyl phenylalanines and incorporation into dipeptides 667
Diazepines
azetidino-, prep β-lactams 2375
Diazo amides
Rh-catalysed C–H insertion, prep β-lactams 2409
Di-*t*-butylphenols
2,6-, linked by S-atom to 1,3,4-thiadiazoles and 1,3,4-oxadiazoles, cyclooxygenase and 5-lipoxygenase inhibition 2827
Dicarboxycyclopropyl-glycines
L-2-(2,3)-deriv, conformationally restricted glutamate analogs, synthesis 15
Dichlorokynurenic acid
2-carboxyl prodrugs, NMDA antagonists 61
derivs and 3-(2-carboxy-6-chloroindol-3-yl) acetic acids, structure–activity 81
Dideazatetrahydrofolic acid
2-desamino and 4-deoxy analogs, synthesis, biological activity 2657
α,β-Didehydrotryptophan
substit CCK ligands, design and synthesis 989
Differentiation
HL-60 cells assay using polyamides 1965
Difluorostatone
type inhibitors, HIV-1 protease 253
Dihydroisoquinolines
1-aryl-3-dimethylamino derivs, synthesis and anti-arthritic activity 2751
Dihydropyridines
amide, BMY 20014 enantiomers, Ca and α1-adrenoreceptor antagonist, prep, evaluation 561
derived delivery system, covalent hydration as side reaction, GABAergic example compd 1309
K_{ATP}, potassium channel openers 2725
Dihydroxy-22-oxa-vitamin D_3
1α,24-analog, synthesis and differentiation-inducing activity 1863
Dihydroxyvitamin D_3
25,26-epoxy-1α,24-analogs, synthesis, evaluation 1863
Diketopiperazine
catalyst, synthesis cyclo[(*S*)-His-(*S*)-Phe] 2061
Dilevalol
catechol metabolite, synthesis 2073
Diltiazem
Ca channel blocker, *cis*-3-methyl-1,5-benzo-thiazepine-4-one analogs 2797
Diol sulfonamides
inhibitors human renin 2739
Dioxane analogs
thromboxane A_2/endoperoxide receptor antagonists 1271
Dioxolane
1,3-dioxane analogs, thromboxane A_2/ endo-peroxide receptor antagonists 1271
purine nucleotide analogs, optically pure, antiviral activity 1543
pyrimidine nucleosides, anti-HIV agents 169
Dipeptides
conformationally constrained *gauche* mimetics, 6-amino-5-oxo-7-phenyl-[1,4-]oxazepines 231
(*E*)-alkene isosteres, stereoselective synthesis 2879
Gly–Asp γ-lactam isostere incorporation, prep fibrinogen receptor antagonists 1675
library, screening at peptide receptor sites 799
peptide azoles as biologically active mimetics 915
trans-olefin isosteres, enantioselective synthesis 1609
Trp–Val non-cleavable transition state isosteres, synthesis 1257
Diphenylethylamines
N-(2,2-diethoxyethyl)-1,2-deriv, monocyclization to 4-aryl-1-hydroxy-2,3,4,5-tetrahydro-1*H*-3-benzazepine 251
Diphenylmethylsilylethyl group
protection in oligonucleotide synthesis via phosphoramidite approach 2637
Diphenylpyrazolidinone
CCK antagonist 875
Diphenylureas
N,N'-substit,inhibitors of acyl-CoA:cholesterol acyltransferase 259
Diphosphonate analogs
myo-inositol 4,5-diphosphate 685

Dipropylaminotetralin
8-OH, effect of aromatic ring substit on pharmacology 2035
Disaccharides
non-reducing, trehalosamine analogs from acosamine and ristosamine 235
Distamycin
antitumour agents, containing nitroarenes, synthesis 1697
Disulfides
unsymmetrical, azetidinones, rearrangement to 2β-(heterocyclylthiomethyl)penams, approach to β-lactamase inhibitors 2247
Dithianes
inhibitors, affinity probes GABA-gated chloride channel 2671
Dithiocarbamates
penem, synthesis 2159
DMEQ–TAD
fluorescence labeling vit D metabolites, analogs 1809
DMSO d_6
conformational preference N-acyl urea containing valine residue 153
DNA
8-amino(2-aminoethyl)-2'-deoxy-adenosine incorporation by solid phase synthesis 689
binding, tryptophan linked monocationic netropsin analogs 2623
biselectrostatic interaction, 2,11-diamino-5,8-dithiaundecane derivs, anti-tumor agents 607
cleavage, hybrid mols with propargyl sulfones and minor groove binding lexitropsins 1565
cleaving metallopeptide, design, synthesis 333
containing 5-NH_2-2'-deoxyuridine, solid phase synthesis 347
design cleaving mols which incorporate metal-complexing moiety of bleomycin, lexitropsin carriers 1751
gyrase, inhibitory activity of flavanones 225
photoirradiated ϕx 174, transfecting activity in presence hydroperoxynaphthalimides 1671
radiosensitizers, targeting minor groove binding, nitroarenes based on netropsin and distamycin 1697
single-stranded, reaction with iron-binding oligonucleotides 1367
Dopamine
autoreceptor agonists, computer, synthetic, biological studies 1477
D-2 receptors, binding chlorpromazine quaternary ammonium derivs by addition H-bonding group 1241
enantiomers, autoreceptor agonist PD 135385, synthesis, evaluation 639
Doxorubicin
synthesis, release from cephalosporin based prodrug by β-lactamase-immunoconjugate 323
triacid amide with ester on 2nd carboxyl, releases DOX lysosomal pH, stable at neutral pH 2843
DPAT
8-OH, derivs, effect substit aromatic ring on pharmacology 2035
Drugs
acid cleavable linker stable at neutral pH, releases doxorubicin at lysosomal pH 2843
discovery, oligonucleotide diversity, proteins epitope targeting 469

E-3710
analgesics, prep enantiomers 269
Ecdysone
biosynthesis, synthesis ecdysteroid inhibitors 1951
Ecdysteroid
inhibitors of ecdysone biosynthesis 1951
ECE
endothelin, hydroxamic acid, thiol inhibitors 1953
ECPCR method
protein overproduction, construction T7-based transcription vector pLM1 1089
Edman degradation
electrospray mass spectrometry, sequence analysis peptide pools 431
Elastase
human leukocyte inactivation by cephem sulfones, β-lactam chemical and enzymatic cleavage 2259, 2265
inhibition:
by 6-substit penicillin esters or amides 2277, 2289
by phthalimide deriv 2745
human leukocytes by 6-alkyl substit penem benzyl esters 2277
inhibitors:
containing conformationally restricted lactams as P_3–P_2 dipeptide replacements 773
monocyclic β-lactam, stereospecific synthesis, activity 3,4-disubstit 2-azetidinones 2295
Electrospray ionization MS
vit D derivs 1805
Enantiomeric purity
β-lactams via chiral ligand accelerated osmylation
rac-4-(2-styryl)-azetidin-2-ones 2397
RP 64406, antiglutamate agents 983
Enantiomers
E-3710 analgesics, prep 269
Enantioselective reactions
acetylation primary amines by *Cylindrocarpon radicicola* 681
Enantioselective syntheses
antielastase activity 1,3,4-trisubstit and 3,4-disubstit β-lactam antibiotics 2547
bicyclo[3.2.0]heptane derivs using ester hydrolysis catalysed by novo lipolase 359
carbapenem(+)-PS-5 via transformation chiral vinylaziridine to β-lactams 2415
trans-olefin dipeptide isosteres 1609
Endopeptidase
neutral 24.11, *gem*-cycloalkyl thiol inhibitors, synthesis via opening 2,2-spiro-β-lactones 825
Endothelin
antagonists structure–activity ET-1[16-21, D-His^{16}] 497
converting enzyme, hydroxamic acid, thiol inhibitors 1953

nonpeptide receptor antagonist, CGS 27830 2099
receptor ligands, multiple D-amino acid replacement 1253
SAR hexapeptide ligands 519
Enedidyne core
synthetic protein damage 1351
Enkephalin
nonpeptide β-turn mimetics 835
Enols
difunctional, N-protected amino acids, low mol wt inhibitors HIV-1 protease 1169
Enzymatic reactions
(2*R*,4*R*,5*S*)-2-amino-4,5-(1,2-cyclohexyl)-7-phosphonoheptanoic acid 12626 27
aromatic pathway plant suspension cells, response to phosphate limitation 1415
β-cleavage, cephem sulfones, mechanism-based inactivators of human leukocyte elastase 2265
catalysed deacetylation, benzyl phenyl ketone peracetates in organic solvents 585
penicillin sensitive, cyclopentenone potential inhibitors 2309
resolution AMPA by α-chymotrypsin 107
Enzymatic syntheses
disaccharide–serine and peptide conjugates 2515
isoprephenate from isochorismate 1441
optically active α-tocopherol side chains 157
Epibatidine
plus isomers, analgesic effect 2759
Epoxidation
6,7- and 10,11-oxidosqualenes by squalene epoxidase, rat liver microsomes 2581
EPSP synthase
inhibitor design 1453
Ergocalciferol
1α,25,28-trihydroxy deriv, synthesis 1821
Escherichia coli
EPSP synthase, inhibitor, synthesis, characterization *N*-amino-glyphosate as analog 2863
chorismate synthase, stoichiometry of binding to FMN hydroquinone 1409
proline auxotroph:
growth on Δ^1-pyrroline-2-carboxylic acid, biosynthetic pathways 1185
reduction Δ^1-pyrroline-2-carboxylic acid to proline 1189
Solanum tuberosum DAHP synthase expression 1421
Esters
D-amino acid, alcalase catalysed incorporation into peptides in *t*-BuOH 539
enolate–metalloimine cycloaddition, synthesis (+)-1β-methyl PS-5 2347
synthesis, bioactivity diesters of zaragozic acid A 2029
Estrone
3-methylthiophosphonate, estrone sulfatase inhibitor 313
3-phosphonates, thiophosphonates as analogs of estrone 3-sulfate with competitive inhibition of estrone sulfatase 313
sulfatase, inhibitors, synthesis estrone 3-methylthiophosphonate 313
Ethoxycoumarin
2,2,2-trifluoroethoxy deriv, resistance cytochrome P-450 metabolism rat liver microsomes with NADPH 179
Etoposide
3',4',5'-trihydroxy, synthesis, activity 1619
Eyes
human lens insoluble protein fraction, new fluorescent compd structure 345

Farnesylation
proteins, stereochemistry via NMR 281
FCE 22891
X-ray crystal structure, chiroptical properties 2333
Fibrinogen
receptor antagonist:
with Arg–Gly–Asp sequence and nitroxide radicals, prep, properties 1179
with γ-lactam Gly–Asp isostere 1675
Fish
vit D_3, mechanism nonphotochemical production 1785
FK-506
excised binding domain, affinity for immunophilin FKBP12 1947
macrocycle, derivs at C21 position, immunosuppressants 657
Flavanones
DNA gyrase inhibition, antibacterial activity 225
Flavin mononucleotide
see FMN hydroquinone
Fluorescence
continuous assay, protein tyrosine phosphatases, synthesis and fluorescence of substrate 1601
labeling vit D metabolites, analogs, with 1,2,3-triazoline-3,5-dione 1809
new compd from human lens insoluble protein fraction 345
probes for 5-HT_{1A} receptors, 5-methyl-3-[*n*-propyl-(4-*n*-aminobutyl)]amino-3,4-dihydro-2*H*-1-benzopyran derivs 1935
Fluorines
aryl, effect on lipase resolution 1655
Fluoroalkyl benzoxazine
pyridine-N-oxide, potassium channel openers 2727
Fluoro-aristeromycin
(*E*)- and (*Z*)-4',5'-didehydro-5'-deoxy-5'-deriv, inhibition S-adenosyl-L-homocysteine hydroxylase 165
Fluoro-azetidinones
synthesis 3-amino-2,3-dideoxy-2-fluoro-xyloses 2457
Fluoro-carbons
synthetic glycolipids, double-tailed, biocompatible non-ionic surfactants 1003
Fluoro-cyclobutanes
nucleoside analog
differences antiviral activity of isomers 1211
optically active, anti-herpes activity 1215
γ-Fluoromethyl-α-methylene-γ-butyrolactone
γ-butyrolactam prep, biological evaluation 2685

Fluoro-xyloses
3-amino-2,3-dideoxy-deriv, via 3-fluoro-azetidinones 2457
Fluoxetine
enantiomeric forms, superpositional analog, synthesis, X-ray structure 2635
FMN hydroquinone
stoichiometry of binding to *E.coli* chorismate synthase 1409
Forskolin
synthesis rigid, water soluble analogs 677
Fucosyltransferase family
acceptors, synthesis
Galβ1→3(Fucα1→4)GlcNAcβ-OR 1333
Fungi
hyphal malformation inducers, β-glucan biosynthesis inhibitors 1219
Furanoid glycals
2+2-cycloaddition to trichloroacetyl isocyanate 2403
Furanones
opioid receptor binding agents 215

$GABA_B$
agonists with CNS activity, 3-aminopropyl-(methyl)phosphinic acid activity 515
γ-Galactosidase
chromogenic substrate based on methyl purple 175
Galactosyl transferase
inhibitors 1747
Gastrin
non-peptide CCK-B receptor antagonist in tritiated form 885
Gel-phase ^{31}P-NMR
analytical tool, evaluation synthesis oligo-nucleotides 2793
Genes
expression, tissue-specific, osteoblast differentiation, effect of vit D analogs and $1,25(OH)_2D_3$ 1885
Geometry
side-chain KH-1060, X-ray evidence 341
Geranylgeranyl diphosphate
4- and 5-methyl derivs, via reaction solanesyl diphosphate synthase with artificial substrates 2733
Glucan
1,3-β-, synthesis, pneumocandin antifungal lipo-peptides, phenolic OH required 2039
biosynthesis, inhibitors isolated from fungi, hyphal malformation inducer 1219
Glucosaminidase
release activity, modified backbone formyl-methionyl tripeptides 953
Glutamate
analogs DCG-1/4, DCG-2/3 15
antagonism, structure–activity 2,3-benzodiazepine compds 99
high affinity transporter, conformationally restricted inhibitors 115
Glutamyl-tRNA
synthetase, inhibitor synthesis 2699

Glutathione
peroxidase-like activity of diaryl tellurides 2553
Glycine
antagonists:
5,6-dichlorokynurenic and 3-(2-carboxy-6-chloro-indol-3-yl)acetic related acids, structure–activity 81
NMDA, AMPA 61, 65
NMDA, AMPA glycine-site, sulfonyl derivs of 6,7-dichloro-3,4-dihydro-3-oxoquinoxaline carboxylate 77
NMDA partial agonist HA-966 71
NMDA receptor, glycine site 2-quinolone derivs 299
Glycolipids
synthetic double-tailed hydrocarbon, fluoro-carbon, biocompatible non-ionic surfactants 1003
Glycopeptidolipid
Mycobacterium fortuitum, synthesis structurally variant complete glycotetrapeptide core 697
Glycosidase
inhibition by α-homofuconojirimycin 2533
Glycosylamino pyrimidines
anti-HIV agents 601
Glycosyl-serine
peptide conjugates 2515
Glycotetrapeptide core
glycopeptidolipid *Mycobacterium fortuitum* 697
Glyphosate
N-amino analog deriv, inhibition of *E. coli* EPSP synthase 2863
GMP synthase
transition state inhibitor imidazo[4,5-c]azepine nucleoside 183
Goniothalamus giganteus
cytotoxicity acetogenin giganin 1153
GPT lowering agent
sarmentosin synthesis 1343
GR117289
amino acid amide benzofuran based angiotensin II related antagonists 2043
angiotensin II benzofuran based antagonist, SAR 589
GR138950
high oral bioavailability of angiotensin II benzo-furan based antagonist related to GR117289 2047
Growth hormone
analog incorporating D-Ala–Pro dipeptide unit, hypoglycaemic activity 1625
Guanidine
N-substit linked nucleoside dimers, incorporation into oligonucleotides 193
GYKI52466
synthesis 1991

HA-966
NMDA receptor glycine-site partial agonist 71
Haloacetophenones
baker's yeast reduction, hydride transfer versus electron transfer 1637
Haptens
generation catalytic antibodies, phenylphos-phonate monoester analogs of cocaine 309

Hemagglutination
influenza A virus, inhibition by methyl α-sialosides N-substit alkanoyl groups 747
HEPT
synthesis, photoaffinity labelling reagent for HIV-1 reverse transcriptase 1681
Herpes simplex
thymidine kinase inhibitors (2*R*,4*S*,5*S*)-1-(tetrahydro-4-hydroxy-5-methoxy-2-furanyl) thymine 1571
Hexapeptide
endothelin ligands, SARs 519
Himbacine
analogs, binding affinity for receptors 1247
Histamines
derived arylureas, 5-HT_3 receptor agonist activity 205
PAF dual antagonists, prep series pyridine ring substit compds 1073
releasing activity substance P diastereomers 441
side-chain unsaturated analogs, inhibitors diamine oxidase 353
HIV
functionalized peptides, synthesis, use of N_α-Fmoc-N_1-Nvoc-lysine 707
inhibitors:
design, synthesis hydroxyproline 1485
discovery, structure directed, GP120 binding to CD4 receptor 2851
hexapeptide, aspartic protease, complexation energy including effect of solvation 2105
peptidomimetic, design, enzyme binding and selectivity, cell permeability 819
proteinase dimeric penicillin dimeric, interaction with catalytic aspartates 503
pseudosymmetric, synthesis 1,3-diamino-2-hydroxypropane derivs 535
reverse transcriptase non-nucleoside, mutations, structural analysis 721
protease inhibitors:
difluorostatone type 253
inhibition by its C- and N-terminal peptides 765
HIV-1, synthesis, evaluation 1595
low mol wt, difunctional enols N-protected amino acids 1169
nonpeptide, designed to replace a bound water 2717
pseudosymmetrical, structure–activity 1589, 2837
reverse transcriptase, synthesis photoaffinity labelling reagent 1681
HL-60 cells
differentiation assay using polyamides 1965
Homofuconojirimycin
α–glycosidase inhibition 2533
Hormones
CCK_A receptor antagonists 1511
growth, analog incorporating D-Ala–Pro dipeptide unit, hypoglycaemic activity 1625
hypertrehalosemic design, synthesis mimetics 1277
luteinising/releasing, leads towards non-peptide antagonists 943
vit D_3, mechanism nonphotochemical production in biological systems 1785
HT3
receptor agonist activity, histamine derived arylureas 205
receptor antagonist *N*-(quinuclidin-3-yl)-1,8-naphthylimides, properties 1375
quinuclidine derivs effect of additional CO group on chirality recognition by receptor 1555
HT4
receptor agonist *N*-(quinuclidin-3-yl)-1,8-naphthylimides, properties 1375
quaternised benzapride 633
Hydration
covalent, side reaction dihydropyridine-derived delivery system, GABAergic example compd 1309
Hydride transfer
versus electron transfer in baker's yeast reduction α-haloacetophenones 1637
Hydrocarbons
synthetic glycolipids, double-tailed, biocompatible non-ionic surfactants 1003
Hydrolysis
4-nitrophenyl 2,3-dihydroxybenzoate, effect boric acid, serine proteases borate inhibition mimic 635
bicyclo[3.2.0]hept-2-en-6-ol esters catalysed with porcine pancreatic lipase 357
Hydrophobic alkyl groups
role, antibacterial activity long-chain alcohols 1305
Hydroxamic acid
inhibitors of endothelin-converting enzyme 1953
Hydroxyacetophenones
1,2,4,5-substit, acid unit modification, effect of LTB_4 receptor antagonism 1147
Hydroxybutyrate
derived chiral imines and silyl ketene acetals, boron mediated aldol reactions 2337
Hydroxylamines
N,O-dibenzoyl deriv, reduction by tertiary amine, Cu catalysis 1245
Hydroxylase
C-25, inhibition 1951
Hydroxylation
vit D side chain, stereochemistry, physiological significance 1789
Hydroxyl groups
function in peptidyl tRNA terminus during elongation in ribosomal peptide biosynthesis 1527
Hydroxyproline
HIV-1 proteinase inhibitors, design, synthesis 1485
Hydroxypyridazopyrimidines
derivs, heterocyclic inhibitors human leukocyte elastase 1163
Hydroxypyridopyrimidines
derivs, heterocyclic inhibitors human leukocyte elastase 1163
Hydroxyquinazoline-[2,4](1*H*,3*H*)dione derivs
heterocyclic inhibitors human leukocyte elastase 1163

Hydroxythieno[3,2-*b*]pyrans
7-(substit benzamido)-6-derivs, antihypertensive activity as K-channel activators, synthesis 1385
Hydroxythreonine
abs config, biosynthetic precursor *Pseudomonas* rhizobitoxine 2095
N-Hydroxyurea
5-lipoxygenase amide-linked inhibitors, synthesis intramolecular O to N acyl transfer 305
Hygromycin A
analogs modified at $C_{4'}$ aryl position, antibacterial activity 1531
structure–activity, application to antibiotic A201A 295
synthesis, antibacterial activity of aryl analogs 289
Hypercholesterolemia
model, plasma cholesterol lowered by ACAT 259
Hypertrehalosemic hormones
design, synthesis mimetics 1277
Hypocholesterolemic 15-ketosterols
chemical synthesis 1339
Hypoglycaemia
activity growth hormone analog incorporating D-Ala–Pro dipeptide unit 1625

IGP-Dehydratase
substrates, IGP stereoisomers 2129
Imidazo[4,5-*c*]azepine
nucleosides design, synthesis 183
Imidazoles
glycerol phosphates stereoisomers, substrates for IGP-dehydratase 2129
oxazole, thiazole derivs of 2,6-di-*t*-butylphenol, dual inhibitors of lipoxygenase, cyclooxygenase 1729
perfluoroalkyl derivs, angiotensin II receptor antagonists 895
2*H*-Imidazol-2-one
angiotensin II, N_1 sterically hindered receptor antagonists 1055
Imidazo[1,2-*a*]pyrazines
2-aryl derivs, synthesis and pharmacology BW315C 509
Imidazo[4,5-*c*]pyridyl derivs
platelet activating factor, cyclic ether acetal receptor antagonists 1499
Imidazoyl allylamines
propargylamines, synthesis as inhibitors diamine oxidase 353
Imines
chiral and silyl ketene acetals derived from 3-hydroxybutyrate, boron mediated aldol reactions 2337
Zn-mediated condensation with amino acid esters to β-lactams 2351
Iminoketones
synthons for stereocontrolled synthesis carbapenem intermediates 2369
Iminothioether
route to 5-thioabbeymycin 743
Immunophilin
FKBP12, affinity of excised binding domain FK-506 1947
Immunostimulants
pyrazolo[3,4-*f*]quinolines, SAR side-chain investigation, formation, injection site toleration 1379
Immunosuppressants
C21 derivs of FK-506, T-cell proliferation assay 657
KH-1060, new CD sython, X-ray structure related cholesterol deriv 341
Inactivation
human leukocyte elastase by cephem sulfones, β-lactam enzymatic and chemical cleavage 2259, 2265
monoamine oxidase B by aminoethyl 3-chlorobenzyl ether 2077
Indoles
derivs, potent, selective serotonin uptake inhibitors 1913
Indolocarbazoles
non-glycosidic lacking aminoalkyl side chain, PKC inhibitors 1959
related to K-252c, synthesis protein kinase inhibition 1537
Influenza A virus
hemagglutination inhibition by methyl α-sialosides N-substit alkanoyl groups 747
Ingenol
analogs with protein kinase C affinity 577
Inhibition
1,3-β-glucan synthesis, pneumocandin antifungal lipopeptides, phenolic OH required 2039
2,3-oxidosqualene cyclase by N-alkylpiperidines 1175
acetylcholinesterase:
  activity of velnacrine 1-substit analogs 2789
  by N-2 methylated quaternary derivs β-carboline-3-carboxylates 2831
activity optically active 2-benzyl-3-mercaptopropanoic acid against carboxypeptidase A 2681
antennal esterases *Spodoptera littoralis* by trifluoromethyl ketones 2593
antifungal activity of squalene synthase, SAR of C6 and C7 modifications squalestatin 2605
β-lactamase, activity of 6-hydroxyethyl thiaclavulanic acid 2255
blood platelet aggregation by 3-oxa-methano-PGI_1 2821
borate, serine protease mimic, boric acid hydrolysis 4-nitrophenyl 2,3-dihydroxybenzoate 635
cell growth, phakellistatin 2 2869
cyclooxygenase, 5-lipoxygenase, activity of 2,6-di-*t*-butylphenols linked by S-atom to 1,3,4-thiadiazoles and 1,3,4-oxadiazoles 2827
glycosidase, by α-homofuconojirimycin 2533
hemagglutination, influenza A virus by methyl α-sialosides N-substit alkanoyl groups 747
HIV-1 protease by its C- and N-terminal peptides 765
human leukocyte elastase:
  by 6-alkyl substit penem benzyl esters 2277
  by 6-substit penicillin esters or amides 2277, 2289

mammalian topoisomerase II, structure relationship to bridged (2,6-dimethyl-4-pyridinyl)-quinolones 1711
myristoylation processes by sulfoximine-modified myristic acid analogs 1717
phosphodiesterase IV by benzopyran derivs of rolipram 1743
protein kinase, indolocarbazoles related to K-252c 1537
PtdIns-3'-kinase, synthesis D-3-deoxy-3-phosphonomethyl-*myo*-inositol and dimethyl ester 1323
S-adenosyl-L-homocysteine hydroxylase, (*E*)- and (*Z*)-5'-fluoroolefin carboxylic nucleosides 165
squalene synthetase, activity tripotassium 1-methyl-1-[(*N*-benzyl-*N*-farnesyl)-aminoethylphosphinato]phosphonate 2051
Inhibitors
ACAT, *N,N*-diphenyl ureas 259
achiral 5-lipoxygenase using cyclobutyl group, design, synthesis 2565
acyl-CoA:cholesterol acyltransferase, substit *N,N'*-diphenylureas 259
affinity probes GABA-gated chloride channel 2671
amide-linked N-hydroxyurea 5-lipoxygenase, synthesis intramolecular O to N acyl transfer 305
aspartic protease HIV-1 and hexapeptide, complexation energy including effect of solvation 2105
β-glucan biosynthesis, isolated from fungi, hyphal malformation inducer 1219
β-lactamase:
  approach via 2β-(heterocyclylthiomethyl)-penams 2247
  substit 6-alkyloxapenems, synthesis, characterization 2205
cephalosporinase, 2-substit penems a possibility 2253
collagenase, synthesis aminoazalactams as cyclic mimetics of basic alkyl amino acids 2537
conformationally restricted acyl-CoA:cholesterol acyl transferase, N-oleoyl 1,2,3,4-tetrahydroisoquinolines 571
conformationally enriched, high affinity glutamate transporter 115
designing dehydroquinate synthase, structural simplicity versus inhibitory potency 1403
diamine oxidase, synthesis imidazoyl allylamines, propargylamines 353
dideazatetrahydrofolic acid, biological activity by replacement either 2-amino or 4-oxo groups by H 2657
dimeric penicillin derived, HIV-proteinase, interaction with catalytic aspartates 503
dual 5-lipoxygenase and cyclooxygenase, oxazole, thiazole and imidazole derivs of 2,6-di-*t*-butylphenol 1729
dual proteinase, unsymmetrical bis-terephthalamides 525
ecdysone biosynthesis, synthesis of ecdysteroid 1951
E. coli EPSP synthase, synthesis, characterization *N*-amino-glyphosate as analog 2863
elastase, containing conformationally restricted lactams as P_3–P_2 dipeptide replacements 773
enzyme activated, irreversible, decarboxylated of S-adenosylmethionine decarboxylase 2811
estrone sulfatase synthesis estrone 3-methylthiophosphonate 313
galactosyl transferase 1747
gem-cycloalkyl thiols, neutral endopeptidase 24.11, synthesis via opening 2,2-spiro-β-lactones 825
glutamyl-tRNA synthetase, synthesis 2699
Herpes simplex thymidine kinase, (2*R*,4*S*,5*S*)-1-(tetrahydro-4-hydroxy-5-methoxy-2-furanyl)-thymine 1571
heterocyclic, human leukocyte elastase, 3-hydroxypyridazopyrimidine, 3-hydroxypyridopyrimidine, 3-hydroxyquinazoline-2,4-(1*H*,3*H*)dione derivs 1163
HIV:
  phosphate derivs d4T 1203
  synthesis R82150 related 1-(2-aminopropyl)-benzimidazoles 543
HIV protease:
  difluorostatone type 253
  low mol wt, difunctional enols N-protected amino acids 1169
  synthesis, evaluation 1595
HIV proteinase, design, synthesis hydroxyproline 1485
human leukocyte elastase by phthalimide deriv 2745
human prostatic steroid 5α-reductase, synthesis evaluation 3-carboxymethyl steroids 1735
human renin, diol sulfonamides 2739
human type 1,5-α-reductase, QSARs benzoquinolines 1157
interleukin-1β converting enzyme, evaluation peptidyl 2,2-difluoro-4-phenylbutyl ketone 2693
leukotriene, justicidin E 2063
monocyclic β-lactam of human leukocyte elastase, stereospecific synthesis, activity 3,4-disubstit 2-azetidinones 2295
non-reducible for trypanothione reductase from *Trypanosoma cruzi* 1971
non-hydrolysable, *myo*-inositol monophosphatase, 4-hydroxyphenoxymethylene bisphosphonic acid derivs 141
non-nucleoside HIV reverse transcriptase mutations, structural analysis 721
nonpeptide HIV protease, designed to replace a bound water 2717
penicillin sensitive enzymes, cyclopentenone potential 2309
peptidomimetic:
  human HIV protease, design, enzyme binding and selectivity, cell permeability 819
  renin incorporating topographically modified isosteres spanning $P_1 \rightarrow P_3$-P_1' sites 2119
phospholipase A_2, oxazolidinone phospholipid analog 2703
protein kinase C, non-glycosidic/non-aminoalkyl substit indolocarbazoles 1959
protein phosphatases conserved acid binding domain model 1029

pseudo-symmetrical HIV-1 protease, structure–activity 1589
pseudosymmetric, of HIV-1 protease 2837
pseudosymmetric HIV proteinase, synthesis 1,3-diamino-2-hydroxypropane derivs 535
reversible, phenylalkyl ketones for interleukin-1β converting enzyme 2689
S-adenosyl-L-homocysteine hydroxylase, prep carbocyclic tubercidin deriv 663
S-adenosylmethionine decarboxylase, restricted rotation analogs S-adenosylmethionine 147
scytalone dehydratase, 6-membered H-bonded array replaced by diazine heterocycle 1605
serine proteinases, design, mechanism-based 2745
serotonin uptake, indole derivs 1913
squalene synthase:
aromatic isosteres of farnesyl chain 595
optimal C1 chain-length requirements 2527
role tricarboxylic acid moiety 2541
structure-directed discovery, binding HIV GP120 to CD4 receptor 2851
thiol, hydroxamic acid, of endothelin-converting enzyme 1953
transition state analogs, acetylcholinesterase, *m*-alkyl-α,α,α-trifluoroacetophenones 2619
trisnorsqualene methyl hydroxylamine, dual, mammalian squalene epoxidase, oxidosqualene cyclase 1319
tubulin polymerization, centaureidin cytotoxic flavone from *Polymnia fruticosa* 581
***myo*-Inositol**
4,5-diphosphate, synthesis 4,5-diphosphonate analog 685
1,2,4,5-tetrakisphosphate, Ca^{2+} potency similar to 1,4,5-trisphosphate deriv 1505
1,4,6-trisphosphate, synthetic Ca^{2+}-mobilizing inositol phosphate 2599
3,4,5-trisphosphate and 1,3,4,5-tetrakisphosphate, syntheses 717
D-3-deoxy-3-phosphonomethyl deriv and dimethyl ester, PtdIns-3'-kinase signalling pathway study 1323
(±)-octadecylphosphodithionly, synthesis, cytotoxicity 1931
monophosphatase inhibitors, 4-hydroxyphenoxymethylenebisphosphonic acid 141
Inositol
monophosphate substrates, structural requirements 1925
Inotropic agents
2-arylimidazo[1,2-*a*]pyrazines, synthesis and pharmacology BW315C 509
active conformation 6-amino-α-(4-diphenylmethyl-1-piperazinyl)methyl-9*H*-purine-9-ethanol 1233
Insertion reactions
Rh-catalysed, C–H in α-diazo amides, prep β-lactams 2409
Interesterification
regioselectivity, lipases in organic solvents 585
Interleukin-β
coverting enzyme inhibitor, evaluation peptidyl 2,2-difluoro-4-phenylbutyl ketone 2693
phenylalkyl ketone reversible inhibitors 2689
Internucleosides
modification O-PO_2^--O linkage by CH_2-CH_2-NH or NH-CH_2-CH_2 linkages 2771
Intestines
permeability and hepatic handling of peptidomimetic analogs 813
Iron
binding oligonucleotides, synthesis, reactions with single-stranded DNA 1367
Isatin oximes
non-NMDA bioavailable antagonists 105
Isocephems
arylogous *vs* vinylogous isocephems 2231
vinylogous *vs* arylogous 2231
Isochorismate
enzymatic formation of isoprephenate 1441
Isocyanates
trichloroacetyl deriv, 2+2-cycloaddition to furanoid glycals 2403
Isohumulone
trans, binding K^+ presence divalent and trivalent cations 769
Isomazole analogs
SAR, non-toxic inotropic agents 509
Isoprephenate
enzymatic formation from isochorismate 1441
Isoquinoline carboxylic acid
enantiomers 1,2,3,4-tetrahydro-5-(2-phosphonoethyl)-3-deriv, anticonvulsant NMDA antagonist 39

Janus compds
unsymmetrical bis-terephthalamides, dual proteinase inhibitors 525
Jasmolactone
(*R*) γ biogeneration by *Pichia stipitis* 2777
Justicidin E
leukotriene inhibitor 2063

K-13
OF4949, key analogs, angiotensin I converting enzyme, aminopeptidase B inhibition 245
Kappa
opioid receptor agonist binding model, design, synthesis kappa opioid ligands 841
KC-399
synthesis, benzopyran K^+ channel opener, action duration with less tachycardia 2005
KDO8P synthase
mechanism, isoteric phosphonate mimic of putative cyclic intermediate, synthesis, evaluation 1583
stereochemistry, synthesis 3-fluoro analogs of KDO8P 1577
Ketones
biotinylation, darglitazone biotin conjugate protocol 703
phenylalkyl, reversible inhibitors interleukin-1β converting enzyme 2689
trifluoromethyl, inhibition *Spodoptera littoralis* antennal esterases 2593

Ketosterols
chemical synthesis 1339
KH-1060
new CD synthon and X-ray evidence unique side-chain geometry 341
Kidney
1,25$(OH)_2$16-ene D_3 metabolism, effect of D-ring modification on side-chain metabolism 1879
Kinase bypass
strategy anti-HIV drug design 1207
Kinetic resolution
p-hydroxyphenyl acetamides, hydrolysis with Pen-G acylase 1041
Klebsiella pneumoniae
production of [2,6,9^{13}C] and [1,3,5,8^{13}C] chorismate 1453
synthesis and testing of substit phenylthioribose analogs 2079
KT2-962
TXA_2 non prostanoid receptor antagonist, sulfonamide moiety modification and activity 1687

Lactamase
β-immunoconjugate, release of doxorubicin from cephalosporin based prodrug 323
inhibitors:
activity 6-hydroxyethyl thiaclavulanic acid 2255
approach via 2β-(heterocyclylthiomethyl)-penams 2247
substit 6-alkyloxapenems, synthesis, characterization 2205
serine, catalysed reactions, mechanism 2317
Lactams
4.2.0 fused, via ring closure substit azetidinones 2443
3,4-dialkyl-deriv, α,β-disubstit-aspartates, stereo-selective synthesis 2461
α-vinyl and α-alkyl, stereocontrolled synthesis 2363
ACC, aminocyclopropane-1-carboxylic acid, synthesis 2423
antibacterials, QSARs of heteroatom substit 3-isopropylidene and 3-isopropyl analogs of N-acyl, 3-alkylidenyl- and 3-alkyl-azetidin-2-ones 2241
antibiotics:
chemistry, biology 2157
synthesis penem dithiocarbamates 2159
chemical and enzymatic cleavage, human leukocyte elastase inactivation by cephem sulfones 2259, 2265
conformationally restricted as P_3–P_2 dipeptide replacements in elastase inhibitors 773
conversion to γ compds, synthesis γ-lactam analogs penam and penem antibiotics 2299
derivs from 1-*H*-1,2-diazepines 2375
enantiomerically pure via chiral ligand accelerated osmylation rac-4-(2-styryl)-azetidin-2-ones 2397
from chirally-enriched (allenymethyl)silanes 2405
fused bicyclic, synthesis prototype $\Delta^{1,6}$-1-carbacephem-4-carboxylic acid deriv 2439
γ, homologs of penems 2303
monocyclic inhibitors, of human leukocyte elastase, stereospecific synthesis, activity [3,4]-disubstit 2-azetidinones 2295
N-acyl-3-hydroxy-deriv, key intermediate for taxotere and analogs 2479
N-hydroxy deriv, conversion to carbacephem precursor 2431
stereocontrolled synthesis carbapenem intermediates using 1,3-iminoketone synthons 2369
stereospecific synthesis 2357
tricyclic bridged, transition state analogs, semi-empirical molecular orbital study 2329
unsat amides prep via *N*-[[(chlorosulfinyl)oxy]-methylene]-*N*-methylmethanaminium chloride 2419
via photo-ring contraction pyrazolidin-3-ones 2383
via Rh-catalysed C–H insertion of α-diazo amides 2409
via transformation chiral vinylaziridine, enantioselective route to carbapenem (+)-PS-5 2415
via Zn-mediated condensation imines with amino acid esters 2351
with 3-(1'-hydroxyethyl) substituents, asymmetric synthesis 2337
Lactones
α–alkyl-γ-derivs, interaction with protein kinase C 1101
α-alkylidene-γ-, interaction with protein kinase C 1107
antibacterial activity C-3-lactonyl substit cephalosporins 2219
diphenyl, inhibitor GP120 binding to CD4 receptor 2851
Leukemia
myelogenous cell line, metabolism, activity 1,25$(OH)_2D_2$ and metabolites 1873
Leukocyte elastase
human, inhibition by phthalimide deriv 2745
Leukocytes
human elastase:
heterocyclic inhibitors, 3-hydroxy-pyridazopyrimidine, 3-hydroxypyrido-pyrimidine, 3-hydroxyquinazoline-2,4-(1*H*,3*H*)dione derivs 1163
inactivation by cephem sulfones, β-lactam chemical and enzymatic cleavage 2259, 2265
inhibition:
by 6-alkyl substit penem benzyl esters 2277
by 6-substit penicillin esters or amides 2277, 2289
by phthalimide deriv 2745
monocyclic β-lactam inhibitors, stereospecific synthesis, activity 3,4-disubstit 2-azetidinones 2295
Leukotriene
B_4, receptor antagonists, diaryl ether/carboxylic acid derivs of LY255283 1985
inhibitor, justicidin E 2063
receptor antagonists, synthesis pharmacology hydroxyacetophenone substit benzophenone/xanthone 1981

Lexitropsin
bleomycin carriers incorporating metal-complexing moiety, design DNA-cleaving mols 1751
Libraries
combinatorial synthetic peptides, for detn peptide ligands in radio-receptor assays 405
dipeptide, screening at peptide receptor sites 799
large random peptide, screening ligands for macromolecular acceptors 419
oligonucleotide, peptide sequences, structure–activity analysis 425
peptide, chemical synthesis 413
synthesized peptides, screening for biologically relevant molecules 397
Lipase
catalysed deacetylation, benzyl phenyl ketone peracetates in organic solvents 585
porcine pancreatic, catalysed-hydrolysis bicyclo-[3.2.0]hept-2-en-6-ol esters 357
resolution, effect of aryl fluorines 1655
Lipolase
catalysed ester hydrolysis, enantioselective prep bicyclo[3.2.0]heptane derivs 359
Lipopeptides
pneumocandin antifungal, inhibition of 1,3-β-glucan synthesis, phenolic OH required 2039
Lipoxygenase
achiral using cyclobutyl group, design, synthesis as inhibitors 2565
cyclooxygenase, dual inhibitors, oxazole, thiazole and imidazole derivs of 2,6-di-*t*-butylphenol 1729
Liver
intestinal permeability and hepatic handling renin inhibitor analogs, rats 813
Losartan
radioligands angiotensin II, synthesis [^{3}H]-L-158641 and [^{3}H]-L-158809 557
Lovastatin
mouse metabolites synthesis 2755
LTD_4
antagonists in styrylquinoline class 1125
receptor antagonism, effect of 1,2,4,5-substit hydroxyacetophenones with acid unit modification 1147
LY255283
diaryl ether/carboxylic acid derivs, LTB_4 receptor antagonists 1985
LY300020
AMPA receptor agonist 95
L-*trans*-4-tetrazolylproline
Lysine
N_α-Fmoc-N_ε-Nvoc-deriv, use in synthesis selectively functionalized peptides 707

Macrocycles
18-membered pyridine bases diamide-diester of Ag, synthesis, ionophore character 363
Macromolecular acceptors
screening ligands large random peptide libraries 419
Malonate ethers
3-phosphate mimic, substrate and inhibitor binding to S3P site of enzyme 1453
Mass spectrometry
electrospray, Edman degradation, sequence analysis peptide pools 431
electrospray ionization, vit D derivs 1805
MC1357
20-*epi*-23-oxa-1α,25-dihydroxy vit D_3, synthesis evaluation 1845
MC 903
side chain triple bond analog calcipotriol, 1α,24*S*-dihydroxy-[26,27]-cyclo-22-yne vit D_3 1841
Mechanisms
KDO8P synthase, isosteric phosphonate mimic of putative cyclic intermediate, synthesis, evaluation 1583
nonphotochemical production vit D_3 in biological systems 1785
serine β-lactamase catalysed reactions 2317
tetrazole-tethered, cephalosporin-quinolone hybrid 209
Mercaptotriazoles
bisbiphenylyl substit, angiotensin II receptor antagonists 375
Metabolic stability
myristic acid analogs as anti-HIV agents 779
Metabolism
1,25$(OH)_2$16-ene D_3 in kidney, effect of D-ring modification on side chain metabolism 1879
activity 1,25$(OH)_2D_2$ and metabolites in myelogenous leukemia cell line, RWLeu-4 1873
Metabolites
catechol dilevalol, synthesis 2073
clavam and clavulanic acid, shared biosynthetic pathway 2313
lovastatin, simvastatin, mouse, synthesis 2755
receptor antagonists of OPC-21268, 1633
Metalloimines
ester-enolate cycloaddition, synthesis (+)-1β-methyl PS-5 2347
Metallopeptide
DNA-cleaving, design, synthesis 333
Methano-PGI_1
3-oxa deriv, inhibition blood platelet aggregation 2821
Methanophenylalanine methyl esters
synthesis, prep and binding affinities cyclopropyl dipeptides 667
Methicillin
resistant *Staphylococcus aureus*, activity of penems 2165
Methyl 3-dehydroquinate
addition of amines 1447
Methyl 3-dehydroshikimate
addition of amines 1447
Methyl purple
basis for chromogenic β-galactosidase substrate 175
Methylation
MDL 100,453, synthesis competitive NMDA receptor antagonists 23

Methylcarbapenems
1β-2-functionalized-vinyl deriv, synthesis, antibacterial activity 2199
1β-, stereoselective route to key intermediate carboxylic acid 2389
α-Methylene-γ-butyrolactone
linear, angular psoralen, anti-proliferative compds 1283
Methylphosphonothioates
oligodeoxynucleosides synthesis 761
α-Methyltryptophan
α,β-didehydrotryptophan surrogate, CCK 'peptoids' related CI-988 989
Mimetics
dipeptide, biologically active peptide azoles 915
nonpeptide β-turn, enkephalin 835
Mineralization
bone loss, prevention, therapy with 2β-(3-hydroxypropoxy)-1α,25-dihydroxy vit D_3, ovariectomized rats 1815
Models
conserved acid binding domain, inhibitors protein phosphatases 1029
molecular, refinement, discovery non-peptide angiotensin II antagonists 909
pharmacophore, design potassium channel openers 625
Molecular design
dopamine autoreceptor agonists 1477
Molecular diversity
generation 387
Molecular modelling
semiempirical calculations, vit D_3 analogs, conformation disubstit side chain 1795
Molecular orbitals
semi-empirical method, study tricyclic bridged β-lactams as transition state analogs 2329
Monoamine oxidase B
selective inactivation by aminoethyl 3-chlorobenzyl ether 2077
Monocyclization
N-(2,2-diethoxyethyl)-1,2-diphenylethyl amines to 4-aryl-1-hydroxy-2,3,4,5-tetrahydro-1*H*-3-benzazepine ring system 251
Monophosphates
β-substit series, isosteric replacement, Ca channel antagonists 2817
Monosaccharides
peracetylated methyl glycopyranosides, *Aspergillus niger* lipase deacetylation secondary acetyl esters 2125
Muscle relaxants
activity 2-substit 6-nitro-2*H*-1-benzopyran-4-carbothioamide 2627
Mutagenesis
5-formyl-2'-deoxyuridine incorporation into oligideoxyribonucleotide 2751
site directed and limited proteolysis, NF-κB p50 DNA-binding subunit 1095
Mycobacterium fortuitum
glycopeptidolipid, synthesis structurally variant complete glycotetrapeptide core 697
Myelogenous leukemia cell line
RWLeu-4, metabolism, activity $1,25(OH)_2D_2$ and metabolites 1873
Myristic acid
analogs with anti-HIV activity resistant to metabolic processing by β-oxidation 779
sulfoximine-modified analogs, synthesis, activity 1717

Naphthalimides
4-alkylamino-3-bromo-*N*-1,8-derivs, antiviral photoinactivators 555
Netropsin
analogs, monocationic tryptophan linked, synthesis, DNA binding 2623
antitumor agents containing nitroarenes, synthesis 1697
Neural networks
back-propagation, use variable selection in QSARs 645
use quantitative structure–activity study, aromatic and heteroaromatic nitro compds 329
Neurokinin A
antagonist SR 48968, synthesis 319
low mol wt antagonists 931
receptor, non-peptide antagonists, pharmacology and synthesis SR 48968 925
Neuropeptide Y
Y_2-selective reduced size agonists 937
Neurotensin
C-terminal pentapeptides, amide bond modified stable isosteres 1035
receptor binding, antinociceptive activity for lipophilic N_α-amido neurotensin analogs 2055
simpler analogs with antinociceptive activity 1767
structure–affinity amino acid side-chains, N and C terminal deletions and Ala-scan 949
Nevirapine
complexed HIV reverse transcriptase, crystal structure 721
NF-κB
p50 DNA-binding subunit, limited proteolysis and site directed mutagenesis 1095
Nitro aromatic and heteroaromatic compds
quantitative structure–activity study using neural network 329
Nitrophenylphosphonate
specific catalytic antibody 48G7, active site via spin-labelled haptens 285
NK-1
quinuclidine based antagonists, absolute stereochemical requirements 1703
NMDA
AMPA, glycine-site antagonists, sulfonyl derivs 6,7-dichloro-3,4-dihydro-3-oxo-quinoxaline-carboxylate 77
antagonists:
2-carboxyl prodrugs 5,7-dichlorokynurenic acid 61
2-quinolone derivs as glycine-site *N*-methyl D-aspartate receptor 299
noncompetitive activity conformationally constrained 4a-phenanthreneamine derivs 49
oxindole *N*-methyl-D-aspartate 91

spiroisoindolines, noncompetitive activity, synthesis 55
trans-2-carboxy-4-substit tetrahydroisoquinolines 65
competitive antagonists:
1,2,3,4-tetrahydro-5-(2-phosphonoethyl)-3-isoquinolinecarboxylic acid 39
receptor (*R*)-4-oxo-5-phosphononorvaline structure–activity 23
synthesis β-ketophosphonate substit piperidine carboxylic acid derivs 19
synthesis (2*R*,4*R*,5*S*)-2-amino-4,5-(1,2-cyclohexyl)-7-phosphonoheptanoic acid 27, 33
tetrazole amino acids 43
unusual stereochemical preferences of decahydroisoquinoline-3-carboxylic acid 2067
receptors:
complex, rat brain, interaction with rigid polyamine analogs 85
glycine-site partial agonists HA-966 71
ligand interactions 9
NMR
characterization of 2,6,9,^{13}C and, 1,3,5,8,^{13}C chorismate 1453
conformational analysis N-acyl urea containing valine residue in DMSO d_6 153
stereochemistry protein farnesylation 281
NOTA
DOTA aminobenzyl derivs macrocyclic bifunctional chelating agents for antibodies labeling 1067
NPC 17742
active constituent of NPC 12626 27, 33
Nucleic acids
minor groove, introduction lipophilic thioether tether for antisense applications 2765
Nucleosides
4'-hydroxy and 4'-fluoro-carbocyclic-2'-deoxyguanosines, anti-viral activity 2577
1,3-oxathiolane analogs anti-HIV agents 1723
achiral inter-linkages CH_2-CH_2-NH and NH-CH_2-CH_2 linkages 2771
adenosine receptor agonist with 6-hydrazinopurine moiety 2661
analogs with [1,5]-anhydrohexitol moiety, synthesis 1013
imidazo[4,5-*c*]azepine, design, synthesis 183
inhibitors S-adenosyl-L-homocysteine hydroxylase, prep carbocyclic tubercidin deriv 663
monophosphates cytosolic delivery, SATE and DTE enzyme-labile phosphate protecting groups 2521
mutagenic 5-formyl-2'-deoxyuridine, incorporation into oligodeoxyribonucleotide 2751
purine, enzyme-cleavable amino-protection by phenylacetyl group 2781
Nucleotide analogs
purine dioxolanes, optically pure, antiviral activity 1543
Octadecylphosphodithionyl-1-*myo*-inositol
synthesis, cytotoxicity 1931
OF4949
K-13, key analogs, angiotensin I converting enzyme, aminopeptidase B inhibition 245
Olefin oxazoles
synthesis thromboxane A_2/endoperoxide antagonists 1267
Oligodeoxynucleosides
synthesis methylphosphonothioates 761
Oligodeoxyribonucleotides
containing N^7-(2-deoxy-β-D-*erythro*-pentafuranosyl)adenine 273
disulfide cross-linked, chemical sequencing 2117
incorporation of mutagenic 5-formyl-2'-deoxyuridine 2751
Oligonucleotides
diversity and drug discovery, proteins epitope targeting 469
generation molecular diversity 387
incorporated 2'-deoxyuridine analog with amino-alkyl tether at 1'-position sugar moiety, duplex formation, intercalating group attached to amino group 615
incorporation N-substit guanidine linked nucleoside dimers 193
iron-binding, synthesis, reactions with single-stranded DNA 1367
peptide sequence libraries structure–activity analysis 425
solid phase synthesis amino(2-aminoethyl)-2'-deoxyadenosine incorporation into DNA 689
synthesis, evaluation by gel-phase ^{31}P-NMR analytical tool 2793
synthesis via phosphoramidite approach, use of diphenylmethylsilylethyl protecting group 2637
with puromycin at 3'-terminal, solid phase synthesis 1371
OPC-21268
N-acetylhemiaminal metabolites of vasopressin V1 receptor antagonists 1633
Osmylation
rac-4-(2-styryl)-azetidin-2-ones, prep enantiomerically pure β-lactams 2397
Osteoblast differentiation
developmental control cell growth and tissue-specific gene expression, effect of vit D analogs and 1,25$(OH)_2D_3$ 1885
Osteoporosis
ovariectomized rats, bone mineral loss, prevention, therapy with 2β-(3-hydroxypropoxy)-[1α,25]-dihydroxy vit D_3 1815
Oxapenem-3-carboxylic acid
(1'*R*,5*R*,6*R*)-2-*t*-butyl-6-(1'-hydroxyethyl) deriv, synthesis, antibacterial activity 2211
Oxapenems
substit 6-alkyl derivs, synthesis, characterization β-lactamase inhibitors 2205
Oxatetradecanoic acid
analogs, anti-viral activity, metabolic stability 779
Oxathiolane
nucleoside analogs anti-HIV agents 1723
pyrimidine nucleoside fcactivity, anti-hepatitis B, anti-immunodeficiency viruses 693

1,4-Oxazepines
6-amino-5-oxo-7-phenyl derivs, conformationally constrained *gauche* (–)- dipeptide mimetics 231
Oxazoles
thiazole and imidazole derivs of 2,6-di-*t*-butylphenol, dual inhibitors of lipoxygenase, cyclooxygenase 1729
Oxazolidinones
phospholipid analog, phospholipase A_2 inhibitor 2703
Oxetane nucleoside
antiviral agent 1061
Oxidation
Baeyer–Villiger, cyclization bisfuran ring formation, aflatoxin B_1 biosynthesis 653
Oxidosqualenes
2,3-analogs, biocyclisation by sterol cyclase 365
6,7- and 10,11-derivs, epoxidation by squalene epoxidase rat liver microsomes 2581
cyclase inhibition by *N*-alkylpiperidines 1175
cyclase, mammalian squalene epoxidase, trinorsqualene methyl hydroxylamine inhibitor 1319
Oxindole
NMDA antagonists 91
Oxytocin
non-peptidic receptor antagonists from natural sources 337

PAF
antagonists, bicyclic thiazolidine, synthesis 2729
Palladium
catalyzed synthesis phenyl substit $PGF_{2\alpha}$ analogs, antiglaucoma agents 241
Papain
modified by thiazolium salts, C–C bond formation 531
PD 134365
noncompetitive NMDA antagonist 49
PD 135385
autoreceptor dopamine enantiomer agonist, synthesis, evaluation 639
Penams
2β-(heterocyclylthiomethyl)-deriv, approach to β-lactamase inhibitors 2247
antibiotics, synthesis γ-lactam analogs, conversion β-lactams to γ-lactams 2299
Penems
2-substit, possible cephalosporinase inhibitors 2253
activity against defined MRSA strains 2165
amino acid derived substituents at C-2 2177
antibiotics:
  stereoselective synthesis and Sch 34343 syntheses 2171
  synthesis γ-lactam analogs, conversion β-lactams to γ-lactams 2299
benzyl esters, 6-alkyl deriv, inhibition human leukocyte elastase 2277
catechol bearing, synthesis, antibacterial activity 2183
dithiocarbamates, synthesis 2159
γ–lactam homologs 2303
Penicillide
source of non-peptidic oxytocin receptor antagonists 337
Penicillin
6-substit esters or amides, inhibition human leukocyte elastase 2277, 2289
acylase, hydrolysis *p*-hydroxyphenyl acetamides 1041
dimeric derived inhibitors of HIV-proteinase, interaction with catalytic aspartates 503
sensitive enzymes, cyclopentenone potential inhibitors 2309
side-chain binding site, Tipper–Strominger hypothesis 2323
Pentamidine congeners
synthesis *cis*- and *trans*-butamidine analogs, anti-*Pneumocystis carinii* pneumonia agents 1137
Pentapeptides
C-terminal, neurotensin amide bond modified stable isosteres 1035
Peptides
acylated palmitic acid at cysteine thiol, synthesis 1025
analogs, binding to vancomycin antibiotics, free energy cost restricting bond rotation 803
bioavailability improved by conjugation δ-opioid agonist to β-cyclodextrin 831
bond cleavage protection against α-chymotrypsin by prodrugs 809
bond formation, s-l' subsite alcalase catalysed, selectivity in anhydrous BuOH 727
C- and N-terminal, HIV-1 protease inhibition 765
C-terminal antagonists, endothelin structure activity ET-1[16-21, D-His^{16}] 497
cyclization on TFA labile resin using trimethylsilyl ester as orthogonal protection 437
D-amino acid ester incorporation catalysed by alcalase in *t*-BuOH 539
generation molecular diversity 387
large random libraries, screening ligands for macromolecular acceptors 419
libraries:
  chemical synthesis 413
  with non-natural amino acids, identification antibody mimotopes 463
  multipin synthesis, technique peptide receptor binding, substance P model 447
pools, sequence analysis, electrospray mass spectrometry, Edman degradation 431
proteins crosslinking, synthesis cysteine homologs 739
receptor sites, screening, dipeptide library 799
selective for cholecystokinin-B receptor, bioactive conformation 2011
selectively functionalized, synthesis, use N_α-Fmoc-N_ε-Nvoc-lysine 707
synthesis substance P-diastereomers using cellulose-based carriers 441
synthesized, screening libraries for biologically relevant molecules 397
synthetic, combinatorial libraries, detn peptide ligands in radio-receptor assays 405
thioamide linkage incorporation, prep 4 monothiothymopentin analogs, biological activity 619

Peptido-leukotrienes
antagonist, BAYx7195 1517
Peptidomimetics
analogs, intestinal permeability and hepatic handling, rats 813
backbone amide bond replacement in tetrapeptide based CCK-A receptor agonists 855
CCK-B, systemically active, selective compds, structure-based design and pharmacology 847
inhibitors, human HIV protease, design, enzyme binding and selectivity, cell permeability 819
Peptidyl-[2,2]-difluoro-4-phenylbutyl ketone
inhibitor interleukin-1β converting enzyme, evaluation 2693
Peracetylated
benzyl phenyl ketones, lipase catalysed deacetylation in organic solvents 585
$PGF_{2\alpha}$
phenyl substit analogs, antiglaucoma agents 241
PGI_1
3-oxa-methano derivs, synthesis, biological properties 2821
Phakellia carteri
phakellistatin 2, isolation and structure 2869
Phakellistatin 2
structure, isolation from *Phakellia carteri* 2869
Pharmacology
8-OH-DPAT effect of substit aromatic ring 2035
dopamine autoreceptor agonists 1477
NPC 17742, selective, competitive NMDA antagonist 33
ω-tetrazole acyclic α-amino acids and 4-(tetrazolylalkyl)-piperazine-2-carboxylic acids, NMDA antagonist 43
Pharmacophore model
design potassium channel openers 625
Phenacetin-[2,2,2]-trifluoroethoxy deriv
resistance cytochrome P-450 metabolism rat liver microsomes with NADPH 179
Phenalene
analogs of U-50,488 kappa opiate agonist 2641
Phenanthreneamines
noncompetitive NMDA antagonist PD 134365 49
Phenylacetyl group
enzyme-cleavable amino-protection of purine nucleosides 2781
Phenylphosphonate monoester analogs of cocaine
potential haptens, generation catalytic antibodies 309
Phenylthioribose
substit analogs, synthesis and testing against *Klebsiella pneumoniae* 2079
Pheromones
synthesis biologically active chlorinated analog codlemone 1629
Phosphates
derivs of d4T, inhibitors HIV 1203
groups:
  ligand binding at shikimate-3-phosphate site 1453
  mimics, identification of 3-malonate ethers 1453
  protecting, SATE and DTE enzyme-labile 2521
limitation, response to aromatic pathway plant suspension cell enzymes 1415
water soluble prodrugs of taxol with *in vivo* antitumour activity 1761
Phosphite triester
method, gel-phase ^{31}P-NMR, evaluation synthesis oligonucleotides 2793
Phosphodiester
triester derivs AZT with tethered *N*-methyl and *N,N,N*-trimethylethylenediamine 1547
Phosphodiesterase
inhibition by benzopyran derivs of rolipram 1743
Phosphoenolpyruvate
phosphoramidate analog, chemical–enzymatic synthesis 1615
Phospholipase A_2
inhibitor oxazolidinone phospholipid analog 2703
Phosphonates
thiophosphonate analogs of estrone sulfate with competitive inhibition of estrone sulfatase 313
Phosphono-1-carba-1-dethiacephalosporins
antibacterial activity 2237
Phosphonoalkynyloxypurines
acyclonucleotides, synthesis antiviral activity 2611
Phosphononorvaline
(*R*)-4-oxo-5-deriv, structure–activity 23
Phosphoramidate
analog phosphoenolpyruvate, chemical–enzymatic synthesis 1615
Phosphorothioate
analogs, complementary to HIV sequences, physicochemical properties anti-HIV activity 1223
Phosphotriester
method, gel-phase ^{31}P-NMR, evaluation synthesis oligonucleotides 2793
Photoaffinity labelling
reagent for HIV-1 reverse transcriptase 1681
Photoinactivators
antiviral 4-alkylamino-3-bromo-*N*-1,8-naphthalimides 555
Photoprotein
chromophore *Symplectoteuthis* bioluminescence, structure, binding form 2647
non-Phototoxicity
double-headed mols based on linear, angular psoralen and α-methylene-γ-butyrolactone 1283
Phthalimide
deriv, inhibition human leukocyte elastase 2745
Pichia stipitis
biogeneration of (*R*)-γ-jasmolactone 2777
Piperidine carboxylic acids
synthesis β-ketophosphonate substit derivs 19
Pivaloyloxymethyl ester
prodrug, oral activity 2193
PKC
binding affinity, conformationally constrained analogs of diacylglycerol 1993
PKC inhibitors
non-glycosidic indolocarbazoles lacking amino-alkyl side chain 1959

Platelet activating factor
cyclic ether acetal receptor antagonists, 3-pyridyl derivs 1493, 1499
histamine, dual antagonists, prep series pyridine ring substit compds 1073
Platinum
catalysed diastereoselective addition, secondary alcohols to acyloxyazetidinones 2393
catalysed transformation chiral vinylaziridine to β-lactam, enantioselective route to carbapenem (+)-PS-5 2415
Pneumocandin
antifungal lipopeptides, inhibition of 1,3-β-glucan synthesis, phenolic OH required 2039
Polyamides
HL-60 cell differentiation assay 1965
Polyamines
rigid analogs, interaction with rat brain rigid NMDA receptor complex 85
Polymerization
inhibitor tubulin, centaureidin cytotoxic flavone from *Polymnia fruticosa* 581
Polymnia fruticosa
cytotoxic flavone centaureidin, inhibitor tubulin polymerization 581
Polyoxin D
degradation uracil polyoxin C, access key intermediates, synthesis antifungal α-aminoacyl derivs UPOC 1079
Polysaccharides
sulfated from *Schizymenia dubyi*, composition, antiviral activity 1141
Polystyrene
gel-phase ^{31}P-NMR, evaluation synthesis oligonucleotides 2793
Porcine pancreatic lipase
catalysed hydrolysis bicyclo[3.2.0]hept-2-en-6-ol esters 357
Porphyrins
boronated, potential in boron neutron capture therapy 2017
Portioning-mixing
synthesis million hexapeptides in 5 days 413
Potassium
channel activator:
antihypertensive activity, 7-(substit benzamido)-6-hydroxythieno[3,2-*b*]pyrans, synthesis 1385
benzopyran related to cromakalim-amide replacements at position 4 999
benzopyran sulfoxide derivs 553
channel openers:
anilide tertiary carbinols 2723
benzopyran-4-carboxamide 1115
benzopyran-4-carbothioamide, 6-substit, structure–activity 1659
design by pharmacophore model 625
KC-399 action duration with less tachycardia 2005
dihydropyridine K_{ATP} 2725
fluoroalkyl benzoxazine pyridine-N-oxide 2727
vasorelaxant activity of 2-substit 6-nitro-2*H*-1-benzopyran-4-carbothioamide 2627
cooperative binding ions to *trans*-isohumulone, presence divalent and trivalent cations 769
Prodrugs
α-chymotrypsin peptide bond cleavage protection 809
phosphate water soluble of taxol with *in vivo* antitumour activity 1761
Propidium
interaction with rat brain rigid NMDA receptor complex 85
Prostate
human steroid 5α-reductase inhibitors synthesis evaluation 3-carboxymethyl steroids 1735
Proteases
alkaline, conformation, solubility, structure, selectivity in anhydrous alcohols 1643
HIV:
inhibition by its C- and N-terminal peptides 765
peptidomimetic inhibitors, design, enzyme binding and selectivity, cell permeability 819
Protecting groups
chiral, application *cis*-3-phthalimido-4-styryl-2-azetidinones 2379
diphenylmethylsilylethyl in oligonucleotide synthesis via phosphoramidite approach 2637
peptide bond cleavage by α-chymotrypsin, protection by prodrugs 809
phenylacetyl, enzyme-cleavable amino-protection of purine nucleosides 2781
SATE and DTE enzyme-labile phosphates 2521
trimethylsilyl ester, peptide cyclization on TFA labile resin 437
Proteinase
dual inhibitors, unsymmetrical bis-terephthalamides 525
HIV-1 inhibitors, design, synthesis hydroxyproline 1485
Protein kinase
affinity, ingenol analogs 577
inhibition, indolocarbazoles related to K-252c 1537
Proteins
damage, synthetic enediyne core 1351
epitope targeting, oligonucleotide diversity and drug discovery 469
farnesylation, stereochemistry via NMR 281
insoluble fraction human lens, new fluorescent compd structure 345
interaction with:
α-alkyl-γ-lactones 1101
α-alkylidene-γ-lactones 1107
overproduction, ECPCR method, construction T7-based transcription vector pLM1 1089
peptides crosslinking, synthesis cysteine homologs 739
phosphatases, inhibitors conserved acid binding domain model 1029
subcellular, solubilization with non-ionic telomeric surfactants 161
tyrosine phosphatases, continuous fluorimetric assay, synthesis and fluorescence of substrate 1601

Protein tyrosine phosphatases
continuous fluorescence assay, synthesis and fluorescence of substrate 1601
Proteolysis
limited and site directed mutagenesis, NF-κB p50 DNA-binding subunit 1095
Proteus vulgaris
β-lactamase inhibitors, substit 6-alkyloxapenems 2205
Pseudomonas
rhizobitoxine, precursor, synthesis, abs config of hydroxythreonine 2095
Psoralen
linear, angular and α-methylene-γ-butyrolactone, anti-proliferative compds 1283
PtdIns-3'-kinase
signalling pathway study, synthesis D-3-deoxy-3-phosphonomethyl-*myo*-inositol and dimethyl ester 1323
Pterocarpans
synthetic, anti-HIV activity 1229
Purines
deriv, active conformation as inotropic agent 1233
dioxolane nucleotide analogs optically pure, anti-viral activity 1543
nucleosides, enzyme-cleavable amino-protection by phenylacetyl group 2781
Puromycin
at 3'-terminal of oligonucleotides, solid phase synthesis 1371
Pyran-4-one
substit 2,3-dihydro-4*H*-deriv, sigma receptor 221
Pyrazolidin-3-ones
photo-ring contraction to β-lactams 2383
Pyrazolo[4,3-*e*]pyrrolo[1,2-*a*][1,4]diazepinone
analogs of pyrrolo[1,4]benzodiazepines, antitumor activity 2511
Pyrazolo[3,4-*f*]quinolines
derivs, active immunostimulants, SAR side-chain investigation, formation, injection site toleration 1379
Pyridazinone
derivs, synthesis, bronchospasmolytic properties 2713
Pyridines
based diamide-diester of Ag, 18-membered macrocycle, synthesis, ionophore character 363
derivs, platelet activating factor, cyclic ether acetal receptor antagonist 1493, 1499
isomers, angiotensin II receptor antagonists 1693
Pyrido[2,3-*b*]indoles
4-amino deriv, synthesis anxiolytic activity 1941
Pyrimidines
5-glycosylamino derivs, anti-HIV agents 601
dioxolanyl nucleosides, anti-HIV agents 169
oxathiolane nucleoside activity, anti-human immunodeficiency and anti-hepatitis B viruses 693
Pyrrolidin-2-one biphenyltetrazoles
substit, angiotensin II antagonists 369
Pyrrolidine oxazoles
synthesis as thromboxane A_2/endoperoxide receptor antagonists 1263
Pyrroline-2-carboxylic acid
Δ^1-deriv effect pH on soln structure, NMR, electrospray MS 1189, 1193
growth *Escherichia coli* proline auxotroph 1185
reduction to proline:
by *Escherichia coli* proline auxotroph 1189
noninvolvement glutamate dehydrogenase and Δ^1-pyrroline-5-carboxylate reductase 1197
Pyrrolobenzodiazepines
carbinolamine-containing iminothioether approach 743

Quaternary ammonium derivs
chlorpromazine binding dopamine D-2 receptors by addition H-bonding group 1241
Quinazolinones
3-nitro-4(3*H*)-deriv, vasodilating, antiaggregating activities 611
with AT_1-selective angiotensin II receptor antagonists, design, synthesis 1293
QSARs, characterization of AT_1 selective AII antagonists 1299
Quinoline
1,5-naphthyridine and pyridine derivs as non-peptide angiotensin II receptor antagonists 899
Quinolones
antibacterial agents, U-87947E incorporating bicyclo[1.1.1]pent-1-yl subunit 671
antibiotics, carbocyclic equivalent tautomers, semiempirical calculations 2631
bridged (2,6-dimethyl-4-pyridinyl)-deriv, structures relationship to mammalian topoisomerase II inhibition 1711
derivs as glycine site NMDA receptor antagonists 299
Quinoxalines
angiotensin receptor antagonist, synthesis, properties, SAR 2667
diones, synthesis, excitatory amino acid pharmacology 2801
Quinuclidin-3-yl-1,8-naphthylimides
5-HT_3, receptor antagonist, properties 1375
5-HT_4, receptor antagonist, properties 1375
Quinuclidines
based NK-1 antagonists, 3-benzyloxy-1-aza-bicyclo[2.2.2]octanes 1361
derivs, 5-HT_3 receptor antagonists, effect of additional CO group on chirality recognition by receptor 1555
substance P antagonists, nuclear variations, 2-diphenylmethyl-1-azabicyclo[3.2.2]nonan-3-amines 921

Radioligands
angiotensin II, synthesis ^{3}H-losartan, ^{3}H-L-158641 and ^{3}H-LI-158809 557
Radiosensitizers
targeting to DNA by minor groove binding 1697
Rapamycin
nonmacrocyclic derivs, structure/activity 1977

Receptors
5-HT_{1A}, fluorescent probes, 5-methyl-3-[*n*-propyl-(4-*n*-aminobutyl)]amino-[3,4]-dihydro-2*H*-1-benzopyran derivs 1935
5-HT_3 antagonists:
N-(quinuclidin-3-yl)-[1,8]-naphthylimides, properties 1375
quinuclidine derivs effect of additional CO group on chirality recognition by receptor 1555
agonists:
5-HT_4 *N*-(quinuclidin-3-yl)-[1,8]-naphthylimides, properties 1375
5-HT_4, quaternized renzapride 633
AMPA, synthesis, pharmacology LY300020 95
dopamine autoreceptor PD 135385, synthesis, evaluation of enantiomers 639
thiadiazolyl-tryptamine $5HT_{1D}$, synthesis, activity, electrostatic properties 993
angiotensin AT_2 study tools, synthesis and binding affinities 905
angiotensin II antagonists:
1,5-naphthyridine and pyridine quinoline derivs 899
AT_2 selective, synthesis and QSAR 2023
bisbiphenylyl substit 3-mercaptotriazoles 375
N_1 sterically hindered 2*H*-imidazol-2-one 1055
non-peptide 4,5,6,7-tetrahydro-8-oxo-cycloheptimidazoles 1559
non-peptide receptor, prep (perfluoroalkyl)-imidazoles 895
quinazolinone-containing AT_1-selective, design, synthesis 1293
with phenylthiophenes and phenylfurans in place of biphenyl 1119
antagonists:
glycine-site *N*-methyl-D-aspartate, design 2-quinolone derivs 299
thromboxane A_2/endoperoxide, 1,3-dioxane and 1,3-dioxolane analogs 1271
thromboxane A_2/endoperoxide, synthesis pyrrolidine oxazoles 1263
vasopressin V1, synthesis *N*-acetylhemiaminal metabolites of OPC-21268 1633
CCK:
multipurpose β-carboline antagonists 867
nonpeptide benzolactams 871
CCK_A:
amino acid side-chain mimetics onto α-carbon of tryptophan 889
hydrophilic nonpeptide antagonist, 2-NAP 1511
XXK_A and $_B$, selective ligands within single structural class 881
CCK_B/gastrin:
C5-cyclohexyl analog of L-365,260 affinity ligand 1919
synthesis selective nonpeptide antagonist tritiated ligand 885
CCK_B,tryptophan-norleucine 1,5-disubstit tetrazoles as *cis* peptide bond mimics 2011
endothelin ligands, multiple D-amino acid replacement net approach 1253
endothelin nonpeptide antagonist, CGS 27830 2099
excitatory amino acid antagonists, synthesis, pharmacology 3(carboxymethoxy)isoxazoles derived from AMPA 1649
fibrinogen antagonists:
containing γ–lactam Gly–Asp isostere 1675 with Arg–Gly–Asp sequence and nitroxide radicals, prep, properties 1179
LTB_4 antagonist:
diaryl ether/carboxylic acid derivs of LY255283 1985
effect of 1,2,4,5-substit hydroxyacetophenones with acid unit modification 1147
synthesis, activity hydroxyacetophenone-substit benzophenone/xanthone 1981
muscarinic, himbacine analogs displaying potent binding affinity 1247
neurokinin A, synthesis SR 48968 nonpeptide antagonist 925
neurotensin binding, antinociceptive activity for lipophilic N^{α} amidoneurotensin (9-13) analogs 2055
NMDA:
complex from rat brain, interaction with polyamine analogs 85
glycine-site partial agonist, derivs of HA-966 71
oxytocin antagonist, nonpeptide from natural sources 337
peptide binding studies, substance P as model system 447
peptide sites, dipeptide library for screening 799
renal vit D, 1,25,28-trihydroxy vit D_3 without causing hyperglycemia 1285
sigma ligands:
high affinity, *N,N'*-disubstit acetamidines 2113
SAR, prep, 3(2*H*)-furanones with selective binding 215
SAR, prep 2,3-dihydro-4*H*-pyran-4-one with selective binding 221
Reductase
steroid, human prostate inhibitors, synthesis evaluation 3-carboxymethyl steroids 1735
Reduction
α-haloacetophenones, hydride transfer versus electron transfer 1637
Δ^1-pyrroline-2-carboxylic acid to proline, *Escherichia coli*, noninvolvement glutamate dehydrogenase and Δ^1-pyrroline-5-carboxylate reductase 1197
Δ^1-pyrroline-2-carboxylic acid to proline by *Escherichia coli* proline auxotroph 1189
N,O-dibenzoylhydroxylamine by tertiary amine, Cu catalysis 1245
Regiochemical purity
synthesis benzoporphyrin derivs 2615
Regioselectivity
deacetylation secondary acetyl esters in peracetylated methyl glycopyranosides by *Aspergillus niger* lipase 2125

enzyme-catalysed deacetylation, benzyl phenyl ketone peracetates in organic solvents 585
Renin
human, diol sulfonamide inhibitors 2739
inhibitor analogs, intestinal permeability and hepatic handling rats 813
peptidomimetic inhibitors incorporating topographically modified isosteres spanning $P_1 \rightarrow P_3$-P_1' sites 2119
Renzapride
quaternised, selective 5-HT_4 receptor agonist 633
Resolution
enzymatic, AMPA by α-chymotrypsin 107
lipase, effect of aryl fluorines 1655
p-hydroxyphenyl acetamides, hydrolysis with Pen-G acylase 1041
Rhizobitoxine
Pseudomonas, precursor, synthesis, abs config of hydroxythreonine 2095
Rhodium
catalysed C–H insertion of α-diazo amides, prep β-lactams 2409
Ring reactions
closure, substit azetidinones, route to [4.2.0] fused β-lactams 2443
contraction, pyrazolidin-3-ones to β-lactams 2383
Ristosamine
acosamine, synthesis trehalosamine non-reducing disaccharide analogs 235
Ritipenem acoxil
X-ray crystal structure, chiroptical properties 2333
Rolipram
benzopyran derivs, phosphodiesterase IV inhibition 1743
RP 64406
antiglutamate agents, optical isomers 983
RWJ 47639
orally active angiotensin II receptor antagonists 1523
RWLeu-4
metabolism, activity $1,25(OH)_2D_2$ and metabolites 1873

SAR
3-pyridyl substit thiazolidines, PAF antagonists 2729
6-substit benzopyran-4-carbothioamide K-channel openers 1659
1,4-diacylpiperazine-2-(*S*)-[(*N*-amino alkyl)-carboxamides], substance P receptor antagonist 2707
analysis, oligonucleotide peptide sequences, libraries 425
aryl analogs hygromycin A 289
AT_2 selective angiotensin II receptor antagonists 2023
benzoquinolines, inhibitors human type 1,5-α-reductase 1157
data base, cocaine, structural variations C-2 center compds of subnanomolar binding potency 1327
difluorostatone type inhibitors HIV-1 protease 253
diverse potent K^+ channel openers 625
endothelin hexapeptide ligands 519
ET-1[16-21, D-His^{16}], endothelin antagonist 497
glutamate antagonists, 2,3-benzodiazepine compds 99
glycine antagonists, 5,6-dichlorokynurenic and 3-(2-carboxy-6-chloro-indol-3-yl)acetic related acids 81
GR117289 angiotensin II benzofuran based on antagonist 589
heteroatom substit 3-isopropylidene and 3-isopropyl analogs of N-acyl, 3-alkylidenyl- and 3-alkyl-azetidin-2-ones 2241
HIV-1 protease pseudo-symmetrical inhibitors 1589
hygromycin A application to antibiotic A201A 295
inositol tris- and tetrakisphosphates 1505
isomazole analogs, non-toxic inotropic agents 509
N-aminoadenosine derivs 2661
nonmacrocyclic derivs of rapamycin 1977
pharmacophore modeling, HIV-protease inhibitors 819
quantitative study aromatic and heteroaromatic nitro compds using natural network 329
quinazolinones, characterization of AT_1 selective AII antagonists 1299
quinoxaline, angiotensin receptor antagonist 2667
(*R*)-4-oxo-5-phosphononorvaline 23
relationships inositol, tris and tetrakisphosphates 2599
selective CCK-A receptor ligands, design, synthesis non-peptide rhegnylogues of CCK-26-33 889
side-chain, investigation, formation, injection site toleration, pyrazolo[3,4-*f*]quinoline derivs, active immunostimulants 1379
study CCK-B antagonists 2805
taxol synthesis, cytotoxicity, analogs with C-2' modified phenylisoserine side chains 2471
topiramate, sugar sulfamate anticonvulsant agents 2653
TXA_2/PHG_2 receptor antagonists 199
variable selection, use of neural networks 645
Sarcoma
osteogenic cells, dose dependent cytocidal effects colchicine derivs 1045
Sarmentosin
GPT lowering agent, synthesis 1343
Sch 34343
syntheses, stereoselective synthesis of penem antibiotics 2171
Schizymenia dubyi
composition, antiviral activity sulfated polysaccharides 1141
Scytalone dehydratase
active site, 6-membered H-bonded array replaced by diazine heterocycle 1605
Sedation
devoid effect of anticonvulsant 3-arylamino-4-aryl-5-(*N*-4-chlorophenylthiocarbamido)-1,2,4-thiadiazoles 547
Sequencing
disulfide cross-linked oligodeoxyribonucleotides 2117

Serine
β-lactamase catalysed reactions, mechanism 2317
proteases, borate inhibition mimic, boric acid hydrolysis 4-nitrophenyl 2,3-dihydroxybenzoate 635
proteinases design, mechanism-based inactivators 2745
Serotonin
uptake, indole derivs, potent, selective inhibitors 1913
Shikimate pathway
dehydroquinase hybrid formation 1429
Shikimic acid
pathway, introduction 1397
Sialic acid
N-substit C4–C14 alkanoic acid groups, inhibition influenza A virus hemagglutination 747
Silanes
(allenylmethyl)-deriv, chirally-enriched, prep β-lactams 2405
Silver
selective pyridine based diamide-diester 18-membered macrocycle, synthesis, ionophore character 363
Silyl ketene acetals
and chiral imines derived from 3-hydroxybutyrate, boron mediated aldol reactions 2337
Simvastatin
mouse metabolites synthesis 2755
Solanesyl diphosphate
synthase, reaction with artificial substrates, (*R*)- and (*S*)-enantiomers 4- and 5-methyl derivs geranylgeranyl diphosphate 2733
Solanum tuberosum
DAHP synthase expression in *Escherichia coli* 1421
Solid phase synthesis
δ-amino(2-aminoethyl)-2'-deoxyadenosine incorporation into DNA 689
simultaneous, segmentation membrane type supports, techniques 425
Solubility
selectivity alkaline proteases in anhydrous alcohols 1643
Solubilization
subcellular proteins, non-ionic telomeric surfactants 161
Sparteine
CYP2D6 model substrate, conformation under physiological conditions 1667
Spin labelled
haptens, probing active site antibody 48G7 285
Spiroepoxycyclohexadienone dimers
cytotoxic bisalkylating agents 735
Spiroisoindoles
noncompetitive NMDA antagonists 55
Spiro-β-lactones
opening, synthesis endopeptidase neutral 24.11 *gem*-cycloalkyl thiol inhibitors 825
Spodoptera littoralis
antennal esterases inhibition by trifluoromethyl ketones 2593
Squalene
epoxidase oxidosqualene cyclase, mammalian, trisnorsqualene methyl hydroxylamine dual inhibitor 1319
rat liver microsomes, epoxidation 6,7- and 10,11-oxidosqualenes 2581
synthase inhibitors:
aromatic isosteres of farnesyl chain 595
antifungal activity, SAR of C6 and C7 modifications squalestatin 2605
optimal C1 chain-length requirements 2527
role tricarboxylic acid moiety 2541
tripotassium 1-methyl-1-[(*N*-benzyl-*N*-farnesyl)-aminoethyl-phosphinato]phosphonate 2051
Squalestatins
modified C1 side-chain, squalene synthase inhibitors 2527
modified C6, squalene synthase inhibition 2541
semi-synthetic, antifungal activity and squalene synthase inhibition 2605
SR 48968
antagonists neurokinin A, synthesis 319
non-peptide antagonist neurokinin A receptor, pharmacology and synthesis 925
Staphylococcus aureus
β-lactamase inhibitors, substit 6-alkyloxapenems 2205
ciprofloxacin-resistant, U-87947E antibacterial agents 671
methicillin resistant activity of penems 2165
Stereochemistry
avermectin B_1-8,9-oxide 2093
C20, effect on conformation side chains vit D analogs 1799
KDO8P synthase, synthesis 3-fluoro analogs of KDO8P 1577
physiological significance, hydroxylation vit D side chain 1789
protein farnesylation via NMR 281
requirements for quinuclidine based NK-1 antagonists 1703
Stereocontrolled synthesis
3-sulfenylazetidin-2-ones 2343
α-vinyl and α-alkyl β-lactams 2363
carbapenem intermediate using 1,3-iminoketone synthons 2369
key intermediate carboxylic acid for 1β-methyl-carbapenems 2389
Stereo-requirements
binding activity substance P using analogs with systematic D-amino acid replacements 451
Stereoselective synthesis
α,β-disubstit aspartates, 3,4-dialkyl substit β-lactams 2461
β-lactams 2351
biologically active chlorinated analog codlemone 1629
(*E*)-alkene dipeptide isosteres 2879
penem antibiotics, Sch 34343 syntheses 2171
tricyclic cephalosporins via cephem P-ylides and ketoaldehydes 2451
Stereospecific synthesis
activity 3,4-disubstit 2-azetidinones 2295
bicyclic β-lactams 2357

Steroids
3-carboxymethyl, synthesis evaluation, human prostatic steroid 5α-reductase inhibitors 1735
Sterol cyclase
biocyclisation 2,3-oxidosqualene analogs 365
Stoichiometry
binding flavin mononucleotide hydroquinone to *Escherichia coli* chorismate synthase 1409
Structure–activity relationship
see SAR
Structures
binding form photoprotein chromophore *Symplectoteuthis* bioluminescence 2647
brevifoliol revision, reinvestigation taxol content *Taxus wallichiana* Zucc. 1345
Δ^1-pyrroline-2-carboxylic acid in soln, effect pH, NMR, electrospray MS 1189, 1193
relationship of bridged (2,6-dimethyl-4-pyridinyl)-quinolones to mammalian topoisomerase II inhibition 1711
requirements substrates for inositol monophosphate, adenosine 2'-monophosphate derivs 1925
selectivity alkaline proteases in anhydrous alcohols 1643
Styrylquinoline class
LTD_4 antagonists 1125
Substance P
antagonist CP-99,994 conformationally restricted analogs, synthesis spirocyclic amine 2083
binding NK1 receptors, stereo-requirements using analogs with systematic D-amino acid replacements 451
diastereomers:
histamine releasing activity 441
synthesis using cellulose-based carriers 441
model, multipin peptide synthesis, technique peptide receptor binding 447
quinuclidine antagonists, nuclear variations, 2-diphenylmethyl-1-azabicyclo[3.2.2]nonan-3-amines 921
receptor antagonist, [1,4]-diacylpiperazine-2-(*S*)-[(*N*-aminoalkyl)carboxamides] 2707
Sugar sulfamates
anticonvulsant agents, cyclic sulfate and sulfite analogs of topiramate 2653
Sulfenylazetidin-2-ones
stereocontrolled synthesis 2343
Sulfonamide moiety
non-prostanoid TXA_2 receptor antagonist KT2-962, modification and activity 1687
Sulfones
propargyl hybrid mols with minor groove binding lexitropsins, DNA cleavage 1565
Sulfonyl derivs
6,7-dichloro-3,4-dihydro-3-oxoquinoxaline-carboxylate, glycine-site NMDA, AMPA antagonists 77
Sulfoxide derivs
benzopyran, potassium channel activator 553
Surfactants
biocompatible non-ionic, synthetic double-tailed hydrocarbon, fluorocarbon glycolipids 1003
non-ionic telomeric, solubilization subcellular proteins 161
Surrogates
α,β-didehydrotryptophan for α-methyltryptophan, CCK 'peptoids' related CI-988 989
Symplectoteuthis **bioluminescence**
photoprotein chromophore, structure, binding form 2647
Synthase
E. coli EPSP, inhibitor, synthesis, characterization N-amino-glyphosate as analog 2863
solanesyl diphosphate, reaction with artificial substrates, (*R*)- and (*S*)-enantiomers 4- and 5-methyl derivs geranylgeranyl diphosphate 2733

Tachykinins
synthesis multipin technique, peptide receptor binding study 447
Tartaric acid
starting synthon for *N*-(tetrazol-5-yl) azetidin-2-ones 2429
Taxol
content *Taxus wallichiana* Zucc., reinvestigation, brevifoliol structure revision 1345
phosphate water soluble prodrugs with *in vivo* antitumour activity 1761
phosphates, evaluation water soluble antitumor agents 1357
QSARs, synthesis, cytotoxicity, analogs with C-2' modified phenylisoserine side chains 2471
semisynthesis from (3*R*,4*S*)-*N*-benzyl-3-[(*t*-butyldimethylsilyl)oxy]-4-phenyl-2-azetidinone and 7-(triethylsilyl)baccatin III 2467
Taxotere
analogs, key intermediates *N*-acyl-3-hydroxy-β-lactams 2479
Taxus wallichiana **Zucc.**
reinvestigation taxol content, brevifoliol structure revision 1345
Techniques
generation molecular diversity 387
Tellurides
diaryl, glutathione peroxidase-like activity 2553
Telomers
non-ionic surfactants, solubilization subcellular proteins 161
bis-Terephthalamides
unsymmetrical, dual proteinase inhibitors 525
Tetrahydroisoquinolines
N-oleoyl amides, conformationally restricted ACAT inhibitors 571
trans-2-carboxy-4-substit, NMDA antagonists 65
Tetrahydropyridines
aryl deriv, antipsychotic agents, selective σ-ligands 277
Tetrapeptides
based receptor agonists, CCK-A backbone amide bond replaced by methylene amino isostere 855
Tetrazoles
amino acids, NMDA competitive antagonists 43
tryptophan–norleucine 1,5-disubstit, as *cis* peptide bond mimics 2011

Therapy
agents non-insulin dependent diabetes mellitus 1007
Thiaclavulanic acid
6-hydroxyethyl deriv, synthesis, β-lactamase inhibitory activity 2255
Thiadiazoles
1,3,4-thiadiazoles and 1,3,4-oxadiazoles linked by S-atom to 2,6-di-*t*-butylphenols, cyclooxygenase and 5-lipoxygenase inhibition 2827
anticonvulsant activity 3-arylamino-4-aryl-5-(*N*-4-chlorophenylthiocarbamido)-1,2,4-thiadiazoles 547
Thiadiazolyl-tryptamine
$5HT_{1D}$ receptor agonist, synthesis, activity, electrostatic properties 993
Thiazole
oxazole and imidazole derivs of 2,6-di-*t*-butylphenol, dual inhibitors of lipoxygenase, cyclooxygenase 1729
Thiazolidines
3-pyridyl substit, PAF antagonists 2729
Thiazolium salts
modified papain, C–C bond formation 531
Thioabbeymycin
synthesis, microbial activity 743
Thioacylation
amino acids, prep 4 monothiothymopentin analogs, biological activity 619
Thioamide linkages
peptide incorporation, prep 4 monothiothymopentin analogs, biological activity 619
Thioethers
lipophilic tether, introduction minor groove nucleic acids for antisense applications 2765
Thiols
gem-cycloalkyl, inhibitors neutral endopeptidase 24.11, synthesis via opening 2,2-spiro-β-lactones 825
inhibitors of endothelin converting enzyme 1953
Thiophene systems
synthesis, antihypertensive activity, 7-(substit benzamido)-6-hydroxythieno[3,2-*b*]pyrans, K-channel activators 1385
Thiothymopentin
prep 4 mono analogs, biological activity 619
Thiourea
azido functionalized analogs, photoaffinity probes for urea channel 2587
Thromboxane
role of sulfonamide moiety in KT2,962, modifications and resulting activity 1687
TXA_2/endoperoxide:
antagonists, synthesis cyclopentane, cyclohexene olefin oxazoles 1267
receptor antagonists 1,3-dioxane, 1,3-dioxolane analogs 1271
synthesis pyrrolidine oxazoles 1263
TXA_2/PGH_2 receptor antagonists based on carbocyclin skeleton 199
Thymidine analogs
Herpes simplex thymidine kinase inhibitors 1571
TIBO
anti-HIV R82150 related 1-(2-aminopropyl)benzimidazoles 543
Tipper–Strominger hypothesis
penicillin side-chain binding site 2323
α-Tocopherol
optically active side chains, enzymatic synthesis 157
Topiramate
cyclic sulfate and sulfite analogs, sugar sulfamate anticonvulsant agents 2653
Topoisomerase II
mammalian inhibition, structure relationship to bridged (2,6-dimethyl-4-pyridinyl)-quinolones 1711
Transfecting activity
photoirradiated ϕx 174 DNA, presence hydroperoxynaphthalimides 1671
Transglycosylations
disaccharide–serine and peptide conjugates 2515
Transition state
analog, purine nucleotide biosynthesis 183
tricyclic bridged β-lactam analogs, semi-empirical molecular orbital study 2329
Transport
biochemistry, function, L-glutamate analogs 115
Trehalosamine
non-reducing disaccharides analogs from acosamine and ristosamine 235
Triazacyclononane
tetraazacyclododecane, dicarboxymethylated, formation macrocyclic bifunctional chelating agent precursors 1071
Triazoline-[3,5]-dione
fluorescence labeling vit D metabolites, analogs 1809
Tricarbonyls
vicinal, synthesis 3,4,7-trisubstit carbacephams 2437
Tricarboxylic acid
role squalene synthase inhibitors 2541
Trichloroacetyl isocyanate
2+2-cycloaddition to furanoid glycals 2403
Trifluoroacetophenones
α-alkyl α,α-derivs, transition state analog inhibitors acetylcholinesterase 2619
Trimethylsilyl ester
protecting group, peptide cyclization on TFA labile resin 437
Trioxabicyclo[2.2.3]nonane
model for putative pharmacophore of artemisinin, antimalarial 1707
Tripeptides
formyl–methionyl chemoattractants, modified backbone 953
Trisnorsqualene methyl hydroxylamine
dual inhibitor mammalian squalene epoxidase, oxidosqualene cyclase 1319
Trypanosoma brucei
inhibition, restricted rotation analogs S-adenosylmethionine 147
Trypanothione reductase
Trypanosoma cruzi, non reducible inhibitors 1971

Tryptophan
linked monocationic netropsin analogs, synthesis, DNA binding 2623
Tubulin
polymerization inhibitor, centaureidin cytotoxic flavone from *Polymnia fruticosa* 581
targeting agents, colchicine–combretastatin hybrids, synthesis, evaluation combretatropones 565
Tumours
necrosis factor activity, selective enhancement, mapping regions with monoclonal antibodies 457
TXA_2
see Thromboxane

U-50488
kappa opiate agonist phenalene analogs 2641
U-87947E
incorporating bicyclo[1.1.1]pent-1-yl subunit, quinolone antibacterial agents 671
***ent*-Udoteatrial diacetate**
analogs, cytotoxicity 1085
UPOC
α-aminoacyl derivs, access key intermediate, synthesis antifungal agents 1079
Urea channel
azido functionalized thiourea analogs, photoaffinity probes 2587
Ureas
N,N-diphenyl, inhibitors of ACAT 259

Vancomycin
antibiotics, binding peptide analogs, free energy cost restricting bond rotation 803
Vasodilation
antiaggregating activities, prep, evaluation 3-nitro-4-(3*H*)-quinazolinone derivs 611
Vasopressin V1
receptor antagonist, synthesis *N*-acetylhemiaminal metabolites of OPC-21268 1633
Vasorelaxants
activity 2-substit 6-nitro-2*H*-1-benzopyran-4-carbothioamide, K^+ channel opener 2627
benzopyran-4-carboxamide 1115
Velnacrine
1-substit analogs, inhibition of acetylcholinesterase 2789
Vinylaziridine
chiral, transformation to β-lactam, enantioselective route to carbapenem (+)-PS-5 2415
Vinylogous isocephems
vs arylogous isocephems 2231
Vitamins
1-(hydroxyalkyl)-25-hydroxy vit D_3 analogs, synthesis, biological evaluation 1829, 1835
20-*epi*-23-oxa-[1α,25]-dihydroxy D_3, synthesis evaluation 1845
23-oxa-, 23-thia- and 23-oxa-24-oxo-[1α,25]–dihydroxy vit D_3, synthesis, evaluation 1859
2β-(3-hydroxypropoxy)-1α,25-dihydroxy vit D_3, prevention, therapy bone mineralization loss, ovariectomized rats 1815
1α,25,28-trihydroxycalciferol, synthesis 1821
1α,25,28-trihydroxyvitamin D_2, up-regulates vit D receptor, absence hypercalcemia 1825
D derivs, electrospray ionization spectrometry 1805
D metabolites and analogs with DMEQ-TAD, fluorescence labelling reaction 1809
D side-chain, hydroxylation, stereochemistry, physiological significance 1789
D analogs:
and $1,25(OH)_2D_3$, effect on developmental control of cell growth and gene expression during osteoblast differentiation 1885
effect of C20 on stereochemistry side chain conformation 1799
regulators, cancer cell growth and differentiation 1893
D_3:
1α,24-dihydroxy-22-oxa analogs, synthesis, differentiation-inducing activity 1869
1α,25-dihydroxy deriv, synthesis, evaluation 18-substit analogs 1855
2β,25-dihydroxy deriv, synthesis 1849
25,26-epoxy-1α,24-dihydroxy analogs, synthesis, evaluation 1863
analogs, disubstit side-chain, conformation, molecular modelling semiempirical calculations 1795
in biological systems 1785
mechanism nonphotochemical production in biological systems 1785
KH-1060, new CD synthon and X-ray structure related cholesterol deriv 341
metabolism:
$1,25(OH)_2D_2$ and metabolites in RWLeu-4 1873
$1,25(OH)_2$16-ene D_3 in kidney, effect of D-ring modification on side-chain metabolism 1873

X-Rays
FCE 22891, crystal structure, chiroptical properties 2333
structure superpositional analog enantiomeric forms of fluoxetine 2635

Zaragozic acid A
diesters, synthesis, bioactivity 2029
Zinc
mediated condensation, amino acid esters with imines to β-lactams 2351

Author Index 1993

Aagaard P. J. see Malaska M. J. 1247

Abad J.-L. Casas J. Abián J. and Messeguer A. Epoxidation of 6,7- and 10,11-oxidosqualenes by the squalene epoxidase present in rat liver microsomes 2581

Abdali A. see Falck J. R. 717

Abell C. see Shneier A. 1399

Abelman M. M. see Wright S. W. 2875

Abián J. see Abad J.-L. 2581

Abram T. S. Böshagen H. Butler J. E. Cuthbert N. J. Francis H. P. Gardiner P. J. Hartwig W. Kluender H. C. Norman P. Meier H. Rosentreter U. Schlemmer K. H. Tudhope S. R. and Taylor W. A. A new structural analogue antagonist of peptido-leukotrienes. The discovery of BAY x7195 1517

Abramski W. Badowska-Rosłonek K. and Chmielewski M. [2+2]Cycloaddition of trichloroacetyl isocyanate to furanoid glycals 2403

Abruzzo G. K. see Balkovec J. M. 2039

Abt J. W. see Biller S. A. 595

Achari B. see Ghoshal N. 329

Adams J. see Tong L. 721

Adams S. P. see Devadas B. 779

Addo M. see Bandurco V. T. 375

Addo M. F. see Murray W. V. 369

Addo M. F. see Murray W. V. 785

Adonias M. Anaya J. Cámara J. Canet E. Gateau-Olesker A. Gero S. D. Grande M. and Hernando J. I. M. Enantioselective synthesis and antielastase activity of 1,3,4-trisubstituted and 3,4-disubstituted β-lactam antibiotics 2547

Advenier C. see Emonds-Alt X. 925

Afonso A. Hon F. Weinstein J. Gentles M. Shapiro E. S. Ganguly A. K. Naples L. Hare R. S. and Miller G. H. Penems containing amino acid derived substituents at C-2 2177

Agrawal S. see Nyilas A. 1371

Agrawal S. see Padmapriya A. A. 761

Ahmad M. see Ansari M. H. 1067

Ahmad M. see Ansari M. H. 1071

Ahmad S. Bisacchi G. S. Field A. K. Jacobs G. A. Tuomari A. V. McGeever-Rubin B. Vite G. D. and Zahler R. Optically active fluorinated cyclobutane nucleoside analogs with potent anti-herpes activity 1215

Ahmed S. Z. see Atwal K. S. 2797

Aizpurua J. M. see Palomo C. 2461

Akashi T. see Kobori T. 2225

Al-Hafidh J. see Mills S. J. 2599

Alcaide B. Pérez-Castells J. Sánchez-Vigo B. and Sierra M. A. 1,3-Iminoketones as new synthons for the stereocontrolled preparation of useful carbapenem intermediates 2369

Aleixo L. M. de Carvalho M. Moran P. J. S. and Rodrigues J. A. R. Hydride transfer versus electron transfer in the baker's yeast reduction of α-haloacetophenones 1637

Alexander D. L. see Sawyer T. K. 819

Alisi M. A. Brufani M. Filocamo L. Gostoli G. Cellai L. Iannelli M. A. Melino G. Cesta M. C. and Lappa S. Synthesis and cytotoxic activity of (±)-octadecylphosphodithionyl-1-*myo*-inositol 1931

Allainmat M. see Langlois M. 1555

Allegrone G. see Fuganti C. 2777

Allen E. E. see de Laszlo S. E. 1299

Allen E. E. de Laszlo S. E. Huang S. X. Quagliato C. S. Greenlee W. J. Chang R. S. L. Chen T.-B. Faust K. A. and Lotti V. J. Quinazolinones—I. Design and synthesis of potent quinazolinone-containing AT_1-selective angiotensin-II receptor antagonists 1293

Allen E. E. see Rivero R. A. 1119

Allewaert K. Van Baelen H. Bouillon R. Zhao X. De Clercq P. and Vandewalle M. Synthesis and biological evaluation of 23-oxa, 23-thia- and 23-oxa-24-oxo-1α,25-dihydroxyvitamin D_3 1859

Allewaert K. see Zhao X. 1863

Allison J. W. see Barbachyn M. R. 671

Allott C. P. Bradbury R. H. Dennis M. Fisher E. Luke R. W. A. Major J. S. Oldham A. A. Pearce R. J. Reid A. C. Roberts D. A. Rudge D. A. and Russell S. T. Quinoline, 1,5-naphthyridine and pyridine derivatives as potent, non-peptidic angiotensin II receptor antagonists 899

Alpegiani M. Bissolino P. Borghi D. Rizzo V. and Perrone E. Studies on cephem sulfones as mechanism-based inactivators of human

leukocyte elastase—III. Reactions ensuing from chemical β-lactam cleavage 2259
Alpegiani M. see Jabès D. 2165
Alpegiani M. see Rizzo V. 2265
Altamura M. Giannotti D. Perrotta E. Sbraci P. Pestellini V. Arcamone F. M. and Satta G. Synthesis of new penem dithiocarbamates 2159
Altenburger J. M. see Schirlin D. 253
Alteri E. see Fässler A. 2837
Anaya J. see Adonias M. 2547
Anderson K. S. see Knowles W. S. 2863
Anderson K. S. see Miller M. J. 1435
Andersson C.-M. Hallberg A. Brattsand R. Cotgreave I. A. Engman L. and Persson J. Glutathione peroxidase-like activity of diaryl tellurides 2553
Ando S. see Ito S. 611
Andrási F. see Tamawa I. 99
Andrei G. see Siddiqi S. M. 663
Andreini B. P. see Jabès D. 2165
Andres C. J. Bernardo J. E. Yan Q. Hastie S. B. and Macdonald T. L. 'Combretatropones'—hybrids of combretastatin and colchicine. Synthesis and biochemical evaluation 565
Andresen L. see Madsen U. 1649
Andrew S. S. see Knowles W. S. 2863
Andrews D. M. Bird M. I. Cunningham M. M. and Ward P. Synthesis of and glycosidase inhibition by α-L-homofuconojirimycin 2533
Angelastro M. R. Bey P. Mehdi S. Janusz M. J. and Peet N. P. Janus compounds: dual inhibitors of proteinases 525
Annunziata R. Benaglia M. Cinquini M. Cozzi F. and Ponzini F. Synthesis of β-lactams of high enantiomeric purity by chiral ligand accelerated osmylation of racemic 4-(2-styryl)-azetidin-2-ones 2397
Ansari M. H. Ahmad M. and Dicke K. A. Synthesis of 2-(*p*-aminobenzyl) derivatives of 1,4,7-triazacyclononane-*N,N',N"*-triacetic acid (NOTA) and 1,4,7,10-tetraazacyclododecane-*N,N',N",N"'*-tetraacetic acid (DOTA): macrocyclic bifunctional chelating agents useful for antibodies labeling 1067
Ansari M. H. Ahmad M. and Dicke K. A. Synthesis of *N*-[3-(*p*-aminophenyl)-1-carboxypropyl] derivatives of 1,4,7-triazacyclononane-*N,N'*-diacetic acid and 1,4,7,10-tetraazacyclododecane-*N,N',N"*-triacetic acid: macrocyclic bifunctional chelating agents useful for antibodies labelling 1071
Anstead G. M. Lin H.-K. and Prestwich G. D. Trisnorsqualene methyl hydroxylamine: a potent dual inhibitor of mammalian squalene epoxidase and oxidosqualene cyclase 1319
Anthes J. C. see Wong J. K. 1073
Antibacterial activity of long-chain alcohols: the role of hydrophobic alkyl groups 1305
Antich P. P. see Mehta V. D. 187
Antich P. P. see Mehta V. D. 785
Araki K. O'Toole J. C. and Welch J. T. The synthesis of 3-amino-2,3-dideoxy-2-fluoro-xyloses from a 3-fluoroazetidinone 2457
Arcamone F. M. see Altamura M. 2159
Archer B. J. see Chang S.-C. 555
Arnold M. B. see Ornstein P. L. 2067
Arnold M. B. see Ornstein P. L. 43
Aronow M. see Stein G. S. 1885
Arvanitis A. see Christos T. E. 1035
Ashe B. M. see Shah S. K. 2295
Ashe B. M. see Thompson K. R. 2283
Ashe B. M. see Thompson K. R. 2289
Ashton W. T. see Wu M. T. 2023
Aspley S. see Leeson P. D. 1925
Aston R. see Rathjen D. A. 457
Aszodi J. Bonnet A. Chantot J.-F. Costerousse G. Didierlaurent S. and Teutsch G. Vinylogous versus arylogous isocephems 2231
Atack J. R. see Fletcher S. R. 141
Atwal K. S. Ahmed S. Z. Floyd D. M. Moreland S. and Hedberg A. (*cis*)-3-Methyl-1,5-benzothiazepine-4-ones: potent analogs of the calcium channel blocker diltiazem 2797
Audia J. E. see Wikel J. H. 1157
Augenstein N. K. see Ornstein P. L. 2067
Aumercier M. see Tromelin A. 1971
Aurenge C. see Mumper M. W. 2847
Avila L. Z. see Schmid W. 747

Baasov T. see Kohen A. 1577
Baasov T. see Sheffer-Dee-Noor S. 1583
Baasov T. see Sheffer-Dee-Noor S. 1615
Baba H. see Yanagisawa T. 1559
Baba M. see Tanaka H. 1681
Babcock E. E. see Mehta V. D. 785
Babine R. E. Zhang N. Schow S. R. Jirousek M. R. Johnson B. D. Kerwar S. S. Desai P. R. Byrn R. A. Hastings R. C. and Wick M. M. Structure activity studies on pseudo-symmetrical HIV-1 protease inhibitors 1589
Babine R. E. see Trova M. P. 1595
Bacchi C. J. see Guo J. Q. 147
Bachi M. D. and Bar-Ner N. Synthesis of a $\Delta^{1,6}$-1-carbacephem-4-carboxylic acid derivative as prototype for a new family of fused bicyclic β-lactams 2439
Bader J. P. see Golebiewski W. M. 1739
Badger A. see Holt D. A. 1977
Badowska-Rosłonek K. see Abramski W. 2403
Baggiolini E. G. see Batcho A. D. 1821
Bahador A. see Lee J. 1101
Bahador A. see Lee J. 1107
Bahador A. see Winkler J. D. 577
Bai D. see Chu G. 1343
Bailey E. J. see Procopiou P. A. 2527
Baizman E. see Gordon T. 915
Baker R. see Castro J. L. 993
Baker R. see Chambers M. S. 1919
Baker R. see Fletcher S. R. 141
Baker R. see Leeson P. D. 299
Baker R. see Leeson P. D. 71
Baker R. see Seward E. M. 1361
Baker R. see Swain C. J. 1703
Bakker A. V. see Faraci W. S. 2271
Baldwin R. F. see Sawyer J. S. 1981
Baldwin R. F. see Sawyer J. S. 1985

Balkovec J. M. Black R. M. Abruzzo G. K. Bartizal K. Dreikorn S. and Nollstadt K. Pneumocandin antifungal lipopeptides. The phenolic hydroxyl is required for 1 3-β-glucan synthesis inhibition 2039
Ball D. see Smith P. W. 931
Ball R. G. see Kozikowski A. P. 1327
Ball R. G. see Swain C. J. 1703
Baltas M. Despeyroux P. and Gorrichon L. Addition of amines to methyl 3-dehydroquinate and 3-dehydroshikimate 1447
Baltzer S. see Schirlin D. 253
Balzarini J. see Siddiqi S. M. 563
Bandini E. Cainelli G. Giacomini D. Martelli G. Panunzio M. and Spunta G. Synthesis of carbapenems via metalloimines–ester enolates conden-sation: a new synthesis of (+)-1β-methyl PS-5 2347
Bandurco V. T. Murray W. V. Gill A. Addo M. Lewis J. Wachter M. P. Hadden S. Underwood D. C. and Cheung W.-M. 1,3- and 1,5-Bisbiphenylyl substituted 3-mercaptotriazoles as angiotensin II receptor antagonists 375
Banik B. K. Manhas M. S. Newaz S. N. and Bose A. K. Facile preparation of carbapenem synthons via microwave-induced rapid reaction 2363
Banville S. C. see Kerr J. M. 463
Bar-Ner N. see Bachi M. D. 2439
Barakat K. J. see Kaluza Z. 2357
Baraldi P. G. Leoni A. Cacciari B. Manfredini S. and Simoni D. Synthesis and antitumor activity of a new class of pyrazolo[4,3-*e*]pyrrolo[1,2-*a*][1,4]diazepinone analogs of pyrrolo[1,4]benzodiazepines (PBDs) 2511
Barawkar D. A. and Ganesh K. N. Solid phase synthesis of DNA containing 5-NH_2-2'-deoxyuridine 347
Barbachyn M. R. Hutchinson D. K. Toops D. S. Reid R. J. Zurenko G. E. Yagi B. H. Schaadt R. D. and Allison J. W. U-87947E, A potent quinolone antibacterial agent incorporating a bicyclo[1.1.1]pent-1-yl (*BCP*) subunit 671
Barbeni M. see Fuganti C. 2777
Barber I. see Périgaud C. 2521
Bardella F. Eritja R. Pedroso E. and Giralt E. Gel-phase ^{31}P-NMR. A new analytical tool to evaluate solid phase oligonucleotide synthesis 2793
Bare T. M. Draper C. W. McLaren C. D. Pullan L. M. Patel J. and Patel J. B. Synthesis and activity of spiroisoindolines as novel noncompetitive NMDA antagonists 55
Barmettler P. see Reddy N. L. 2113
Baron B. M. see Whitten J. P. 19
Baron B. M. see Whitten J. P. 23
Barone L. see Stein G. S. 1885
Barraclough P. Black J. W. Cambridge D. Gerskowitch V. P. Giles H. Glen R. C. Hull R. A. D. Iyer R. King W. R. Nobbs M. S. Randall P. Shah G. P. Stone D. Vine S. J. and Whiting M. V. Synthesis and pharmacological properties of BW315C and other inotropic 2-arylimidazo[1,2-*a*]pyrazines 509
Barrett J. F. see Ohemeng K. A. 225
Barsony J. see Posner G. H. 1835
Bartizal K. see Balkovec J. M. 2039
Bartizal K. F. see Wilkening R. R. 1287
Bastow K. F. Tatematsu H. Bori I. D. Fukushima Y. Sun L. Goz B. and Lee K.-H. Induction of reversible protein-linked DNA breaks in human osteogenic sarcoma cells by novel cytocidal colchicine derivatives which inhibit DNA topoisomerase II *in vitro*: absence of cross-resistance in a colchicine-resistant sub-clone 1045
Batcho A. D. Sereno J. F. Hennessy B. M. Baggiolini E. G. Uskokovic M. R. and Horst R. L. Total synthesis of 1α,25,28-trihydroxyergocalciferol 1821
Bateson J. H. Burton G. and Fell S. C. M. Synthesis and antibacterial activity of some C-3-lactonyl substituted cephalosporins 2219
Batley B. L. see Plummer M. 2119
Batta G. see Pitlik J. 2451
Batta G. see Sztaricskai F. 235
Baudin M.-L. see Besson T. 1935
Baxter G. S. Boyland P. Gaster L. M. and King F. D. Quaternised renzapride as a potent and selective 5-HT_4 receptor agonist 633
Bay S. Namane A. and Cantacuzene D. Enzymatic synthesis of disaccharide–serine and peptide conjugates 2515
Bayliss M. K. see Dowle M. D. 2047
Bayliss M. K. see Middlemiss D. 589
Beardsley P. M. see Chandrakumar N. S. 309
Beaudoin F. see Jimonet P. 983
Bebbington D. S. see Whittaker M. 1493
Bebbington D. S. see Wood L. M. 1499
Beck-Sickinger A. G. Hoffmann E. Gaida W. Grouzmann E. Dürr H. and Jung G. Novel Y_2-selective reduced-size agonists of neuropeptide Y 937
Beck-Sickinger A. G. see Stevanovic S. 431
Becker E. L. see Formaggio F. 953
Bedeschi A. see Cabri W. 2255
Bedeschi A. see Franceschi G. 2333
Bednarski M. D. see Lyssikatos J. P. 685
Belakhov V. see Kohen A. 1577
Belakhov V. see Sheffer-Dee-Noor S. 1583
Bell P. Cheon S. H. Fillers S. Foley J. Fraser J. Smith H. Young D. and Revesz L. Design of novel agents for the therapy of non-insulin dependent diabetes mellitus (NIDDM) 1007
Bell R. see Giblin G. M. P. 2605
Bell R. see Watson N. S. 2541
Belleau B. Brasili L. Chan L. DiMarco M. P. Zacharie B. Nguyen-Ba N. Jenkinson H. J. Coates J. A. V. and Cameron J. M. A novel class of 1,3-oxathiolane nucleoside analogues having potent anti-HIV activity 1723
Belleau B. see Zacharie B. 619
Bemis K. G. see Wikel J. H. 1157
Benaglia M. see Annunziata R. 2397
Benezra C. see Bussey C. 1283
Benzaria S. see Périgaud C. 2521
Bercovici A. see Tulshian D. B. 2073

Beresford I. see Smith P. W. 931
Beresis R. and Panek J. S. A concise enantioselective synthesis of *trans*-olefin dipeptide isosteres 1609
Berger G. D. see Chiang Y.-C. P. 2029
Berger J. see Clark R. D. 1375
Bergmann J. S. see Kozikowski A. P. 1327
Bergstrom J. D. see Chiang Y.-C. P. 2029
Berkovich R. see Kohen A. 1577
Bermudez J. Boyland P. King F. D. and Summersell R. J. Synthesis and 5-HT_3 receptor agonist activity of arylureas derived from histamine 205
Bermudez J. Hughes I. Karran E. H. Mangan F. R. Markwell R. E. Smith S. A. Thomson M. J. and Wyman P. A. Synthesis and anti-arthritic activity of a series of 1-aryl-3-dimethylamino-1,4-dihydroisoquinolines 2571
Bernabei A. see Hamilton H. 813
Bernad N. see Rolland M. 851
Bernardo J. E. see Andres C. J. 565
Berrocal J. see Hueso-Rodríguez J. A. 269
Bertelsen A. H. see Sherman M. I. 469
Bertenshaw S. R. Talley J. J. Rogers R. S. Carter J. S. Moore W. M. Branson L. M. and Koboldt C. M. Thiol and hydroxamic acid containing inhibitors of endothelin converting enzyme 1953
Berzsenyi P. see Tamawa I. 99
Besson T. Podona T. Baudin M.-L. Coudert G. and Guillaumet G. Fluorescent probes for 5-HT_{1A} receptors: synthesis and characterization of 5-methoxy-3-[*n*-propyl-(4-*n*-aminobutyl)]amino-3,4-dihydro-2*H*-1-benzopyran derivatives 1935
Bethell R. C. see Holmes D. S. 1485
Beutler J. A. Cardellina, II J. H. Lin C. M. Hamel E. Cragg G. M. and Boyd M. R. Centaureidin, a cytotoxic flavone from *Polymnia fruticosa*, inhibits tubulin polymerization 581
Bey P. see Angelastro M. R. 525
Beyermann M. see Schmidt M. 441
Bezsoudnova K. Yu. see Yatsimirsky A. K. 635
Bhakuni D. S. see Pratap R. 1061
Bienert M. see Schmidt M. 441
Biftu T. see Chiang Y.-C. P. 2029
Biggadike K. see Borthwick A. D. 2577
Bigge C. F. Wu J.-P. Malone T. C. Taylor C. P. and Vartanian M. G. Synthesis and anticonvulsant activity of the (+)- and (−)-enantiomers of 1,2,3,4-tetrahydro-5-(2-phosphonoethyl)-3-isoquinolinecarboxylic acid, a competitive NMDA antagonist 39
Billah M. M. see Wong J. K. 1073
Biller S. A. Abt J. W. Pudzianowski A. T. Rich L. C. Siusarchyk D. A. and Ciosek, Jr C. P. Aromatic isosteres as conformational probes for an isoprenyl subunit: application to inhibitors of squalene synthase 595
Binderup L. Vitamin D analogues: new regulators of cancer cell growth and differentiation 1891
Binderup L. see Calverley M. J. 1845
Bird J. E. see Kim K. S. 2667
Bird M. I. see Andrews D. M. 2533
Bisacchi G. see Kim C. U. 1571
Bisacchi G. S. see Ahmad S. 1215
Bishop R. W. see McCombie S. W. 1537
Bisht K. S. see Parmar V. S. 585
Bissolino P. see Alpegiani M. 2259
Black J. W. see Barraclough P. 509
Black R. M. see Balkovec J. M. 2039
Blackwell G. J. see Hodgson S. T. 2565
Blair K. T. see Hecker S. J. 289
Blair K. T. see Jaynes B. H. 1531
Blakely T. N. see Bridges R. J. 115
Blanchet G. see Dekhane M. 2831
Blankley J. see Hamilton H. 813
Bleiberg B. B. see Lawson J. E. 561
Blizzard T. A. Mrozik H. and Fisher M. H. Avermectin B_1-8,9-oxide: reactivity, bioactivity, and stereochemistry 2093
Blizzard T. A. see Waddell S. T. 1757
Blumberg P. M. see Lee J. 1101
Blumberg P. M. see Lee J. 1107
Blumberg P. M. see Sharma R. 1993
Blumberg P. M. see Winkler J. D. 577
Bock M. G. DiPardo R. M. Veber D. F. Chang R. S. L. Lotti V. J. Freedman S. B. and Freidinger R. M. Benzolactams as non-peptide cholecystokinin receptor ligands 871
Bodkin M. J. see McDonald I. M. 1511
Boesten W. H. J. see Formaggio F. 953
Boger D. L. and Yohannes D. K-13 and OF4949: evaluation of key partial structures and pharmacophore delineation 245
Boissard C. G. see Epperson J. R. 2801
Bold G. see Fässler A. 2837
Bolton D. Forbes I. T. Hayward C. J. Piper D. C. Thomas D. R. Thompson M. and Upton N. Synthesis and potential anxiolytic activity of 4-amino-pyrido[2,3-*b*]indoles 1941
Bolton G. L. see Padia J. K. 2805
Bonner C. A. see Fischer R. S. 1415
Bonner C. A. see Zamir L. O. 1441
Bonnet A. see Aszodi J. 2231
Borer X. see Papageorgiou C. 2559
Bores G. M. see Kapples K. J. 2789
Borghi D. see Alpegiani M. 2259
Borghi D. see Rizzo V. 2265
Bori I. D. see Bastow K. F. 1045
Bornemeier D. A. see Kramer J. B. 2827
Borosky S. A. see Ferkany J. W. 33
Borthwick A. D. Biggadike K. Paternoster I. L. Coates J. A. V. and Knight D. J. Chiral carbocyclic nucleosides: the synthesis and antiviral activity of 4'-hydroxy and 4'-fluorocarbocyclic-2'-deoxyguanosines 2577
Boschelli D. H. see Kramer J. B. 2827
Bose A. K. see Banik B. K. 2363
Bose A. K. see Kaluza Z. 2357
Böshagen H. see Abram T. S. 1517
Bossard M. J. see Holt D. A. 1977

Bostrom L. L. see Wright S. W. 2875
Boteju L. W. Zalewska T. Yamamura H. I. and Hruby V. J. Tryptophan–norleucine 1,5-disubstituted tetrazoles as *cis* peptide bond mimics: investigation of the bioactive conformation of a potent and selective peptide for the cholecystokinin-B receptor 2011
Botka P. see Tarnawa I. 99
Boughton-Smith N. see Hodgson S. T. 2565
Bouillon R. see Allewaert K. 1859
Bouillon R. see Zhao X. 1863
Bourgougnon N. Lahaye M. Chermann J.-C. and Kornprobst J.-M. Composition and antiviral activities of a sulfated polysaccharide from *Schizymenia dubyi* (Rhodophyta, Gigartinales) 1141
Bourne G. T. Horwell D. C. and Pritchard M. C. The rational design and synthesis of non-peptide 'rhegnylogues' of CCK-26-33—a novel series of CCK-A selective ligands 889
Bowles S. A. see Whittaker M. 1493
Bowles S. A. see Wood L. M. 1499
Bowlin T. L. see McDonald I. A. 1717
Boxer P. A. see Hays S. J. 77
Boyd M. R. see Beutler J. A. 581
Boyland P. see Baxter G. S. 633
Boyland P. see Bermudez J. 205
Braccolino D. S. see Miller M. J. 1435
Bradbury R. H. see Allott C. P. 899
Bradford V. S. see Sawyer T. K. 819
Bradshaw J. see Middlemiss D. 589
Brandt M. see Holt D. A. 1735
Brandt M. see Holt D. A. 1977
Branson L. M. see Bertenshaw S. R. 1953
Brasili L. see Belleau B. 1723
Brattsand R. see Andersson C.-M. 2553
Brause K. A. see Shah S. K. 2295
Bray A. M. see Wang J. 447
Bray A. M. see Wang J. 451
Breen A. L. see Jarvest R. L. 2851
Brehm L. see Madsen U. 1649
Brelière J.-C. see Emonds-Alt X. 925
Brémont B. see Langlois M. 2035
Bretting C. Aa. S. see Calverley M. J. 1841
Brickner S. J. Gaikema J. J. Greenfield L. J. Zurenko G. E. and Manninen P. R. N-Acyl 3-alkylidenyl- and 3-alkyl azetidin-2-ones: a new class of monocyclic β-lactam antibacterial agents—II. Synthesis and structure–activity relationships of heteroatom substituted 3-isopropylidene and 3-isopropyl analogs 2241
Bridges R. J. Lovering F. E. Humphrey J. M. Stanley M. S. Blakely T. N. Cristofaro M. F. and Chamberlin A. R. Conformationally restricted inhibitors of the high affinity L-glutamate transporter 115
Brittain R. J. see Poss M. A. 2739
Britton T. C. see Howbert J. J. 875
Broekman M. see Howson W. 515
Broughton H. B. see Castro J. L. 993
Broughton H. B. see McDonald I. M. 1511
Brown C. B. see Doyle M. P. 2409
Brown F. J. see Russell K. 2727
Brown S. see Spellmeyer D. C. 1253
Brown S. see Spellmeyer D. C. 519
Brown W. L. see Siddiqui M. A. 1543
Brubaker M. J. see Groutas W. C. 1163
Brufani M. see Alisi M. A. 1931
Bruns R. F. see Howbert J. J. 875
Bruton G. Tricyclic bridged β-lactams as transition state analogues: a study using semi-empirical molecular orbital methods 2329
Bryson C. see Poindexter G. S. 2817
Buccheri E. see Miltz W. 1233
Buckle D. R. see Pinto I. L. 1743
Budhu R. J. see Mills S. G. 2707
Bundgaard H. see Kahns A. H. 809
Burke-Howie K. J. see Reddy N. L. 2113
Burkholder T. P. Huber E. W. and Flynn G. A. The synthesis of 6-amino-5-oxo-7-phenyl-1,4-oxazepines as conformationally constrained *gauche* (–) dipeptide mimetics 231
Burrell G. Evans J. M. Hicks F. and Stemp G. Benzopyran potassium channel activators related to cromakalim—amide replacements at position 4 999
Burrier R. E. see Dugar S. 571
Burton G. see Bateson J. H. 2219
Burton P. S. see Sawyer T. K. 819
Bush K. see Hudyma T. W. 323
Bussey C. Lepoittevin J.-P. and Benezra C. Double-headed molecules based on linear or angular psoralen and α-methylene-γ-butyrolactone: a search for non-phototoxic potential anti-proliferative compounds 1283
Butler J. E. see Abram T. S. 1517
Butler T. W. see Chenard B. L. 1991
Butler T. W. see Chenard B. L. 91
Buyniski J. P. see Poindexter G. S. 2817
Byrn R. A. see Babine R. E. 1589
Byrn R. A. see Trova M. P. 1595

Cabri W. Bedeschi A. Perrone E. Visentin G. Jabes D. and Franceschi G. Synthesis and β-lactamase inhibitory activity of 6-hydroxyethyl thiaclavulanic acid 2255
Cacciapuoti A. see Cooper A. B. 1079
Cacciari B. see Baraldi P. G. 2511
Cackett K. S. see Wood L. M. 1499
Cain G. A. Christos T. E. Johnson A. L. Pottorf R. S. Confalone P. N. Tam S. W. and Schmidt W. K. Neurotensin receptor binding and antinociceptive activity for lipophilic N^{α}-amido neurotensin(9-13) analogs 2055
Cain G. A. Christos T. E. Johnson A. L. Pottorf R. S. Tam S. W. and Schmidt W. K. Identification of simpler analogs of neurotensin(9–13) which retain anti-nociceptive activity 1767
Cain G. A. see Christos T. E. 1035
Cainelli G. see Bandini E. 2347
Calligaro D. O. see Ornstein P. L. 2067
Calligaro D. O. see Smith E. C. R. 81
Calverley M. J. and Binderup L.

Synthesis and biological evaluation of MC 1357, a new 20-*epi*-23-oxa-1α,25-dihydroxy-vitamin D_3 analogue with potent non-classical effects 1845
Calverley M. J. and Bretting C. Aa. S. 1α,24*S*-Dihydroxy-26,27-cyclo-22-yne-vitamin D_3: the side chain triple bond analogue of MC 903 (calcipotriol) 1841
Cámara J. see Adonias M. 2547
Cambridge D. see Barraclough P. 509
Cameron J. M. see Belleau B. 1723
Cameron J. M. see Siddiqui M. A. 1543
Campbell M. M. Horwell D. C. Mahon M. F. Pritchard M. C. and Walford S. P. Diastereoselective synthesis of cyclopropyl phenylalanines and their incorporation into dipeptides 667
Campbell M. M. see Dutta A. S. 943
Canet E. see Adonias M. 2547
Canning P. C. see Moyer M. P. 1379
Cannon D. see Wilson L. J. 169
Cantacuzene D. see Bay S. 2515
Caprathe B. W. see Jaén J. C. 639
Cardellina, II J. H. see Beutler J. A. 581
Cardozo M. see Tong L. 721
Cardwell K. S. see Middlemiss D. 589
Carini D. J. Chiu A. T. Wong P. C. Johnson A. L. Wexler R. R. and Timmermans P. B. M. W. M. The preparation of (perfluoroalkyl)imidazoles as nonpeptide angiotensin II receptor antagonists 895
Carling R. W. Leeson P. D. Moseley A. M. Smith J. D. Saywell K. Tricklebank M. D. Kemp J. A. Marshall G. R. Foster A. C. and Grimwood S. Anticonvulsant activity of glycine-site NMDA antagonists—II. *trans* 2-Carboxy-4-substituted tetrahydroquinolines 65
Carling R. W. see Leeson P. D. 299
Carling R. W. see Moore K. W. 61
Carr D. see McCombie S. W. 1537
Carron C. P. see Chandrakumar N. S. 309
Carter G. W. see Davidsen S. K. 2729
Carter J. S. see Bertenshaw S. R. 1953
Casas J. see Abad J.-L. 2581
Casas J. see Irurre, Jr J. 179
Casazza A. M. see Ueda Y. 1761
Casazza A. M. see Vyas D. M. 1357
Casazza A. M. see Zein N. 1351
Cascieri M. A. see Mills S. G. 2707
Cascieri M. A. see Seward E. M. 1361
Cascieri M. A. see Swain C. J. 1703
Casida J. E. see Li Q. X. 2671
Casscles, Jr W. T. see Trova M. P. 1595
Castedo L. see Nilsson K. 1855
Casteel D. A. Peri S. P. and Gerena L. Synthesis and antimalarial evaluation of 2 3,5-trioxabicyclo[2.2.3]nonane, a model for the putative pharmacophore of artemisinin 1707
Castrisos J. C. see Groutas W. C. 1163
Castro J. L. Matassa V. G. Broughton H. B. Mosley R. T. Street L. J. and Baker R. Synthesis, biological activity and electrostatic properties of 3-[2-(dimethylamino)ethyl]-5-[(3-amino-1,2,4-thiadiazol-5-yl)methyl]-1*H*-indole, a novel 5-HT_{1D} receptor agonist 993
Caulfield T. J. Prasad C. V. C. Prouty C. P. Saha A. K. Sardaro M. P. Schairer W. C. Yawman A. Upson D. A. and Kruse L. I. Achiral internucleoside linkages: CH_2–CH_2–NH and NH–CH_2–CH_2 linkages 2771
Cavanagh R. L. see Lawson J. E. 561
Cavanagh R. L. see Poindexter G. S. 2817
Cellai L. see Alisi M. A. 1931
Cerny R. L. see Pettit G. R. 2869
Cesta M. C. see Alisi M. A. 1931
Cetenko W. A. see Unangst P. C. 1729
Chaikin M. A. see Jarvest R. L. 2851
Chakravarty P. K. see Rivero R. A. 557
Chamberlin A. R. see Bridges R. J. 115
Chambers M. S. Hobbs S. C. Fletcher S. R. Matassa V. G. Mitchell P. J. Watt A. P. Baker R. Freedman S. B. Patel S. and Smith A. J. L-708,474: The C5-cyclohexyl analogue of L-365,260, a selective high affinity ligand for the CCK_B/gastrin receptor 1919
Chan C. see Watson N. S. 2541
Chan L. see Belleau B. 1723
Chan O. H. see Hamilton H. 813
Chan T.-M. see Hou D. 2171
Chandler G. O. see Shah S. K. 2295
Chandrakumar N. S. Carron C. P. Meyer D. M. Beardsley P. M. Nash S. A. Tam L. L. and Rafferty M. Phenylphosphonate monoester analogs of cocaine. Potential haptens for the generation of catalytic antibodies 309
Chandrasekaran E. V. see Jain R. K. 1333
Chang R. S. see de Laszlo S. E. 1299
Chang R. S. L. see Allen E. E. 1293
Chang R. S. L. see Bock M. G. 871
Chang R. S. L. see Evans B. E. 867
Chang R. S. L. see Mantlo N. B. 1693
Chang R. S. L. see Wu M. T. 2023
Chang S.-C. Archer B. J. Utecht R. E. Lewis D. E. Judy M. M. and Matthews J. L. 4-Alkylamino-3-bromo-*N*-alkyl-1,8-naphthalimides: new photochemically activatable antiviral compounds 555
Chantot J.-F. see Aszodi J. 2231
Chapman K. T. see Mjalli A. M. M. 2689
Chapman K. T. see Mjalli A. M. M. 2693
Chase K. see Church K. M. 2623
Chauhan P. M. S. Varma N. and Tandon J. S. The synthesis of novel, rigid and water soluble analogues of coleonol (forskolin) 677
Chen B. see Su T. 835
Chen H.-J. see Chen S.-T. 727
Chen L. see Sodeoka M. 1089
Chen L. see Sodeoka M. 1095
Chen R. see Rivero R. A. 557
Chen S.-T. Chen S.-Y. Chen H.-J. Huang H.-C. and Wang K.-T. Probing the s-1' subsite selectivity of an industrial alkaline protease in anhydrous *t*-butanol 727
Chen S.-T. Chen S.-Y. Tu C.-C. and Wang K.-T. Investigation of the conformation, solubility, structure and selectivity of alkaline proteases in anhydrous alcohols 1643

Chen S.-T. Tu C.-C. and Wang K.-T.
Selective incorporation of D-amino acid esters into peptides catalyzed by alcalase in *t*-butanol 539
Chen S.-Y. see Chen S.-T. 1643
Chen S.-Y. see Chen S.-T. 727
Chen S. T. see Reitz D. B. 1055
Chen T.-B. see Allen E. E. 1293
Chen T.-B. see de Laszlo S. E. 1299
Chen Y. K. C. C. F. see Ong C. W. 607
Chenard B. L. Butler T. W. Menniti F. S. Prochniak M. A. and Richter K. E. G.
A short synthesis of GYKI 52466 1991
Chenard B. L. Butler T. W. Shalaby I. A. Prochniak M. A. Koe B. K. and Fox C. B.
Oxindole N-methyl-D-aspartate (NMDA) antagonists 91
Chenera B. DesJarlais R. L. Finkelstein J. A. Eggleston D. S. Meek T. D. Tomaszek, Jr T. A. and Dreyer G. B.
Nonpeptide HIV protease inhibitors designed to replace a bound water 2717
Chênevert R. see Dorion C. 2599
Cheng H.-Y. Davis L. L. Holl W. W. Nichols A. Hwang S. M. Johanson K. and Wong A.
Preparation and properties of a fibrinogen receptor antagonist containing the Arg–Gly–Asp sequence and nitroxide radicals 1179
Cheng H. C. see Maynard G. D. 753
Cheon S. H. see Bell P. 1007
Chermann J.-C. see Bourgougnon N. 1141
Cheruvallath Z. S. see Georg G. I. 1349
Cheruvallath Z. S. see Georg G. I. 2467
Cheung W.-M. see Bandurco V. T. 375
Chevé M. see Jimonet P. 983
Chiang Y.-C. P. Biftu Doss G. A. Pievyak S. P. Marquis R. W. Bergstrom J. D. Kurtz M. M. Rew D. J. and Berger G. D.
Diesters of zaragozic acid A: synthesis and biological activity 2029
Chin M. H. see Mugrage B. 2099
Chiu A. T. see Carini D. J. 895
Chmielewski J. see Franciskovich J. 765
Chmielewski J. see Lutgring R. 739
Chmielewski M. see Abramski W. 2403
Chodyński M. see Kutner A. 1795
Choi W.-B. Yeola S. Liotta D. C. Schinazi R. F. Painter G. R. Davis M. St. Clair M. and Furman P. A.
Synthesis, anti-human immunodeficiency virus, and anti-hepatitis B virus activity of pyrimidine oxathiolane nucleosides 693
Choi W.-B. see Wilson L. J. 169
Choliński J. see Kutner A. 1795
Chong L. S. see Groutas W. C. 1163
Chong L. S. see Groutas W. C. 2745
Choo L. Y. see Thérien M. 2063
Chou Y. M. see Ong C. W. 607
Christodoulou M. S. see Wood L. M. 1499
Christos T. E. Arvanitis A. Cain G. A. Johnson A. L. Pottorf R. S. Tam S. W. and Schmidt W. K.
Stable isosteres of neurotensin C-terminal pentapeptides derived by modification of the amide function 1035
Christos T. E. see Cain G. A. 1767
Christos T. E. see Cain G. A. 2055
Chu G. Zhou Q. and Bai D.
The total synthesis of sarmentosin, a potent GPT lowering agent 1343
Church K. M. Moore T. A. Luckey S. Schaeper M. and Chase K.
Synthesis and DNA binding properties of tryptophan linked monocationic netropsin analogues 2623
Cimarusti M. P. see Poss M. A. 2739
Cinquini M. see Annunziata R. 2397
Cioffi C. see Mugrage B. 2099
Ciosek, Jr C. P. see Biller S. A. 595
Clader J. W. see Dugar S. 571
Clark D. S. see Skerker P. S. 285
Clark J. W. Reddy G. S. Santos-Moore A. Wankadiya K. F. Reddy G. P. Ell C. Lasky S. Tserng K.-Y. Horst R. L. and Uskokovic M. R.
Metabolism and biological activity of 1,25$(OH)_2D_2$ and its metabolites in a chronic myelogenous leukemia cell line, RWLeu-4 1873
Clark J. W. see Posner G. H. 1835
Clark J. W. see Reddy G. S. 1879
Clark K. L. see Dowle M. D. 2047
Clark K. L. see Middlemiss D. 589
Clark R. D. Weinhardt K. K. Berger J. Lee C.-H. Leung E. Wong E. H. F. Smith W. L. and Eglen R. M.
N-(Quinuclidin-3-yl)-1,8-naphthalimides with 5-HT_3 receptor antagonist and 5-HT_4 receptor agonist properties 1375
Cleary D. G. see Miller M. J. 1435
Clemens I. R. see Holmes D. S. 503
Clineschmidt B. V. see Salituro G. M. 337
Clissold D. B. see Ferkany J. W. 33
Coates J. A. V. see Belleau B. 1723
Coates J. A. V. see Borthwick A. D. 2577
Cobley K. N. see Holmes D. S. 503
Cockerham S. L. see Sofia M. J. 1147
Cody W. L. see Doherty A. M. 497
Coggins J. R. see Ramjee M. K. 1409
Coggins J. R. see Reilly A. 1429
Coggins J. R. see Shneier A. 1399
Cohen E. see Vaillancourt M. 1169
Colatsky T. see Soll R. M. 757
Cole D. L. see Ravikumar V. T. 2637
Collins J. T. see Reitz D. B. 1055
Colson K. L. see Hudyma T. W. 323
Colvin E. W. König W. A. Loreto M. A. Rowden J. Y. and Tommasini I.
β-Lactams from chirally-enriched (allenylmethyl)silanes 2405
Combs D. W.
Synthesis and cardiotonic activity of 2 9-dihydro-6-(5-methyl-3-oxo-2,3,4,5-tetrahydropyridazin-6-yl)pyrazolo[4,3-*b*][1 4]benzoxazine 1663
Confalone P. N. see Cain G. A. 2055
Connor D. T. see Kramer J. B. 2827
Connor D. T. see Unangst P. C. 1729
Conradi R. A. see Sawyer T. K. 819
Consttantinescu A. see Mehta V. D. 785
Conway R. G. see Davidsen S. K. 2729

Cook A. F. see Sherman M. I. 469
Cook J. see Hamilton H. 813
Cook P. D. see Manoharan M. 2765
Cooper A. B. Desai J. Lovey R. G. Saksena A. K. Girijavallabhan V. M. Ganguly A. K. Loebenberg D. Parmegiani R. and Cacciapuoti A.
A convenient degradation of polyoxin D to uracil polyoxin C: access to key intermediates and synthesis of antifungal α-aminoacyl derivatives of UPOC 1079
Cooper C. B. see Hecker S. J. 289
Cooper C. B. see Jaynes B. H. 1531
Cooper G. see Howarth N. M. 313
Coote S. see Middlemiss D. 589
Corbett R. L. see Wright S. W. 2875
Corey E. J. Reichard G. A. and Sarshar S.
Synthesis and X-ray structure of a potent superpositional analog of the enantiomeric forms of fluoxetine 2635
Corey P. F.
A new chromogenic beta-galactosidase substrate based on the redox indicator dye 'methyl purple' 175
Corey S. D. Pansegrau P. D. Walker M. C. and Sikorski J. A.
EPSP Synthase inhibitor design—III. Synthesis and evaluation of a new 5-oxamic acid analog of EPSP which incorporates a malonate ether as a 3-phosphate mimic 2857
Cornell K. A. see Winter R. W. 2079
Cornell L. A. see Dubowchik G. M. 1965
Corringer P.-J. see Roques B. P. 847
Corsano S. Strappaghetti G. Scapicchi R. and Scalise O.
Synthesis and bronchospasmolytic properties of some pyridazinone derivatives 2713
Costanzo M. J. see Maryanoff B. E. 2653
Costerousse G. see Aszodi J. 2231
Cotgreave I. A. see Andersson C.-M. 2553
Coudert G. see Besson T. 1935
Coughlin S. A. see Wentland M. P. 1711
Couplet B. see Marchand-Brynaert J. 2303
Couture C. A. see Hanessian S. 2323
Cox B. see Watson N. S. 2541
Cozzi F. see Annunziata R. 2397
Cragg G. M. see Beutler J. A. 581
Craig C. see Hodgson S. T. 2565
Craig C. see Streith J. 2375
Craik C. see Sawyer T. K. 819
Crisma M. see Formaggio F. 953
Cristofaro M. F. see Bridges R. J. 115
Crosswell A. R. see Dubowchik G. M. 1965
Crosswell A. R. see Saulnier M. G. 1619
Crosswell A. R. see Vyas D. M. 1357
Cube R. V. see Whitten J. P. 19
Cunningham M. M. see Andrews D. M. 2533
Curtis D. R. see Nielsen B. 107
Cushman M. see Golebiewski W. M. 1739
Cuthbert N. J. see Abram T. S. 1517
Czarnik A. W. see Wathen S. P. 1245

Dahlgren M. E. see Finke P. E. 2277
Dahlgren M. E. see Thompson K. R. 2283
Dahlgren M. E. see Thompson K. R. 2289
Dai H. see Posner G. H. 1829
Damour D. see Mignani S. 1913
Dan A. Yoshimura Y. Ono A. and Matsuda A.
Nucleosides and nucleotides—CXVIII. Synthesis of oligonucleotides containing a novel 2'-deoxyuridine analogue that carries an aminoalkyl tether at 1'-position; stabilization of duplex formation by an intercalating group accommodated in the minor groove 615
Das J. Hall S. E. Reid J. A. Han W.-C. Harris D. N. Goldenberg H. Michel I. M. Monshizadegan H. and Webb M. L.
Syntheses of cyclopentane, cyclohexene and olefin oxazoles as thromboxane A_2/endoperoxide receptor antagonists 1267
Das J. Reid J. A. Harris D. N. Goldenberg H. Michel I. M. Monshizadegan H. and Webb M. L.
Thromboxane A_2/endoperoxide receptor antagonists: 1 3-dioxane and 1,3-dioxolane analogs 1271
Dasaradhi L. and O'Hagan D.
The effect of aryl fluorines in a lipase resolution 1655
Daugé V. see Roques B. P. 847
Davidsen S. K. Summers J. B. Conway R. G. Rhein D. A. and Carter G. W.
Synthesis of bicyclic thiazolidine PAF antagonists 2729
Davidson A. H. see Whittaker M. 1493
Davidson A. H. see Wood L. M. 1499
Davies L. K. see Parrick J. 1697
Davis L. L. see Cheng H.-Y. 1179
Davis M. see Choi W.-B. 693
Davis P. see Hristova-Kazmierski M. K. 831
Dax S. L. Pruess D. L. Rossman P. L. and Wei C.-C.
Synthesis and mechanistic studies of a 'tetrazole-tethered' cephalosporin–quinolone hybrid 209
Deal M. J. see Smith P. W. 931
DeCamp D. see Sawyer T. K. 819
de Carvalho M. see Aleixo L. M. 1637
De Clercq E. see Siddiqi S. M. 663
De Clercq E. see Tanaka H. 1681
De Clercq P. see Allewaert K. 1859
De Clercq P. see Zhao X. 1863
Deeter J. B. see Ornstein P. L. 2067
DeForrest J. M. see Poss M. A. 2739
Dégeilh F. see Lamotte H. 2587
Dejneka T. see Poss M. A. 2739
Dekhane M. Dubois L. Blanchet G. Garrigue H. Sentenac-Roumanou H. Potier P. and Dodd R. H.
N-2 Methylated quaternary derivatives of β-carboline-3-carboxylates inhibit acetylcholinesterase *in vitro* 2831
Delaney C. L. see Kim K. S. 2667
de Laszlo S. E. Allen E. E. Quagliato C. S. Greenlee W. J. Patchett A. A. Nachbar R. B. Siegl P. K. S. Chang R. S. Kivlighn S. D. Schorn T. S. Faust K. A. Chen T.-B. Zingaro G. J. and Lotti V. J.
Quinazolinones—II. QSAR and *in vivo* characterization of AT, selective All antanists 1299
de Laszlo S. E. see Allen E. E. 1293
Dellaria, Jr J. F. Sallin K. J. and Rodriques K.
Synthesis of new amide-linked *N*-hydroxyurea 5-lipoxygenase inhibitors by an

intramolecular oxygen to nitrogen acyl transfer 305
Della Bruna C. see Jabès D. 2165
Dellea P. S. see Thompson K. R. 2289
DeLucca I. see Wilkerson W. W. 2087
DeLucca I. see Wilkerson W. W. 711
Dennis M. see Allott C. P. 899
Dennis M. F. see Parrick J. 1697
DePue P. L. see Doherty A. M. 497
Derrien M. see Roques B. P. 847
Desai J. see Cooper A. B. 1079
Desai M. C. and Lefkowitz S. L.
Conformationally restricted analogs of CP-99,994: synthesis of a spirocyclic amine 2083
Desai P. R. see Babine R. E. 1589
Descoins C. see Tellier F. 1629
DesJarlais R. L. see Chenera B. 2717
Despeyroux P. see Baltas M. 1447
Desseaux C. and Huynh-Dinh T.
Synthesis of phosphodiester and triester derivatives of AZT with tethered *N*-methyl piperazine and *N,N,N'*-trimethylethylenediamine 1547
Devadas B. Kishore N. S. Adams S. P. and Gordon J. I.
Synthesis of myristic acid analogs with anti-HIV activity that may be resistant to metabolic processing by β-oxidation 779
Dewan J. see Wilson S. R. 341
Dibó G. see Sebestyén F. 413
Dicke K. A. see Ansari M. H. 1067
Dicke K. A. see Ansari M. H. 1071
Dickinson K. E. J. see Kim K. S. 2667
Didierlaurent S. see Aszodi J. 2231
DiMarco M. P. see Belleau B. 1723
Dineva M. A. Galunsky B. Kasche V. and Petkov D. D.
Phenylacetyl group as enzyme-cleavable aminoprotection of purine nucleosides 2781
Ding C. Z. and Silverman R. B.
Selective inactivation of monoamine oxidase B by aminoethyl 3-chlorobenzyl ether 2077
DiNinno F. Muthard D. A. and Salzmann T. N.
The synthesis and antibacterial activity of 2-*para*-quaternary ammoniomethylphenyl-carbapenems 2187
Dinish J. see Soll R. M. 757
DiPardo R. M. see Bock M. G. 871
DiPasquale A. J. see Wang J. 447
DiPasquale A. J. see Wang J. 451
DiPietro R. A. see Griffith R. K. 353
Dive G. see Marchand-Brynaert J. 2303
Dixit D. M. see Siddiqui M. A. 1543
Dobek E. see McCombie S. W. 1537
Doble A. see Mignani S. 1913
Dodd R. H. see Dekhane M. 2831
Doherty A. M. Cody W. L. He J. X. DePue P. L. Leonard D. M. Dunbar, Jr J. B. Hill K. E. Flynn M. A. and Reynolds E. E.
Design of C-terminal peptide antagonists of endothelin: structure–activity relationships of ET-1[16–21 D-His[16]] 497
Doherty A. M. see Kornberg B. E. 1257
Doherty J. B. see Finke P. E. 2277
Doherty J. B. see Shah S. K. 2295
Doherty J. B. see Thompson K. R. 2283
Doherty J. B. see Thompson K. R. 2289
Donald A. E. see Leeson P. D. 71
Donkor I. O. Jones S. K. and Tidwell R. R.
Pentamidine congeners—I. Synthesis of *cis*- and *trans*-butamidine analogues as anti-*Pneumocystis carinii* pneumonia agents 1137
Donnelly M. see Dowle M. D. 2047
Donnelly M. see Middlemiss D. 589
Dooley C. T. see Houghten R. A. 405
Dorion C. Chênevert R. Lacoste L. and Lapointe J.
Synthesis of an inhibitor of glutamyl-tRNA synthetase 2699
Dorn, Jr C. P. see Mills S. G. 2707
Doss G. A. see Chiang Y.-C. P. 2029
Doss G. A. see Wilkening R. R. 1287
Dougherty T. J. see Pandey R. K. 2615
Douglas K. A. see Guo J. Q. 147
Dow E. R. see Wikel J. H. 645
Dowle M. D. Judd D. B. Middlemiss D. Scopes D. I. C. Ross B. C. Pass M. Tranquillini E. Jack T. I. Hobson J. E. Panchal T. A. Stuart P. G. Drew G. M. Robertson M. J. Hilditch A. Clark K. L. Travers A. Hunt A. A. E. Manchee G. R. Walker D. G. Eddershaw P. J. Donnelly M. and Bayliss M. K.
Benzofuran based angiotensin II antagonists related to GR117289—III. GR138950, a triflamide with high oral bioavailability 2047
Dowle M. D. see Middlemiss D. 2043
Dowle M. D. see Middlemiss D. 589
Doyle M. P. Oon S.-M. van der Heide F. R. and Brown C. B.
β-Lactam formation via rhodium(II) catalyzed carbon–hydrogen insertion reactions of α-diazo amides 2409
Doyle T. W. see Vyas D. M. 1357
Doyle T. W. see Zein N. 1351
Drach J. C. see Swayze E. E. 543
Draper C. W. see Bare T. M. 55
Dreikorn S. see Balkovec J. M. 2039
Drejer J. see Wåtjen F. 105
Drew G. M. see Dowle M. D. 2047
Drew G. M. see Middlemiss D. 2043
Drew G. M. see Middlemiss D. 589
Dreyer G. B. see Chenera B. 2717
Droescher P. see Schönecker B. 1849
Droghini R. see Endo M. 2483
Drozda S. E. see Lowe, III J. A. 921
Drummond A. H. see Whittaker M. 1493
Dubois L. see Dekhane M. 2831
Dubowchik G. M. Cornell L. A. Crosswell A. R. and Firestone R. A.
Novel polyamide inducers of HL-60 cellular differentiation 1965
Dubowchik G. M. Padilla L. M. and Firestone R. A.
An acid-cleavable linker stable at neutral pH that releases doxorubicin at lysosomal pH 2843
Duclos O. see Ojima I. 2479
Ducrotoy G. see Jimonet P. 983
Dugar S. Clader J. W. Burrier R. E. and Kogan T. P.
N-Oleoyl-1,2,3,4-tetrahydroisoquinolines as conformationally restricted

inhibitors of acyl-CoA:cholesterol acyl transferase (ACAT) 571
Dumant A. see Guy A. 1041
Dumont F. J. see Organ H. M. 657
Dunbar, Jr J. B. see Doherty A. M. 497
Duncan L. see Howarth N. M. 313
Dunn B. M. see Sawyer T. K. 819
Dunstone D. J. see McDonald I. M. 1511
Durán I. Parrilla A. Feixas J. and Guerrero A. Inhibition of antennal esterases of the Egyptian armyworm *Spodoptera littoralis* by trifluoromethyl ketones 2593
Durand T. Marchand-Brynaert J. and Ghosez L. Cyclopentenones as potential inhibitors of penicillin sensitive enzymes 2309
Durieux C. see Roques B. P. 847
Dürr H. see Beck-Sickinger A. G. 937
Dutruc-Rosset G. see Jimonet P. 983
Dutta A. S. Gormley J. J. Woodburn J. R. Paul P. K. C. Osguthorpe D. J. and Campbell M. M. Antagonists of luteinising hormone-releasing hormone (LHRH). Progress towards non-peptide leads 943
Dyer R. D. see Kramer J. B. 2827
Dyer R. D. see Unangst P. C. 1729

Ebert B. see Madsen U. 1649
Ebert B. see Nielsen B. 107
Ebner T. see Schneider F. 1667
Eckman J. see Li T. 2759
Eddershaw P. J. see Dowle M. D. 2047
Eden J. M. Horwell D. C. and Pritchard M. C. α,β-Didehydrotryptophan as a surrogate for α-methyltryptophan in CCK 'peptoids' related to CI-988 989
Edge C. M. see Jarvest R. L. 2851
Edmunds J. J. see Hodges J. C. 905
Edwards M. L. see Matthews D. P. 165
Egan L. A. see Janc J. W. 2313
Eggleston D. S. see Chenera B. 2717
Eglen R. M. see Clark R. D. 1375
Eichler J. see Schmidt M. 441
Eil C. see Clark J. W. 1873
Eissenstat M. A. see Wentland M. P. 1711
Elliott N. C. see Jaynes B. H. 1531
Emmert D. E. see Sawyer T. K. 819
Emonds-Alt X. Proietto V. Van Broeck D. Vilain P. Advenier C. Neliat G. Le Fur G. and Brelière J.-C. Pharmacological profile and chemical synthesis of SR 48968, a non-peptide antagonist of the neurokinin A (NK_2) receptor 925
Endermann R. see Schmidt G. 2193
Endo M. and Droghini R. Synthesis of *trans*-1-*p*-methoxyphenyl-3-acetoxy-4-phenylazetidin-2-one. A key starting β-lactam for 2'-*epi*-taxol 2483
Engler T. A. Lynch, Jr K. O. Reddy J. P. and Gregory G. S. Synthetic pterocarpans with anti-HIV activity 1229
Engman L. see Andersson C.-M. 2553
Ennis M. D. Hoffman R. L. and Lahti R. A. 4-Aminomethyl chromans: dependence of serotonin and dopamine binding upon aromatic ring substitution 1131
Epp J. B. see Groutas W. C. 1163
Epp J. B. see Groutas W. C. 2745
Epperson J. R. Hewawasam P. Meanwell N. A. Boissard C. G. Gribkoff V. K. and Post-Munson D. Synthesis and excitatory amino acid pharmacology of some novel quinoxalinediones 2801
Eritja R. see Bardella F. 2793
Essenburg A. D. see Trivedi B. K. 259
Evans B. E. Rittle K. E. Chang R. S. L. Lotti V. J. Freedman S. B. and Freidinger R. M. Multipurpose receptor ligands: β-carboline cholecystokinin antagonists 867
Evans J. M. see Burrell G. 999
Evrard D. see Ornstein P. L. 43
Ewan G. B. see Smith P. W. 931

Fairchild C. see Kant J. 2471
Falck J. R. and Abdali A. Total synthesis of D-*myo*-inositol 3,4,5-trisphosphate and 1,3,4,5-tetrakisphosphate 717
Falgueyret J. P. see Thérien M. 2063
Falotico R. see Sanfilippo P. J. 1385
Fang X. Song R. Gu Z. Rieser M. J. Miesbauer L. R. Smith D. L. and McLaughlin J. L. A new type of cytotoxic Annonaceous acetogenin: giganin from *Goniothalamus giganteus* 1153
Faraci W. S. Bakker A. V. Spencer R. W. Williams R. A. Jasys V. J. Kellogg M. S. and Volkmann R. A. Inhibition of human leukocyte elastase (HLE) by novel bicyclic β-lactams 2271
Farina V. see Kant J. 2471
Farmer W. L. see Guo J. Q. 147
Farooqui T. see Markovich K. M. 1241
Farouz-Grant F. and Miller M. J. Syntheses of novel 1-aminocyclopropane-1-carboxylic acid (ACC)-containing β-lactams 2423
Farré A. J. see Hueso-Rodríguez J. A. 269
Fässler A. Rösel J. Grütter M. Tintelnot-Blomley M. Alteri E. Bold G. and Lang M. Novel pseudosymmetric inhibitors of HIV-1 protease 2837
Fauq A. H. see Malaska M. J. 1247
Faust K. A. see de Laszlo S. E. 1299
Faust K. A. see Allen E. E. 1293
Feixas J. see Durán I. 2593
Fell S. C. M. see Bateson J. H. 2219
Ferkany J. W. Willetts J. Borosky S. A. Clissold D. B. Karbon E. W. and Hamilton G. S. Pharmacology of (2*R*,4*R*,5*S*)-2-amino-4,5-(1,2-cyclohexyl)-7-phosphonoheptanoic acid (NPC 17742); a selective, systemically active, competitive NMDA antagonist 33
Ferkany J. W. see Hamilton G. S. 27
Field A. K. see Ahmad S. 1215
Field A. K. see Vite G. D. 1211
Fillers S. see Bell P. 1007
Filocamo L. see Alisi M. A. 1931
Finke P. E. Dahlgren M. E. Weston H. Maycock A. L. and Doherty J. B. Inhibition of human leukocyte elastase—V. Inhibition by 6-alkyl substituted penem benzyl esters 2277
Finke P. E. see Hale J. J. 319
Finke P. E. see Shah S. K. 2295
Finke P. E. see Thompson K. R. 2283

Finke P. E. see Thompson K. R. 2289
Finkelstein J. A. see Chenera B. 2717
Firestone R. A. see Dubowchik G. M. 1965
Firestone R. A. see Dubowchik G. M. 2843
Firestone R. A. see Hudyma T. W. 323
Fischer J. B. see Reddy N. L. 2113
Fischer P. see Schneider F. 1667
Fischer R. S. Bonner C. A. Theodorou M. E. Plaxton W. C. Hrazdina G. and Jensen R. A.
Response of aromatic pathway enzymes of plant suspension cells to phosphate limitation 1415
Fisher E. see Allott C. P. 899
Fisher J. F. see Sawyer T. K. 819
Fisher M. H. see Blizzard T. A. 2093
Fisher M. H. see Meinke P. T. 2675
Fisker H. see Nielsen B. 107
Fitzsimmons B. J. see Thérien M. 2063
Fleisch J. H. see Sofia M. J. 1147
Fletcher D. S. see Thompson K. R. 2289
Fletcher S. R. Baker R. Ladduwahetty T. Sharpe A. Teall M. and Atack J. R.
4-Hydroxyphenoxymethylene bisphosphonic acid derivatives: potent, non-hydrolysable inhibitors of *myo*-inositol monophosphatase 141
Fletcher S. R. see Chambers M. S. 1919
Floreancig P. see Sofia M. J. 1147
Florineth A. see Papageorgiou C. 2559
Floyd C. D. see Whittaker M. 1493
Floyd D. M. see Atwal K. S. 2797
Flynn G. see Schirlin D. 253
Flynn G. A. see Burkholder T. P. 231
Flynn M. A. see Doherty A. M. 497
Foley J. see Bell P. 1007
Foley M. A. see Poindexter G. S. 2817
Forbes I. T. see Bolton D. 1941
Formaggio F. Pantano M. Crisma M. Toniolo C. Boesten W. H. J. Schoemaker H. E. Kamphuis J. and Becker E. L.
Backbone modified formyl-methionyl tripeptide chemoattractants 953
Forst J. see Russell K. 2727
Forst J. M. see Frank C. A. 2725
Foster A. C. see Carling R. W. 65
Foster A. C. see Leeson P. D. 299
Foster A. C. see Leeson P. D. 71
Fox C. B. see Chenard B. L. 91
Franceschi G. Bedeschi A. Rizzo V. Vigevani A. and Oberti R.
Structural studies of Ritipenem Acoxil (FCE 22891). X-Ray crystal structure and chiroptical properties 2333
Franceschi G. see Cabri W. 2255
Franceschi G. see Jabès D. 2165
Francis H. P. see Abram T. S. 1517
Franciskovich J. Houseman K. Mueller R. and Chmielewski J.
A systematic evaluation of the inhibition of HIV-1 protease by its C- and N-terminal peptides 765
Frank C. A. Forst J. M. Grant T. Harris R. J. Kau S. T. Li J. H. Ohnmacht C. J. Smith R. W. Trainor D. A. and Trivedi S.
Dihydropyridine K_{ATP} potassium channel openers 2725
Frank C. A. see Grant T. 2723
Frank R.
Strategies and techniques in simultaneous solid phase synthesis based on the segmentation of membrane type supports 425
Fraser F. see Whittaker M. 1493
Fraser J. see Bell P. 1007
Free C. A. see Poss M. A. 2739
Freedman S. B. see Evans B. E. 867
Freedman S. B. see Bock M. G. 871
Freedman S. B. see Chambers M. S. 1919
Freeman J. P. see Zhao S. 2641
Freidinger R. M. see Bock M. G. 871
Freidinger R. M. see Evans B. E. 867
French R. see Papageorgiou C. 2559
Frigola J. see Hueso-Rodríguez J. A. 269
Friis G. J. see Kahns A. H. 809
Frische K. see Schmidt R. R. 1747
Froelich L. L. see Sawyer J. S. 1981
Froelich L. L. see Sawyer J. S. 1985
Froelich L. L. see Sofia M. J. 1147
Frost J. W. see Montchamp J.-L. 1403
Früh Th. see Saika H. 2129
Fu K. P. see Ohemeng K. A. 225
Fuganti C. Grasselli P. Zucchi G. Allegrone G. and Barbeni M.
On the microbial biogeneration of (*R*) γ-jasmolactone 2777
Fuganti C. Lanati S. Servi S. and Tagliani A.
pH Dependence of the baker's yeast conversion of 4-benzoyloxycrotonaldehyde into the 1-benzoate of (2*R*) 1,2,4-butanetriol 2785
Fujii S. see Katsumura S. 2703
Fujiki H. see Quinn R. J. 1029
Fujisawa T. Sato D. and Shimizu M.
Stereocontrolled construction of 3-sulfenylazetidin-2-ones 2343
Fujita M. see Kobori T. 2225
Fukushima Y. Sakagami Y. and Marumo S.
β-Glucan biosynthesis inhibitors isolated from fungi as hyphal malformation inducer 1219
Fukushima Y. see Bastow K. F. 1045
Fulcrand P. see Rolland M. 851
Funayama N. see Ito S. 611
Furka Á. see Sebestyén F. 413
Furman P. A. see Choi W.-B. 693
Furman P. A. see Wilson L. J. 169

Gaida W. see Beck-Sickinger A. G. 937
Gaikema J. J. see Brickner S. J. 2241
Galarza R. see Palomo C. 2461
Galas M.-C. see Rolland M. 851
Galbraith W. see Wilkerson W. W. 2087
Galbraith W. see Wilkerson W. W. 711
Gallais C. see Langlois M. 1555
Gallegos A. see Kozikowski A. P. 1323
Galloway W. A. see Whittaker M. 1493
Galunsky B. see Dineva M. A. 2781
Ganesh K. N. see Barawkar D. A. 347
Ganesh K. N. see Prakash T. P. 689
Ganguly A. K. see Afonso A. 2177
Ganguly A. K. see Cooper A. B. 1079
Ganguly A. K. see Wong J. K. 1073
García-Echeverría C. and Rich D. H.

Synthesis and fluorescence properties of a substrate for a continuous fluorimetric assay of protein tyrosine phosphatases 1601
Gardiner P. J. see Abram T. S. 1517
Garland D. J. see Reitz D. B. 1055
Garofalo J. see Guo J. Q. 147
Garrick L. see Soll R. M. 757
Garrigue H. see Dekhane M. 2831
Gasparski C. M. see Teng M. 2431
Gaster L. M. see Baxter G. S. 633
Gateau-Olesker A. see Adonias M. 2547
Gaudy F. see Langlois M. 2035
Gauthier J. Y. see Guay D. 1125
Ge Y. Nakatani K. and Isoe S. Cytotoxicity of *ent*-udoteatrial diacetate and its analogues 1085
Gee K. R. Weber E. and Keana J. F. W. Monocyclization of *N*-(2,2-diethoxyethyl)-1,2-diphenylethylamines to the 4-aryl-1-hydroxy-2,3,4,5-tetrahydro-1*H*-3-benzazepine ring system 251
Gentles M. see Afonso A. 2177
Georg G. I. Cheruvallath Z. S. Harriman G. C. B. Hepperle M. and Park H. An efficient semisynthesis of taxol from (3*R*,4*S*)-*N*-benzoyl-3-[(*t*-butyldimethylsilyl)oxy]-4-phenyl-2-azetidinone and 7-(triethylsilyl)baccatin III 2467
Georg G. I. Cheruvallath Z. S. Vander Velde D. Ye Q.-M. Mitscher L. A. and Himes R. H. Semisynthesis and biological evaluation of brevifoliol 13-[*N*-benzoyl-(2'*R*,3'*S*)-3'-phenylisoserinate] 1349
Georg G. I. Gollapudi S. R. Grunewald G. L. Gunn C. W. Himes R. H. Rao B. K. Liang X.-Z. Mirhom Y. W. Mitscher L. A. Vander Velde D. G. and Ye Q.-M. A reinvestigation of the taxol content of Himalayan *Taxus wallichiana* Zucc. and a revision of the structure of brevifoliol 1345
George C. X. see Pratap R. 1061
Georgopapadakou N. see Hanessian S. 2323
Gerena L. see Casteel D. A. 1707
Gerhard U. Searle M. S. and Williams D. H. The free energy change of restricting a bond rotation in the binding of peptide analogues to vancomycin group antibiotics 803
Gero S. D. see Adonias M. 2547
Gerskowitch V. P. see Barraclough P. 509
Gesson J.-P. and Mondon M. Spiroepoxycyclohexadienone dimers: cytotoxic bisalkylating agents 735
Geysen H. M. and Mason T. J. Screening chemically synthesized peptide libraries for biologically-relevant molecules 397
Geysen H. M. see Spellmeyer D. C. 1253
Geysen H. M. see Spellmeyer D. C. 519
Geysen H. M. see Wang J. 447
Geysen H. M. see Wang J. 451
Ghosez L. see Durand T. 2309
Ghosez L. see Marchand-Brynaert J. 2303
Ghoshal N. Mukhopadhyay S. N. Ghoshal T. K. and Achari B. Quantitative structure–activity relationship studies of aromatic and hetero-aromatic nitro compounds using neural network 329
Ghoshal T. K. see Ghoshal N. 329
Giacomini D. see Bandini E. 2347
Giannotti D. see Altamura M. 2159
Giardino E. see Sanfilippo P. J. 1385
Gibbs E. M. see Hulin B. 703
Gibbs R. A. Mu Y. and Wang F. An NMR method for elucidating the stereochemistry of protein farnesylation 281
Giblin G. M. P. Bell R. Hancock A. P. Hartley C. D. Inglis G. G. A. Payne J. J. Procopiou P. A. Shingler A. H. Smith C. and Spooner S. J. Semi-synthetic squalestatins: squalene synthase inhibition and antifungal activity. The SAR of C6 and C7 modifications 2605
Gibson K. H. Wood R. Oldham A. A. and Major J. S. The synthesis of heterosubstituted benzimidazole derivatives with potent angiotensin II antagonist activity 1019
Giles H. see Barraclough P. 509
Gill A. see Bandurco V. T. 375
Gill A. see Hsi J. D. 1523
Gill A. see Murray W. V. 369
Gill A. see Murray W. V. 785
Giralt E. see Bardelia F. 2793
Girardet J.-L. see Périgaud C. 2521
Girijavallabhan V. M. see Cooper A. B. 1079
Glen R. C. see Barraclough P. 509
Glick G. D. see Swanson P. C. 2117
Gliesing S. see Schönecker B. 1849
Gmeiner P. Sommer J. Mierau J. and Höfner G. Dopamine autoreceptor agonists: computational studies, synthesis and biological investigations 1477
Goff J. P. Horst R. L. and Uskokovic M. 1,25,28-Trihydroxyvitamin D_2 up-regulates renal vitamin D receptor without causing hypercalcemia 1825
Goggins G. D. see Lawson J. E. 561
Goggins G. D. see Poindexter G. S. 2817
Goldberg S. I. and Liu X.-P. On the function of the 2'-hydroxyl group in the peptidyl tRNA terminus during elongation in ribosomal peptide biosynthesis 1527
Goldenberg H. see Das J. 1267
Goldenberg H. see Das J. 1271
Goldenberg H. see Hall S. E. 1263
Golebiewski W. M., Bader J. P. and Cushman M. Design and synthesis of cosalane, a novel anti-HIV agent 1739
Gollapudi S. R. see Georg G. I. 1345
Goodfellow V. see Vite G. D. 1211
Gordon J. I. see Devadas B. 779
Gordon T. Hansen P. Morgan B. Singh J. Baizman E. and Ward S. Peptide azoles: a new class of biologically-active dipeptide mimetics 915
Gormley J. J. see Dutta A. S. 943
Gorrichon L. see Baltas M. 1447
Gosselin G. see Périgaud C. 2521
Gossett L. S. see Shih C. 2657
Gostoli G. see Alisi M. A. 1931
Goz B. see Bastow K. F. 1045
Graham A. C. see Wilkening R. R. 1287
Grande M. see Adonias M. 2547
Grant T. Frank C. A. Kau S. T. Li J. H. McLaren F. M. Ohnmacht C. J. Russell K. Shapiro H. S. and Trivedi S. Anilide tertiary carbinols: a

new structural class of potent potassium channel openers 2723
Grant T. see Frank C. A. 2725
Grant T. see Russell K. 2727
Grasselli P. see Fuganti C. 2777
Green A. M. see Wright S. W. 2875
Green M. J. see Wong J. K. 1073
Greenfield L. J. see Brickner S. J. 2241
Greenlee W. J. see de Laszlo S. E. 1299
Greenlee W. J. see Allen E. E. 1293
Greenlee W. J. see Mills S. G. 2707
Greenlee W. J. see Rivero R. A. 557
Greenlee W. J. see Wu M. T. 2023
Gregory G. S. see Engler T. A. 1229
Gribkoff V. K. see Epperson J. R. 2801
Griffith R. K. and DiPietro R. A. Synthesis of 4(5)-imidazolyl allylamines and propargylamines as inhibitors of diamine oxidase 353
Grimwood S. see Carling R. W. 65
Grindey G. B. see Shih C. 2657
Gross J. L. see Moyer M. P. 1379
Groutas W. C. Castrisos J. C. Stanga M. A. Kuang R. Venkataraman R. Epp J. B. Brubaker M. J. and Chong L. S. Heterocyclic inhibitors of human leukocyte elastase: 3-hydroxypyridazopyrimidine, 3-hydroxypyridopyrimidine and 3-hydroxyquinazoline-2,4-(1*H*,3*H*)dione derivatives 1163
Groutas W. C. Chong L. S. Venkataraman R. Huang H. Epp J. B. and Kuang R. A general approach toward the design of mechanism-based inactivators of serine proteinases: inactivation of human leukocyte elastase by a phthalimide derivative 2745
Grouzmann E. see Beck-Sickinger A. G. 937
Groves J. T. see Kady I. O. 1367
Grunewald G. L. see Georg G. I. 1345
Grütter M. see Fässler A. 2837
Gruys K. J. see Miller M. J. 1435
Gu Z. see Fang X. 1153
Guay D. Gauthier J. Y. Metters K. M. Roy P. and Zamboni R. J. A new series of potent LTD_4 antagonists in the styrylquinoline class 1125
Guay J. see Thérien M. 2063
Guedj C. see Pucci B. 1003
Gueremy C. see Mignani S. 1913
Guerrero A. see Durán I. 2593
Guillaumet G. see Besson T. 1935
Guittet E. see Krief A. 365
Guiati D. see Pratap R. 1061
Gunda T. E. and Sztaricskai F. Asymmetric synthesis of *cis*-3-phthalimido-4-styryl-2-azetidinones. Application of a new chiral N-protecting group in monobactam chemistry 2379
Gunda T. E. see Pitlik J. 2451
Gunn C. W. see Georg G. I. 1345
Guo J. Q. Wu Y. Q. Farmer W. L. Douglas K. A. Woster P. M. Garofalo J. and Bacchi C. J. Restricted rotation analogs of *S*-adenosylmethionine: synthesis, evaluation as inhibitors of *S*-adenosylmethionine decarboxylase, and potential use as selective antitrypanosomal agents 147
Guo J. Q. see Wu Y. Q. 2811
Gurjar M. K. and Saha U. K. Synthesis of the complete glycotetrapeptide core of structurally variant *Mycobacterium fortuitum* glycopeptidolipid 697
Gutiérrez B. see Hueso-Rodríguez J. A. 269
Guy A. Dumant A. and Sziraky P. Kinetic resolution of *p*-hydroxyphenyl acetamides by hydrolysis with Pen-G acylase 1041
Guyton K. Z. see Posner G. H. 1835

Habeck L. L. see Shih C. 2657
Hacksell U. see Liljebris C. 241
Hadden S. see Bandurco V. T. 375
Hagan R. M. see Smith P. W. 931
Hale J. J. Finke P. E. and MacCoss M. A facile synthesis of the novel Neurokinin A antagonist SR 48968 319
Halkes S. J. see Kutner A. 1795
Halkes S. J. see Nilsson K. 1855
Hall S. E. Han W.-C. Harris D. N. Goldenberg H. Michel I. M. Monshizadegan H. and Webb M. L. Synthesis of pyrrolidine oxazoles as thromboxane A_2/endoperoxide receptor antagonists 1263
Hall S. E. see Das J. 1267
Hallberg A. see Andersson C.-M. 2553
Haltiner R. see Papageorgiou C. 2559
Hamblett J. see Middleniss D. 589
Hamby J. M. see Plummer M. 2119
Hamel E. see Beutler J. A. 581
Hamelehle K. L. see Trivedi B. K. 259
Hamilton G. S. Huang Z. Patch R. J. Narayanan B. A. and Ferkany J. W. Enzymatic asymmetric synthesis of (2*R*,4*R*,5*S*)-2-amino-4,5-(1,2-cyclohexyl)-7-phosphonoheptanoic acid, a potent selective and competitive NMDA antagonist 27
Hamilton G. S. see Ferkany J. W. 33
Hamilton H. Steinbaugh B. Blankley J. Taylor M. Chan O. H. Stewart B. Schroeder R. Ryan M. Rapundalo S. Cook J. Bernabei A. and Stewart C. Evaluation of the intestinal permeability and hepatic handling of peptidomimetic analogs 813
Hammoud A. see Tellier F. 1629
Hámori T. see Tarnawa I. 99
Han C. Y. see Miller M. J. 1435
Han W.-C. see Das J. 1267
Han W.-C. see Hall S. E. 1263
Hanada K. see Kobori T. 2225
Hancock A. P. see Giblin G. M. P. 2605
Hand K. M. see Thompson K. R. 2289
Hanessian S. Couture C. A. and Georgopapadakou N. Probing the binding site of the penicillin side-chain based on the Tipper–Strominger hypothesis 2323
Hann M. M. see Holmes D. S. 1485
Hansen J. J. see Nielsen B. 107
Hansen P. see Gordon T. 915
Hare R. S. see Afonso A. 2177
Harriman G. C. B. see Georg G. I. 2467
Harris D. N. see Das J. 1267
Harris D. N. see Das J. 1271
Harris D. N. see Hall S. E. 1263
Harris J. see Shneier A. 1399
Harris R. see Wilkerson W. W. 711
Harris R. J. see Frank C. A. 2725
Harris R. R. see Wilkerson W. W. 2087
Harrison A. W. see Sawyer T. K. 819

Harte W. E. see Yu K.-L. 535
Hartenstein J. see Kleinschroth J. 1959
Hartley C. D. see Giblin G. M. P. 2605
Hartupee D. see Soll R. M. 757
Hartwig W. see Abram T. S. 1517
Haruyama H. see Miyauchi M. 2447
Hastie S. B. see Andres C. J. 565
Hastings R. C. see Babine R. E. 1589
Hastings R. C. see Trova M. P. 1595
Hattori K. and Yamamoto H. Novel asymmetric synthesis of β-lactams with 3-(1'-hydroxyethyl) substituents: boron reagent mediated aldol reaction of chiral imines and silyl ketene acetals derived from 3-hydroxybutyrate 2337
Hausschild U. see Schönecker B. 1849
Hawkes T. R. see Ramjee M. K. 1409
Hawkins A. R. see Shneier A. 1399
Hay A. see McGuigan C. 1203
Hayakawa K. see Saika H. 2129
Hayes T. K. see Sato M. 1277
Haye S. J. Boxer P. A. Taylor C. P. Vartanian M. G. Robichaud L. J. and Nielsen E. Ø. N-Sulfonyl derivatives of 6,7-dichloro-3,4-dihydro-3-oxo-quinoxalinecarboxylate as glycine-site NMDA and AMPA antagonists 77
Hayward C. J. see Bolton D. 1941
He J. X. see Doherty A. M. 497
Hearn M. T. W. see Thompson P. E. 1625
Hecker S. J. Cooper C. B. Blair K. T. Lilley S. C. Minich M. L. and Werner K. M. Semisynthetic modification of hygromycin A—II. Synthesis and antibacterial activity of aryl analogs 289
Hecker S. J. Lilley S. C. Minich M. L. and Werner K. M. Application of hygromycin A structure activity relationships to the antibiotic A201A 295
Hecker S. J. see Jaynes B. H. 1531
Hedberg A. see Atwal K. S. 2797
Heffner T. G. see Jaén J. C. 639
Heffner T. G. see Wustrow D. J. 277
Heinrikson R. L. see Sawyer T. K. 819
Hennessy B. M. see Batcho A. D. 1821
Henry J. A. Horwell D. C. Meecham K. G. and Rees D. C. A structure–affinity study of the amino acid side-chains in neurotensin: N and C terminal deletions and Ala-scan 949
Hepperle M. see Georg G. I. 2467
Herbert C. M. see Jones A. B. 1999
Herbert C. M. see Wilkening R. R. 1287
Herdewijin P. see Van Aerschot A. 1013
Herdewijn P. see Vandendriessche F. 193
Herin M. see Krief A. 365
Hernando J. I. M. see Adonias M. 2547
Herrmann K. M. see Weaver L. M. 1421
Hersh E. M. see Lam K. S. 419
Hertzberg R. P. see Jarvest R. L. 2851
Hester J. B. see Sawyer T. K. 819
Hetru C. see Mauvais A. 1951
Hewawasam P. see Epperson J. R. 2801
Hicks F. see Burrell G. 999
Higginbottom M. Horwell D. C. and Roberts E. Selective ligands for cholecystokinin receptor subtypes CCK-A and CCK-B within a single structural class 881
Higginbottom M. Nolan W. O'Toole J. Ratcliffe G. S. Rees D. C. and Roberts E. The design and synthesis of kappa opioid ligands based on a binding model for kappa agonists 841
Hilditch A. see Dowle M. D. 2047
Hilditch A. see Middlemiss D. 2043
Hilditch A. see Middlemiss D. 589
Hill D. Horwell D. C. Hunter J. C. Kneen C. O. Pritchard M. C. and Suman-Chauhan N. Synthesis of a potent and selective non-peptide CCK-B/gastrin receptor antagonist tritiated ligand 885
Hill D. see Padia J. K. 2805
Hill K. E. see Doherty A. M. 497
Hills J. M. see Howson W. 515
Himejima M. see Kubo I. 1305
Himes R. H. see Georg G. I. 1345
Himes R. H. see Georg G. I. 1349
Hingorani G. see Plummer M. 2119
Hirsch K. R. see Wikel J. H. 1157
Hirst G. C. see Middlemiss D. 2043
Hirst G. C. see Middlemiss D. 589
Hiyama T. see Kobori T. 2225
Hobbs S. C. see Chambers M. S. 1919
Hobson J. E. see Dowle M. D. 2047
Hodge C. N. and Pierce J. A diazine heterocycle replaces a six-membered hydrogen-bonded array in the active site of scytalone dehydratase 1605
Hodges J. C. Edmunds J. J. Nordblom G. D. and Lu G. H. The syntheses and binding affinities of tools for the study of angiotensin AT_2 receptors 905
Hodgson S. T. Wates P. J. Blackwell G. J. Craig C. Yeadon M. and Boughton-Smith N. Design and synthesis of achiral 5-lipoxygenase inhibitors employing the cyclobutyl group 2565
Hoffman R. L. see Ennis M. D. 1131
Hoffmann E. see Beck-Sickinger A. G. 937
Hoffmeyer L. see von Daehne W. 2247
Höfner G. see Gmeiner P. 1477
Holl W. W. see Cheng H.-Y. 1179
Holmes D. S. Clemens I. R. Cobley K. N. Humber D. C. Kitchin J. Orr D. C. Patel B. Paternoster I. L. and Storer R. Novel dimeric penicillin derived inhibitors of HIV-1 proteinase: interaction with the catalytic aspartates 503
Holmes D. S. Bethell R. C. Hann M. M. Kitchin J. Starkey I. D. and Storer R. The design and synthesis of novel hydroxyproline inhibitors of HIV-1 proteinase 1485
Holmes M. A. see Organ H. M. 657
Holt D. A. Konialian A. L. Brandt M. Levy M. A. Bossard M. J. Luengo J. I. Newman-Tarr T. and Badger A. Structure–activity studies of nonmacrocyclic rapamycin derivatives 1977
Holt D. A. Oh H.-J. Rozamus L. W. Yen H.-K. Brandt M. Levy M. A. and Metcalf B. W. Synthesis and evaluation of 3-carboxymethyl steroids as inhibitors of human protatic steroid 5a-reductase 1735
Holton R. A. and Liu J. H. A novel asymmetric synthesis

of *cis*-3-hydroxy-4-aryl azetidin-2-ones 2475
Hon F. see Afonso A. 2177
Hong B.-C. see Winkler J. D. 577
Hong K. W. see Yoo S. 553
Hoogmartens J. see Vandendriessche F. 193
Hooker E. see Siddiqui M. A. 1543
Hooper J. N. A. see Pettit G. R. 2669
Horan P. see Hristova-Kazmierski M. K. 831
Hornyák M. see Sztaricskai F. 235
Horst R. L. see Batcho A. D. 1821
Horst R. L. see Clark J. W. 1873
Horst R. L. see Goff J. P. 1825
Horvath R. see Hristova-Kazmierski M. K. 831
Horwell D. C. see Bourne G. T. 889
Horwell D. C. Howson W. Ratcliffe G. S. and Rees D. C.
The design of a dipeptide library for screening at peptide receptor sites 799
Horwell D. C. see Campbell M. M. 667
Horwell D. C. see Eden J. M. 989
Horwell D. C. see Henry J. A. 949
Horwell D. C. see Higginbottom M. 881
Horwell D. C. see Hill D. 885
Horwell D. C. see Padia J. K. 2805
Hosmane R. S. see Mumper M. W. 2847
Hou D. Mas J. L. Chan T.-M. Wong Y.-S. Steinman M. and McPhail A. T.
Novel, stereoselective syntheses of penem antibiotics: efficient, formal syntheses of Sch 34343 2171
Houghten R. A. and Dooley C. T.
The use of synthetic peptide combinatorial libraries for the determination of peptide ligands in radio-receptor assays: opioid peptides 405
Houseman K. see Franciskovich J. 765
Howarth N. M. Cooper G. Purohit A. Duncan L. Reed M. J. and Potter B. V. L.
Phosphonates and thiophosphonates as sulfate surrogates: synthesis of estrone 3-methylthiophosphonate, a potent inhibitor of estrone sulfatase 313
Howbert J. J. Lobb K. L. Britton T. C. Mason N. R. and Bruns R. F.
Diphenylpyrazolidinone and benzodiazepine cholecystokinin antagonists: a case of convergent evolution in medicinal chemistry 875
Howe B. see Russell K. 2727
Howe W. J. see Sawyer T. K. 819
Howson W. Mistry J. Broekman M. and Hills J. M.
Biological activity of 3-aminopropyl (methyl) phosphinic acid, a potent and selective $GABA_B$ agonist with CNS activity 515
Howson W. see Horwell D. C. 799
Hrazdina G. see Fischer R. S. 1415
Hristova-Kazmierski M. K. Horan P. Davis P. Yamamura H. I. Kramer T. Horvath R. Kazmierski W. M. Porreca F. and Hruby V. J.
A new approach to enhance bioavailability of biologically active peptides: conjugation of a δ opioid agonist to β-cyclodextrin 831
Hruby V. J. see Boteju L. W. 2011
Hruby V. J. see Hristova-Kazmierski M. K. 831
Hruby V. J. see Lam K. S. 419
Hsi J. D. Murray W. V. and Gill A.
A highly efficient synthesis of RWJ 47639: a novel, orally active angiotensin II receptor antagonist 1523
Hsiao K.-F. Wu S.-H. and Wang K.-T.
Regioselective deacetylation of secondary acetyl esters in peracetylated methyl glycopyranosides by *Aspergillus niger* lipase 2125
Hsu G. C. see Trova M. P. 1595
Hu Y. see Shih C. 2657
Huang D. F. see Li T. 2759
Huang H. see Groutas W. C. 2745
Huang H.-C. see Chen S.-T. 727
Huang L. Morgan A. R. and Lown J. W.
Design of DNA-cleaving molecules which incorporate a simplified metal-complexing moiety of bleomycin and lexitropsin carriers 1751
Huang S. see Kant J. 2471
Huang S. X. see Allen E. E. 1293
Huang Z. see Hamilton G. S. 27
Hubbard T. see Middleniss D. 2043
Hubbard T. see Middleniss D. 589
Huber E. W. see Burkholder T. P. 231
Hudyma T. W. Bush K. Colson K. L. Firestone R. A. and King H. D.
Synthesis and release of doxorubicin from a cephalosporin based prodrug by a β-lactamase-immunoconjugate 323
Hueso-Rodríguez J. A. Berrocal J. Gutiérrez B. Farré A. J. and Frigola J.
Preparation of the enantiomers of the analgesic E-3710 269
Huger F. P. see Kapples K. J. 2789
Hughes I. see Bermudez J. 2571
Hughes P. S. see Simpson W. J. 769
Hui J. O. see Sawyer T. K. 819
Hulin B. Lau C. L. and Gibbs E. M.
Synthesis of a biotin conjugate of darglitazone, a new antidiabetic agent. A general protocol for the reversible biotinylation of ketones 703
Hull R. A. D. see Barraclough P. 509
Humber D. C. see Holmes D. S. 503
Humphrey G. R. see Madar A.-M. 2393
Humphrey J. M. see Bridges R. J. 115
Hunt A. A. E. see Dowle M. D. 2047
Hunt A. A. E. see Middleniss D. 2043
Hunter J. C. see Hill D. 885
Hutchinson D. K. see Barbachyn M. R. 671
Hutson J. L. see Procopiou P. A. 2527
Hutson J. L. see Watson N. S. 2541
Huynh-Dinh T. see Desseaux C. 1547
Hwang S. M. see Cheng H.-Y. 1179

Iannelli M. A. see Alisi M. A. 1931
Ikeda K. see Katsumura S. 2703
Ikeda S. see Siddiqi S. M. 663
Ikekawa N.
Stereochemistry and physiological significance of hydroxylation of vitamin D side chain 1789
Ikeler T. J. see Wu M. T. 2023
Imagawa J. see Koga H. 1111
Imagawa J. see Koga H. 2005
Imamaki K. see Yokota M. 1687
Imbach J.-L. see Périgaud C. 2521
Imuta M. Itani H. Nishi K. Ona H. Uyeo S. and Kimura Y.

Synthesis and antibacterial activity of 2-functionalized-vinyl 1β-methylcarbapenems and related compounds 2199
Inada M. see Matsuda A. 2751
Inglis G. G. A. see Giblin G. M. P. 2605
Inoue A. and Satoh K. Identification of a new fluorescent compound isolated from human lens insoluble protein fraction 345
Ireland S. J. see Smith P. W. 931
Irurre, Jr J. Casas J. and Messeguer A. Resistance of the 2,2,2-trifluoroethoxy aryl moiety to the cytochrome P-450 metabolism in rat liver microsomes 179
Ishida M. see Ohfune Y. 15
Ishiguro M. see Tanaka R. 2299
Ishizawa T. Koga H. Ohta M. Sato H. Makino T. Kuromaru K. Taka N. Takahashi T. Sato T. and Nabata H. Structure–activity relationships of 6-substituted benzopyran-4-carbothio-amide potassium channel openers 1659
Ishizawa T. see Koga H. 625
Ishizawa T. see Koga H. 1111
Ishizawa T. see Koga H. 1115
Ishizawa T. see Koga H. 2005
Ishizawa T. see Sato H. 2627
Isobe M. see Takahashi H. 2647
Isoe S. see Ge Y. 1085
Itani H. see Imuta M. 2199
Ito S. Ando S. Yamaguchi K. Funayama N. Yamamoto T. Kuroiwa Y. Kubota T. and Komoda Y. Preparation and evaluation of the antiaggregating and vasodilating activities of the novel 3-nitro-4(3*H*)-quinazolinone derivatives 611
Iturburu M. see Palomo C. 2461
Iwama S. see Katsumura S. 2703
Iwasaki G. see Saika H. 2129
Iyer M. S. and Lipton M. A. An improved synthesis of the diketopiperazine catalyst *cyclo*[(*S*)-His-(*S*)-Phe] 2061
Iyer R. see Barraclough P. 509

Jabès D. Rossi R. Della Bruna C. Perrone E. Alpegiani M. Andreini B. P. Visentin G. Zarini F. and Franceschi G. Activity of new penems against defined MRSA strains 2165
Jabes D. see Cabri W. 2255
Jack T. I. see Middlemiss D. 589
Jack T. I. see Dowle M. D. 2047
Jackson R. G. see Leeson P. D. 1925
Jackson W. T. see Sawyer J. S. 1981
Jackson W. T. see Sawyer J. S. 1985
Jackson W. T. see Sofia M. J. 1147
Jacober S. see Skiles J. W. 773
Jacobs G. A. see Ahmad S. 1215
Jacobs J. W. see Skerker P. S. 285
Jaén J. C. Caprathe B. W. Wise L. D. Meltzer L. T. Pugsley T. A. and Heffner T. G. Synthesis and pharmacological evaluation of the enantiomers of the dopamine autoreceptor agonist PD 135385 639
Jaffe E. K. see Rajagopalan J. S. 1453
Jagerovic N. see Pandey R. K. 2615
Jain R. K. Pawar S. M. Chandrasekaran E. V. Piskorz C. F. and Matta K. L. Synthesis of Galβ1→3(Fucα1→4)GlcNAcβ -OR as potential acceptors for a new member of the α-1 2-L-fucosyltransferase family 1333
James K. and Palmer M. J. *gem*-Cycloalkyl substituted thiol inhibitors of neutral endopeptidase 24.11. Synthesis via nucleophilic opening of 2,2-spiro-β-lactones 825
James K. see Leeson P. D. 1925
Janc J. W. Egan L. A. and Townsend C. A. Emerging evidence for a shared biosynthetic pathway among clavulanic acid and the structurally diverse clavam metabolites 2313
Janusz M. J. see Angelastro M. R. 525
Jarvest R. L. Breen A. L. Edge C. M. Chalkin M. A. Jennings L. J. Truneh A. Sweet R. W. and Hertzberg R. P. Structure-directed discovery of an inhibitor of the binding of HIV GP120 to the CD4 receptor 2851
Jastrzebski J. T. B. H. and van Koten G. The zinc mediated condensation of amino acid esters with imines to β-lactams 2351
Jasys V. J. see Faraci W. S. 2271
Jayakumar R. and Pattabhi V. Conformational preference of N-acyl urea containing valine residue in DMSO-d_6 153
Jaynes B. H. Cooper C. B. Hecker S. J. Blair K. T. Elliott N. C. Lilley S. C. Minich M. L. Schicho D. L. and Werner K. M. Synthesis and *in vitro* antibacterial activity of hygromycin A analogs modified at the $C_{4'}$ aryl position 1531
Jeko J. see Pitlik J. 2451
Jenkinson H. J. see Belleau B. 1723
Jennings L. J. and Parratt M. J. Synthesis and antiviral activity of 9-(phosphonoalkynyloxy)purines : novel acyclonucleotides 2611
Jennings L. J. see Jarvest R. L. 2851
Jensen L. H. see Wätjen F. 105
Jensen R. A. see Fischer R. S. 1415
Jensen R. A. see Zamir L. O. 1441
Jimonet P. Beaudoin F. Chevé M. Ducrotoy G. Dutruc-Rosset G. Lurier D. Rataud J. Stutzmann J.-M. and Mignani S. Optical isomers of RP 64406: new potent antiglutamate agents 983
Jirousek M. R. see Babine R. E. 1589
Jirousek M. R. see Trova M. P. 1595
Johanson K. see Cheng H.-Y. 1179
Johnson A. L. see Cain G. A. 1767
Johnson A. L. see Cain G. A. 2055
Johnson A. L. see Carini D. J. 895
Johnson A. L. see Christos T. E. 1035
Johnson B. D. see Babine R. E. 1589
Johnson B. D. see Trova M. P. 1595
Johnson G. see Malone T. C. 49
Johnson K. A. see Knowles W. S. 2863
Johnson K. M. see Kozikowski A. P. 1327
Johnson L. K. see Manoharan M. 2765
Johnson L. L. see Winter R. W. 2079
Johnson M. E. see Sato M. 1277
Johnson M. E. see Su T. 835

Jones A. B. and Herbert C. M. Assessment of the biological value of the 11-hydroxy group of the azalides 1999
Jones C. D. see Wikel J. H. 1157
Jones P.-J. see Tong L. 721
Jones S. K. see Donkor I. O. 1137
Jordan C. L. see Ternansky R. J. 2443
Jordan C. C. see Smith P. W. 931
Joseph M. and Nagaraj R. A convenient method for the synthesis of peptides acylated with palmitic acid specifically at cysteine thiol 1025
Judd D. B. see Dowle M. D. 2047
Judy M. M. see Chang S.-C. 555
Jung G. see Beck-Sickinger A. G. 937
Jung G. see Stevanovic S. 431

Kadarpik V. see Parve O. 357
Kadarpik V. see Parve O. 359
Kadow J. F. see Zein N. 1351
Kady I. O. and Groves J. T. Synthesis of iron-binding oligonucleotides and their reactions with single-stranded DNA 1367
Kahn M. see Sato M. 1277
Kahn M. see Su T. 835
Kahns A. H. Friis G. J. and Bundgaard H. Protection of the peptide bond against α-chymotrypsin by the prodrug approach 809
Kalindjian S. B. see McDonald I. M. 1511
Kaluza Z. Manhas M. S. Barakat K. J. and Bose A. K. Stereospecific synthesis of a novel bicyclic β-lactam 2357
Kamal A. Reddy B. S. P. and Thurston D. E. Synthesis and antimicrobial activity of 5-thioabbeymycin: limitations of the iminothioether approach to carbinolamine-containing pyrrolobenzodiazepines 743
Kameyama Y. see Tanaka H. 2253
Kamphuis J. see Formaggio F. 953
Kanbara K. see Kim S.-G. 1223
Kane J. M. see Maynard G. D. 753
Kaneda Y. see Kobori T. 2225
Kaneko S. see Murata K. 2685
Kant J. Huang S. Wong H. Fairchild C. Vyas D. and Farina V. Studies toward structure–activity relationships of Taxol®: synthesis and cytotoxicity of Taxol® analogues with C-2′ modified phenylisoserine side chains 2471
Kapples K. J. Shutske G. M. Bores G. M. and Huger F. P. Synthesis and *in vitro* acetylcholinesterase inhibitory activity of some 1-substituted analogues of velnacrine 2789
Karbon E. W. see Ferkany J. W. 33
Karran E. H. see Bermudez J. 2571
Kasche V. see Dineva M. A. 2781
Katagiri T. see Takabe K. 157
Katsumura S. Iwama S. Matsuda T. Tani T. Fujii S. and Ikeda K. Synthesis of oxazolidinone phospholipid analogue as a new inhibitor of phospholipase A_2 2703
Katz L. B. see Sanfilippo P. J. 1385
Kau S. T. see Frank C. A. 2725
Kau S. T. see Grant T. 2723
Kau S. T. see Russell K. 2727
Kaura A. C. and Pearson M. J. Synthesis and antibacterial activity of two catechol-bearing penems 2183
Kawai T. see Yanagisawa T. 1559
Kawakami H. Muraoka M. Sugie A. Ono K. and Kojima A. Syntheses of new 3-oxa-methano-PGI_1 derivatives and their biological properties 2821
Kawamoto I. see Miyauchi M. 2447
Kawata H. see Shinozuka K. 2883
Kazanietz M. G. see Lee J. 1101
Kazanietz M. G. see Lee J. 1107
Kazanietz M. G. see Winkler J. D. 577
Kazmierski W. M. see Hristova-Kazmierski M. K. 831
Kazmierski W. M. see Lam K. S. 419
Keana J. F. W. see Gee K. R. 251
Keana J. F. W. see Reddy N. L. 2113
Keeling S. E. see Watson N. S. 2541
Keenan R. M. see Samanen J. M. 909
Keiding J. see von Daehne W. 2247
Kellogg M. S. see Faraci W. S. 2271
Kemp J. A. see Leeson P. D. 299
Kemp J. A. see Carling R. W. 65
Kemp J. A. see Leeson P. D. 71
Kennedy J. A. see Kramer J. B. 2827
Kensler T. W. see Posner G. H. 1835
Kerr J. see Wilkerson W. W. 711
Kerr J. M. Banville S. C. and Zuckermann R. N. Identification of antibody mimotopes containing non-natural amino acids by recombinant and synthetic peptide library affinity selection methods 463
Kerwar S. S. see Babine R. E. 1589
Kerwar S. S. see Trova M. P. 1595
Kevin N. J. see Rivero R. A. 1119
Kim C. U. Misco P. F. Luh B. Y. Terry B. Bisacchi G. and Mansuri M. M. (2*R*4*S*,5*S*)-1-(Tetrahydro-4-hydroxy-5-methoxy-2-furanyl)thymine: a potent selective inhibitor of herpes simplex thymidine kinase 1571
Kim D. H. A proposal for a three-dimensional representation of the S_1 subsite of α-chymotrypsin 1313
Kim D. H. Lee S.-S. Whang D. and Kim K. Aromatic–aromatic ring interactions tested in cyclophanes 263
Kim D. H. and Kim Y. J. Synthesis and inhibitory activity of optically active 2-benzyl-3-mercaptopropanoic acid against carboxypeptidase A 2681
Kim H.-S. and Oh S. H. Chemical synthesis of 15-ketosterols 1339
Kim K. see Kim D. H. 263
Kim K. S. Qian L. Dickinson K. E. J. Delaney C. L. Bird J. E. Waldron T. L. and Moreland S. Synthesis, biological properties, and structure–activity relationships of quinoxaline angiotensin II receptor antagonists 2667
Kim S.-G. Kanbara K. Nakashima H. Yamamoto N. Murakami K. and Takaku H. Anti-HIV activities and physicochemical properties of phosphorothioate analogues complementary to HIV sequences 1223
Kim S.-J. see Yoo S. 553
Kim W. S. see Nahm K. 2631
Kim Y. J. see Kim D. H. 2681
Kimura Y. see Imuta M. 2199
Kinchington D. see McGuigan C. 1207

Kindt R. M. see Wright S. W. 2875
King F. D. see Baxter G. S. 633
King F. D. see Bermudez J. 205
King H. D. see Hudyma T. W. 323
King W. R. see Barraclough P. 509
Kinner J. H. see Sawyer T. K. 819
Kinney W. A. see Soll R. M. 757
Kirk B. E. see Procopiou P. A. 2527
Kirk B. E. see Watson N. S. 2541
Kirkup M. P. see McCombie S. W. 1537
Kirschmeier P. see McCombie S. W. 1537
Kishore N. S. see Devadas B. 779
Kitazume T. see Murata K. 2685
Kitchin J. see Holmes D. S. 503
Kitchin J. see Holmes D. S. 1485
Kivlighn S. D. see de Laszlo S. E. 1299
Klar U. and Pletsch A. New TXA_2/PGH_2 receptor antagonists based on the carbacyclin skeleton 199
Kleanthous C. see Reilly A. 1429
Kleanthous C. see Shneier A. 1399
Kleinschroth J. Hartenstein J. Rudolph C. and Schächtele C. Non-glycosidic/non-aminoalkyl-substituted indolocarbazoles as inhibitors of protein kinase C 1959
Klich M. and Teutsch G. Synthesis of an *N*-(tetrazol-5-yl) azetidin-2-one from L-tartaric acid 2429
Kluender H. C. see Abram T. S. 1517
Knapp R. J. see Lam K. S. 419
Kneen C. O. see Hill D. 885
Knight D. J. see Borthwick A. D. 2577
Knipe J. O. see Ueda Y. 1761
Knipe J. O. see Vyas D. M. 1357
Knowles W. S. Anderson K. S. Andrew S. S. Phillion D. P. Ream J. E. Johnson K. A. and Sikorski J. A. Synthesis and characterization of N-amino-glyphosate as a potent analog inhibitor of *E. coli* EPSP synthase 2863
Knutsen L. J. S. Lau J. Sheardown M. J. and Thomsen C. The synthesis and biochemical evaluation of new A_1 selective adenosine receptor agonists containing 6-hydrazinopurine moieties 2661
Kobayashi T. Okano T. Tsugawa N. Murano M. Masuda S. Takeuchi A. Sato K. and Nishii Y. 2β-(3-Hydroxypropoxy)-1α,25-dihydroxyvitamin D_3 (ED-71), preventive and therapeutic effects on bone mineral loss in ovariectomized rats 1815
Koboldt C. M. see Bertenshaw S. R. 1953
Kobori T. Fujita M. Yamamoto R. Hiyama T. Kondo K. Numata K. Sugita K. Akashi T. Kaneda Y. Nagate T. and Hanada K. Synthesis and biological properties of 3-[(*Z*)-2-(1,2,3-thiadiazolyl)ethenyl]-substituted cephalosporins and related compounds: new oral cephalosporins 2225
Kodaira K. see Matsugo S. 1671
Koe B. K. see Chenard B. L. 91
Koehl J. R. see Matthews D. P. 165
Koehler K. F. see Reitz D. B. 1055
Koga H. Ohta M. Sato H. Ishizawa T. and Nabata H. Design of potent K^+ channel openers by pharmacophore model 625
Koga H. Sato H. Imagawa J. Ishizawa T. Yoshida S. Sugo I. Taka N. Takahashi T. and Nabata H. Synthesis and antihypertensive activity of KC-399, a benzopyran K^+ channel opener with long duration of action and less tachycardia 2005
Koga H. Sato H. Ishizawa T. Kuromaru K. Makino T. Taka N. Takahashi T. Sato T. and Nabata H. Benzopyran-4-carboxamide K^+ channel openers 1115
Koga H. Sato H. Ishizawa T. Kuromaru K. Nabata H. Imagawa J. Yoshida S. and Sugo I. *N,N*-Disubstituted benzopyran-4-(*N*'-cyano)carboxamidines, cromakalim analogs with selective activity for guinea pig trachealis 1111
Koga H. see Ishizawa T. 1659
Koga H. see Sato H. 2627
Kogan T. P. see Dugar S. 571
Kohen A. Berkovich R. Belakhov V. and Baasov T. Stereochemistry of the KDO8P synthase. An efficient synthesis of the 3-fluoro analogues of KDO8P 1577
Koizumi S. see Saika H. 2129
Kojima A. see Kawakami H. 2821
Komáromi I. see Sztaricskai F. 235
Komoda Y. see Ito S. 611
Kondo K. see Kobori T. 2225
Kondo M. see Yokota M. 1687
Konialian A. L. see Holt D. A. 1977
König W. A. see Colvin E. W. 2405
Kornberg B. E. and Doherty A. M. Synthesis of Trp–Val non-cleavable dipeptide transition state isosteres 1257
Kornprobst J.-M. see Bourgougnon N. 1141
Kőrösi J. see Tarnawa I. 99
Kosakai K. see Yokota M. 1687
Kosan H. see Schönecker B. 1849
Kostlan C. R. see Kramer J. B. 2827
Kottirsch G. Tapparelli C. and Zerwes H.-G. Fibrinogen receptor antagonists containing a gamma-lactam Gly–Asp isostere 1675
Kovács A. see Sebestyén F. 413
Koyama T. see Ohnuma S. 2733
Kozakai K. see Yanagisawa T. 1559
Kozikowski A. P. Powis G. Gallegos A. and Tückmantel W. Synthesis of D-3-deoxy-3-phosphonomethyl-*myo*-inositol and its dimethyl ester—compounds of use in studying the PtdIns-3'-kinase signalling pathway 1323
Kozikowski A. P. Roberti M. Johnson K. M. Bergmann J. S. and Ball R. G. SAR of cocaine: further exploration of structural variations at the C-2 center provides compounds of subnanomolar binding potency 1327
Kozikowski A. P. see Malaska M. J. 1247
Kramer J. B. Boschelli D. H. Connor D. T. Kostlan C. R. Kuipers P. J. Kennedy J. A. Wright C. D. Bornemeier D. A. and Dyer R. D. Cyclooxygenase and 5-lipoxygenase inhibitory activity of 2,6 di-*t*-butylphenols linked by a sulfur atom to 1,3,4-thiadiazoles and 1,3,4-oxadiazoles 2827
Kramer T. see Hristova-Kazmierski M. K. 831
Krause B. R. see Trivedi B. K. 259
Krause E. see Schmidt M. 441

Krief A. Pasau P. Guittet E. Shan Y. Y. and Herin M. Novel results on the biocyclisation of 2,3-oxidosqualene analogs by sterol cyclase 365
Krishnan B. S. see Zein N. 1351
Krogsgaard-Larsen P. see Madsen U. 1649
Krogsgaard-Larsen P. see Nielsen B. 107
Kruse L. I. see Caulfield T. J. 2771
Ku G. S. see McDonald I. A. 1717
Kuang R. see Groutas W. C. 1163
Kuang R. see Groutas W. C. 2745
Kubo A. see Kubo I. 1305
Kubo I. Muroi H. Himejima M. and Kubo A. **Kubodera N. Watanabe H. Miyamoto K. and Matsumoto M.** Synthesis and differentiation-inducing activity of 1α,24-dihydroxy-22-oxa-vitamin D_3 analogues 1869
Kubota T. see Ito S. 611
Kucera L. S. see Swayze E. E. 543
Kuduk S. D. see Ojima I. 2479
Kuipers P. J. see Kramer J. B. 2827
Kulagowski J. J. see Leeson P. D. 299
Kulkarni P. V. see Mehta V. D. 187
Kulkarni P. V. see Mehta V. D. 785
Kumar S. Singh R. and Singh H. Silver selective pyridine based diamide–diester 18-membered macrocycle—synthesis and ionophore character 363
Kuroiwa Y. see Ito S. 611
Kuromaru K. see Ishizawa T. 1659
Kuromaru K. see Koga H. 1111
Kuromaru K. see Koga H. 1115
Kuromaru K. see Sato H. 2627
Kurtz M. M. see Chiang Y.-C. P. 2029
Kutner A. Choliński J. Chodyński M. and Halkes S. J. Conformational analysis of disubstituted side-chain of vitamin D_3 analogs: molecular modeling and semiempirical calculations 1795

Labaudinière R. see Mignani S. 1913
Lacoste L. see Dorion C. 2699
Ladduwahetty T. see Fletcher S. R. 141
Lahaye M. see Bourgougnon N. 1141
Lahe L. see Parve O. 359
Lahti R. A. see Ennis M. D. 1131
Lalan P. see Murray W. V. 369
Lalan P. see Murray W. V. 785
Lam K. S. Hruby V. J. Lebl M. Knapp R. J. Kazmierski W. M. Hersh E. M. and Salmon S. E. The chemical synthesis of large random peptide libraries and their use for the discovery of ligands for macromolecular acceptors 419
Lamotte H. Dégeilh F. Rousseau B. Neau P. and Ripoche P. Azido-functionalized thiourea analogues acting as efficient photoaffinity probes for the urea channel 2587
Lanati S. see Fuganti C. 2785
Lane W. S. see Sodeoka M. 1095
Lang M. see Fässler A. 2837
Langlois M. Gaudy F. Shen S. and Brémont B. Synthesis of new derivatives of 8-OH-DPAT: influence of substitution on the aromatic ring on the pharmacological profile 2035
Langlois M. Soulier J. L. Allainmat M. Shen S. and Gallais C. Derivatives of quinuclidine as 5-HT_3 receptor antagonists: influence of an additional carbonyl group on the recognition of chirality by the receptor 1555
Lapointe J. see Dorion C. 2699
Lappa S. see Alisi M. A. 1931
Larson C. J. see Sodeoka M. 1089
Larson C. J. see Sodeoka M. 1095
Lasky S. see Clark J. W. 1873
Lau C. L. see Hulin B. 703
Lau J. see Knutsen L. J. S. 2661
Lawhorn D. E. see Wikel J. H. 1157
Lawrence T. see Wu Y. Q. 2811
Laws A. P. Page M. I. and Slater M. J. The mechanism of reactions catalysed by the serine β-lactamases 2317
Lawson J. E. Poindexter G. S. Owens D. A. Cavanagh R. L. Goggins G. D. Sarmiento J. G. Bleiberg B. B. and Weselcouch E. O. Preparation and *in vitro* biological evaluation of the enantiomers of the dihydropyridine BMY 20014, a combination calcium and α_1-adrenoreceptor antagonist 561
Leander J. D. see Monn J. A. 95
Leander J. D. see Ornstein P. L. 2067
Leander J. D. see Ornstein P. L. 43
Leanna M. R. see Shiosaki K. 855
Lebl M. see Lam K. S. 419
LeBouliuec K. L. see Saulnier M. G. 1619
LeClair K. P. see Sodeoka M. 1089
Lee C.-H. see Clark R. D. 1375
Lee D. K. H. see Murray W. V. 369
Lee D. K. H. see Murray W. V. 785
Lee J. Marquez V. E. Lewin N. E. Bahador A. Kazanietz M. G. and Blumberg P. M. Conformationally constrained analogues of diacylglycerol (DAG)—IV. Interaction of α-alkylidene-γ-lactones with protein kinase C (PK-C) 1107
Lee J. Marquez V. E. Lewin N. E. Kazanietz M. G. Bahador A. and Blumberg P. M. Conformationally constrained analogues of diacylglycerol (DAG)—III. Interaction of α-alkyl-γ-lactones with protein kinase C (PK-C) 1101
Lee K.-H. see Bastow K. F. 1045
Lee S.-S. see Kim D. H. 263
Leeson P. D. Baker R. Carling R. W. Kulagowski J. J. Mawer I. M. Ridgill M. P. Rowley M. Smith J. D. Stansfield I. Stevenson G. I. Foster A. C. and Kemp J. A. Amino acid bioisosteres: design of 2-quinolone derivatives as glycine-site N-methyl-D-aspartate receptor antagonists 299
Leeson P. D. James K. Lennon I. C. Liverton N. J. Aspley S. and Jackson R. G. Adenosine-2'-monophosphate derivatives: structural requirements as substrates for inositol monophosphatase 1925
Leeson P. D. Williams B. J. Rowley M. Moore K. W. Baker R. Kemp J. A. Priestley T. Foster A. C. and Donald A. E. Derivatives of 1-hydroxy-3-aminopyrrolidin-2-one (HA-966). Partial agonists at the glycine site of the NMDA receptor 71
Leeson P. D. see Carling R. W. 65
Leeson P. D. see Moore K. W. 61
Lefebvre I. see Périgaud C. 2521

Lefkowitz S. L. see Desai M. C. 2083
Le Fur G. see Emonds-Alt X. 925
Legido M. see Palomo C. 2461
Lenfant M. see Mouna A. 681
Lennon I. C. see Leeson P. D. 1925
Leonard D. M. see Doherty A. M. 497
Leoni A. see Baraldi P. G. 2511
Lepoittevin J.-P. see Bussey C. 1283
Lesher G. Y. see Wentland M. P. 1711
Leung E. see Clark R. D. 1375
Levy M. A. see Holt D. A. 1735
Levy M. A. see Holt D. A. 1977
Lewin N. E. see Lee J. 1101
Lewin N. E. see Lee J. 1107
Lewin N. E. see Sharma R. 1993
Lewis D. E. see Chang S.-C. 555
Lewis J. see Bandurco V. T. 375
Lewis J. M. see Murray W. V. 369
Lewis J. M. see Murray W. V. 785
Lewis M. L. Martin S. L. Rowe C. J. Sutherland J. D. Wilson E. J. and Wright M. C.
Reduction of Δ^1-pyrroline-2-carboxylic acid to proline by an *Escherichia coli* proline auxotroph 1189
Lewis M. L. Martin S. L. Rowe C. J. Sutherland J. D. Wilson E. J. and Wright M. C.
Reduction of Δ^1-pyrroline-2-carboxylic acid to proline in *Escherichia coli*: lack of involvement of glutamate dehydrogenase and Δ^1-pyrroline-5-carboxylate reductase 1197
Lewis M. L. Rowe C. J. Sewald N. Sutherland J. D. Wilson E. J. and Wright M. C.
The effect of pH on the solution structure of Δ^1-pyrroline-2-carboxylic acid as revealed by NMR and electrospray mass spectroscopy 1193
Li J. H. see Frank C. A. 2725
Li J. H. see Grant T. 2723
Li J. H. see Russell K. 2727
Li Q. X. and Casida J. E.
1,3-Dithianes with acid functionalities: potent inhibitors and candidate affinity probes for the GABA-gated chloride channel 2671
Li T. Qian C. Eckman J. Huang D. F. and Shen T. Y.
The analgesic effect of epibatidine and isomers 2759
Lian J. B. see Stein G. S. 1885
Liang X.-Z. see Georg G. I. 1345
Lieberman M. E. see Posner G. H. 1835
Lignon M.-F. see Rolland M. 851
Liljebris C. Resul B. and Hacksell U.
Palladium catalyzed syntheses of phenyl-substituted $PGF_{2\alpha}$ analogues: potential antiglaucoma agents 241
Lille U. see Parve O. 357
Lille U. see Parve O. 359
Lilley S. C. see Hecker S. J. 289
Lilley S. C. see Hecker S. J. 295
Lilley S. C. see Jaynes B. H. 1531
Lim N. see Thompson P. E. 1625
Lin C. M. see Beutler J. A. 581
Lin C. W. see Shiosaki K. 855
Lin H.-K. see Anstead G. M. 1319
Lin K.-C. see Miller M. J. 1435
Lin S.-I. see McCombie S. W. 1537
Lin Z. see Sato M. 1277
Ling I. see Tamawa I. 99
Linget J. M. Schiewer G. and Wermuth C. G.
Covalent hydration: a side reaction for dihydropyridine-derived chemical delivery systems. An example with GABAergic compounds 1309
Linstrumelle G. see Tellier F. 1629
Liotta D. C. see Choi W.-B. 693
Liotta D. C. see Wilson L. J. 169
Lipson K. E. see Mugrage B. 2099
Lipton M. A. see Iyer M. S. 2061
Lipton M. A. see Yong Y. F. 2879
Liu J. H. see Holton R. A. 2475
Liu L. see Sawyer T. K. 819
Liu X.-P. see Goldberg S. I. 1527
Liverton N. J. see Leeson P. D. 1925
Lobb K. L. see Howbert J. J. 875
Lodge D. see Monn J. A. 95
Lodge D. see Ornstein P. L. 2067
Lodge D. see Ornstein P. L. 43
Loebenberg D. see Cooper A. B. 1079
Long B. H. see Saulnier M. G. 1619
Long E. C. see Shullenberger D. F. 333
Longo K. P. see Lowe, III J. A. 921
Lõokene A. see Parve O. 357
Lõokene A. see Parve O. 359
Loreto M. A. see Colvin E. W. 2405
Lotti V. J. see de Laszlo S. E. 1299
Lotti V. J. see Allen E. E. 1293
Lotti V. J. see Bock M. G. 871
Lotti V. J. see Evans B. E. 867
Lotti V. J. see Wu M. T. 2023
Lovering F. E. see Bridges R. J. 115
Lovey R. G. see Cooper A. B. 1079
Low C. M. R. see McDonald I. M. 1511
Lowe D. J. see Ramjee M. K. 1409
Lowe, III J. A. Drozda S. E. Snider R. M. Longo K. P. and Rizzi J. P.
Nuclear variations of quinuclidine substance P antagonists: 2-diphenylmethyl-1-azabicyclo[3.2.2]nonan-3-amines 921
Lown J. W. see Huang L. 1751
Lown J. W. see Xie G. 1565
Lowther W. T. see Sawyer T. K. 819
Lu G. H. see Hodges J. C. 905
Luckey S. see Church K. M. 2623
Luengo J. I. see Holt D. A. 1977
Luh B. Y. see Kim C. U. 1571
Luke R. W. A. see Allott C. P. 899
Lurier D. see Jimonet P. 983
Lutgring R. Sujatha K. and Chmielewski J.
Synthesis of homologs of cysteine suitable for peptide and protein crosslinking 739
Luu B. see Mauvais A. 1951
Lynch, Jr K. O. see Engler T. A. 1229
Lyssikatos J. P. and Bednarski M. D.
Synthesis of the 4,5 diphosphonate analog of D,L-*myo*-inositol 4,5-diphosphate 685

MacCoss M. see Hale J. J. 319
MacCoss M. see Mills S. G. 2707
MacCoss M. see Mjalli A. M. M. 2689
MacCoss M. see Mjalli A. M. M. 2693
Macdonald D. see Thérien M. 2063
Macdonald J. E. see Poindexter G. S. 2817
Macdonald T. L. see Andres C. J. 565
Madar A.-M. Humphrey G. R. Thompson A. S. Verhoeven T. R. and Reider P. J.
Palladium catalyzed diastereoselective addition of secondary alcohols to acyloxyazetidinones 2393

Madsen U. Andresen L. Poulsen G. A. Rasmussen T. B. Ebert B. Krogsgaard-Larsen P. and Brehm L. Excitatory amino acid receptor antagonists: synthesis and pharmacology of 3-(carboxymethoxy)isoxazoles derived from AMPA 1649
Madsen U. see Nielsen B. 107
Maeji N. J. see Wang J. 447
Maeji N. J. see Wang J. 451
Maggiora L. L. see Sawyer T. K. 819
Magolda R. L. see Wright S. W. 2875
Mahmood N. see McGuigan C. 1203
Mahon M. F. see Campbell M. M. 667
Major J. S. see Gibson K. H. 1019
Major J. S. see Allott C. P. 899
Makino T. see Ishizawa T. 1659
Makino T. see Koga H. 1115
Makino T. see Sato H. 2627
Makovec F. Mennuni L. Peris W. Revel L. and Rovati L. C. Biological properties of (*R*)-4-benzamido-5-oxopentanoic basic derivatives as CCK-antagonists 861
Malaska M. J. Fauq A. H. Kozikowski A. P. Aagaard P. J. and McKinney M. Simplified analogs of himbacine displaying potent binding affinity for muscarinic receptors 1247
Maligres P. E. Nicolaou K. C. and Wrasidlo W. A new designed tumor selective daunomycin derivative 1051
Malleron J.-L. see Mignani S. 1913
Malone T. C. Ortwine D. F. Johnson G. and Probert, Jr A. W. Synthesis and biological activity of conformationally constrained 4a-phenanthrenearnine derivatives as noncompetitive NMDA antagonists 49
Malone T. C. see Bigge C. F. 39
Mamber S. W. see Vyas D. M. 1357
Manchee G. R. see Dowle M. D. 2047
Manchee G. R. see Middlemiss D. 2043
Manchee G. R. M. see Middlemiss D. 589
Manfredini S. see Baraldi P. G. 2511
Mangan F. R. see Bermudez J. 2571
Manhas M. S. see Banik B. K. 2363
Manhas M. S. see Kaluza Z. 2357
Manninen P. R. see Brickner S. J. 2241
Manning R. E. see Reitz D. B. 1055
Manoharan M. Johnson L. K. Tivel K. L. Springer R. H. and Cook P. D. Introduction of a lipophilic thioether tether in the minor groove of nucleic acids for antisense applications 2765
Mansour T. S. see Siddiqui M. A. 1543
Mansuri M. M. see Kim C. U. 1571
Mansuri M. M. see Yu K.-L. 535
Mantlo N. B. Chang R. S. L. and Siegl P. K. S. Angiotensin II receptor antagonists containing a phenylpyridine element 1693
Marchand-Brynaert J. Couplet B. Dive G. and Ghosez L. New γ-lactam homologs of penems 2303
Marchand-Brynaert J. see Durand T. 2309
Marder P. see Sofia M. J. 1147
Markovich K. M. Farooqui T. Wallace L. J. Uretsky N. J. and Miller D. D. Enhancement of binding of quaternary ammonium derivatives of chlorpromazine to dopamine D-2 receptors by the addition of a H-bonding group 1241
Markwell R. E. Rahman S. S. and Ward R. W. Synthesis of aminoazalactams as cyclic mimetics of basic alkyl amino acids 2537
Markwell R. E. see Bermudez J. 2571
Marlowe C. K. Peptide cyclization on TFA labile resin using the trimethylsilyl (TMSE) ester as an orthogonal protecting group 437
Marquez V. E. see Lee J. 1101
Marquez V. E. see Lee J. 1107
Marquez V. E. see Sharma R. 1993
Marquis R. W. see Chiang Y.-C. P. 2029
Marshall G. R. see Carling R. W. 65
Martel R. see Zacharie B. 619
Martelli G. see Bandini E. 2347
Martin J. C. see Yu K.-L. 535
Martin S. L. see Lewis M. L. 1189
Martin S. L. see Lewis M. L. 1197
Martinez J. see Rolland M. 851
Marumo S. see Fukushima Y. 1219
Maryanoff B. E. Costanzo M. J. Shank R. P. Schupsky J. J. Ortegon M. E. and Vaught J. L. Anticonvulsant sugar sulfamates. Potent cyclic sulfate and cyclic sulfite analogues of topiramate 2653
Mas J. L. see Hou D. 2171
Mason N. R. see Howbert J. J. 875
Mason R. P. see Mehta V. D. 187
Mason R. P. see Mehta V. D. 785
Mason T. J. see Geysen H. M. 397
Masuda S. see Kobayashi T. 1815
Matassa V. G. see Castro J. L. 993
Matassa V. G. see Chambers M. S. 1919
Matsuda A. Inada M. Nara H. Ohtsuka E. and Ono A. Nucleosides and nucleotides—CXXVI. Incorporation of a mutagenic nucleoside, 5-formyl-2'-deoxyuridine, into an oligodeoxyribonucleotide 2751
Matsuda A. see Dan A. 615
Matsuda A. see Minakawa N. 183
Matsuda T. see Katsumura S. 2703
Matsugo S. Kodaira K. and Saito I. Transfecting activity of photoirradiated φx 174 DNA in the presence of hydroperoxynaphthalimides 1671
Matsumoto M. see Kubodera N. 1869
Matta K. L. see Jain R. K. 1333
Matthews D. P. Edwards M. L. Mehdi S. Koehl J. R. Wolos J. A. and McCarthy J. R. (*E*) and (*Z*) 5'-Fluoro olefin carbocyclic nucleosides: effect of olefin geometry on inhibition of *S*-adenosyl-L-homocysteine hydrolase 165
Matthews J. L. see Chang S.-C. 555
Maurizis J. C. Pavia A. A. and Pucci B. Efficiency of non-ionic telomeric surfactants for the solubilization of subcellular fractions proteins 161
Mauvais A. Hetru C. and Luu B. Synthesis of ecdysteroid inhibitors of ecdysone biosynthesis. Inhibition of the C-25 hydroxylation 1951
Mawer I. M. see Leeson P. D. 299
Maycock A. L. see Finke P. E. 2277
Maycock A. L. see Shah S. K. 2295
Maycock A. L. see Thompson K. R. 2283

Maycock A. L. see Thompson K. R. 2289
Maynard G. D. Cheng H. C. Kane J. M. and Staeger M. A.
A convergent synthesis of 4-(2-benzothiazoyl)piperidines with anti-histaminic activity 753
McCallum J. see Soll R. M. 757
McCarthy J. R. see Matthews D. P. 165
McCaully R. J. see Soll R. M. 757
McCombie S. W. Bishop R. W. Carr D. Dobek E. Kirkup M. P. Kirschmeier P. Lin S.-I. Petrin J. Rosinski K. Shankar B. B. and Wilson O.
Indolocarbazoles—I. Total synthesis and protein kinase inhibiting characteristics of compounds related to K-252c 1537
McDonald I. A. Nyce P. L. Ku G. S. and Bowlin T. L.
Synthesis and biological activity of sulfoximine-modified myristic acid analogues 1717
McDonald I. A. see Whitten J. P. 19
McDonald I. A. see Whitten J. P. 23
McDonald I. M. Bodkin M. J. Broughton H. B. Dunstone D. J. Kalindjian S. B. and Low C. M. R.
2-NAP: A selective, hydrophilic, non-peptide CCK_A-receptor antagonist derived from the cholecystokinin C-terminal dipeptide 1511
McElroy A. B. see Smith P. W. 931
McGee D. P. C. see Saulnier M. G. 1619
McGeever-Rubin B. see Ahmad S. 1215
McGeever-Rubin B. see Vite G. D. 1211
McGuigan C. Kinchington D. Nicholls S. R. Nickson C. and O'Connor T. J.
Kinase bypass: a new strategy for anti-HIV drug design 1207
McGuigan C. Sheeka H. M. Mahmood N. and Hay A.
Phosphate derivatives of d4T as inhibitors of HIV 1203
McGuire S. M. and Townsend C. A.
Demonstration of Baeyer–Villiger oxidation and the course of cyclization in bisfuran ring formation during aflatoxin B_1 biosynthesis 653
McKinney M. see Malaska M. J. 1247
McLane J. A. see Reddy G. S. 1879
McLaren C. D. see Bare T. M. 55
McLaren F. M. see Grant T. 2723
McLaren F. M. see Russell K. 2727
McLaughlin J. L. see Fang X. 1153
McMahon E. G. see Reitz D. B. 1055
McNally J. J. see Sanfilippo P. J. 1385
McNeil D. see Skiles J. W. 773
McPhail A. T. see Hou D. 2171
McPhail A. T. see Pirrung M. C. 2095
McQuade T. J. see Sawyer T. K. 819
McQuaid L. A. see Smith E. C. R. 81
McQuaid L. A. see Wikel J. H. 1157
Meanwell N. A. see Epperson J. R. 2801
Meecham K. G. see Henry J. A. 949
Meek T. D. see Chenera B. 2717
Meese C. O. see Schneider F. 1667
Mehdi S. see Angelastro M. R. 525
Mehdi S. see Matthews D. P. 165
Mehta V. D. Kulkarni P. V. Mason R. P. and Antich P. P.
Fluorinated macromolecular probes for non-invasive assessment of pH by magnetic resonance spectroscopy 187
Mehta V. D. Kulkarni P. V. Rajur S. B. Mason R. P. Babcock E. E. Consttantinescu A. and Antich P. P. Additions and Corrections 785
Meier H. see Abram T. S. 1517
Meinke P. T. O'Connor S. P. Ostlind D. A. Shoop W. L. Fisher M. H. and Mrozik H.
New, potent anthelmintic and acaricidal agents: 4"-deoxy-4"-thio-substituted avermectin derivatives 2675
Melgarejo M. see Nogueras M. 601
Melguizo M. see Nogueras M. 601
Melino G. see Alisi M. A. 1931
Meltzer L. T. see Jaén J. C. 639
Meltzer L. T. see Wustrow D. J. 277
Mendelsohn L. G. see Shih C. 2657
Menniti F. S. see Chenard B. L. 1991
Mennuni L. see Makovec F. 861
Merchant K. J. see Seward E. M. 1361
Messeguer A. see Abad J.-L. 2581
Messeguer A. see Irurre, Jr J. 179
Metcalf B. W. see Holt D. A. 1735
Metters K. M. see Guay D. 1125
Metzger J. see Stevanovic S. 431
Metzger K. see Pfaendler H. R. 2211
Metzger K.-G. see Wild H. 2205
Meyer D. M. see Chandrakumar N. S. 309
Meziane-Cherif D. see Tromelin A. 1971
Miao C. see Skiles J. W. 773
Michel I. M. see Das J. 1267
Michel I. M. see Das J. 1271
Michel I. M. see Hall S. E. 1263
Middlemiss D. Watson S. P. Ross B. C. Dowle M. D. Scopes D. I. C. Montana J. G. Shah P. Hirst G. C. Panchal T. A. Paton J. M. S. Pass M. Hubbard T. Hamblett J. Cardwell K. S. Jack T. I. Stuart G. Coote S. Bradshaw J. Drew G. M. Hilditch A. Clark K. L. Robertson M. J. Bayliss M. K. Donnelly M. Palmer E. and Manchee G. R. M.
Benzofuran based angiotensin II antagonists related to GR117289: enhancement of potency *in vitro* and oral activity 589
Middlemiss D. Watson S. P. Ross B. C. Dowle M. D. Scopes D. I. C. Montana J. G. Hirst G. C. Panchal T. A. Paton J. M. S. Hubbard T. Stuart G. Drew G. M. Hilditch A. Travers A. Robertson M. J. Hunt A. A. E. Palmer E. and Manchee G. R.
Benzofuran based angiotensin II antagonists related to GR117289—II. Amino acid amides 2043
Middlemiss D. see Dowle M. D. 2047
Midland M. M. Plumet J. and Okamura W. H.
Effect of C2O stereochemistry on the conformational profile of the side chains of vitamin D analogs 1799
Mierau J. see Gmeiner P. 1477
Miertus S.
Evaluation of complexation energies between aspartic protease of HIV-1 and its hexapeptide inhibitors including the effect of solvation 2105
Miesbauer L. R. see Fang X. 1153
Mignani S. Damour D. Doble A. Labaudinière R.

Malleron J.-L. Piot O. and Gueremy C.
New indole derivatives as potent and selective serotonin uptake inhibitors 1913
Mignani S. see Jimonet P. 983
Mikkilineni A. B. see Ueda Y. 1761
Miller A. see Whittaker M. 1493
Miller A. see Wood L. M. 1499
Miller D. D. see Markovich K. M. 1241
Miller G. H. see Afonso A. 2177
Miller M. J. Anderson K. S. Braccolino D. S. Cleary D. G. Gruys K. J. Han C. Y. Lin K.-C. Pansegrau P. D. Ream J. E. Sammons R. D. and Sikorski J. A.
EPSP Synthase inhibitor design—II. The importance of the 3-phosphate group for ligand binding at the shikimate-3-phosphate site and the identification of 3-malonate ethers as novel 3-phosphate mimics 1435
Miller M. J. see Farouz-Grant F. 2423
Miller M. J. see Teng M. 2431
Miller T. R. see Shiosaki K. 855
Mills S. G. Wu M. T. MacCoss M. Budhu R. J. Dorn, Jr C. P. Cascieri M. A. Sadowski S. Strader C. D. and Greenlee W. J.
1,4-Diacylpiperazine-2-(*S*)-[(N-aminoalkyl)carboxamides] as novel, potent substance P receptor antagonists 2707
Mills S. J. Al-Hafidh J. Westwick J. and Potter B. V. L.
myo-Inositol 1,4,6-trisphosphate: a new synthetic Ca^{2+}-mobilising inositol phosphate 2599
Mills S. J. Safrany S. T. Wilcox R. A. Nahorski S. R. and Potter B. V. L.
Synthesis of *myo*-inositol 1,2,4,5-tetrakisphosphate, a Ca^{2+}-mobilising tetrakisphosphate with a potency similar to *myo*-inositol 1,4,5-trisphosphate 1505
Milne G. W. A. see Sharma R. 1993
Miltz W. Zierhut W. Buccheri E. Schultz R. and Stirnimann R.
Determination of the active conformation of 6-amino-α-[(4-diphenylmethyl-1-piperazinyl)methyl-9*H*-purine]-9-ethanol: a positive inotropic agent 1233
Minakawa N. Sasaki T. and Matsuda A.
Nucleosides and nucleotides—CXVII. A transition-state analogue in purine nucleotide biosynthesis: the design and synthesis of an imidazo[4,5-*c*]azepine nucleoside 183
Minich M. L. see Hecker S. J. 289
Minich M. L. see Hecker S. J. 295
Minich M. L. see Jaynes B. H. 1531
Mirhom Y. W. see Georg G. I. 1345
Misco P. F. see Kim C. U. 1571
Mistry J. see Howson W. 515
Mitchell P. J. see Chambers M. S. 1919
Mitchell R. E. see Pirrung M. C. 2095
Mitscher L. A. see Georg G. I. 1345
Mitscher L. A. see Georg G. I. 1349
Miyamoto K. see Kubodera N. 1869
Miyasaka T. see Tanaka H. 1681
Miyauchi M. Haruyama H. Yoda K. and Kawamoto I.
Transformation of 3-thiazoliomethylcephalosporin into 3-spirocephalosporin by intramolecular Michael addition 2447
Mjalli A. M. M. Chapman K. T. MacCoss M. and Thornberry N. A.
Phenylalkyl ketones as potent reversible inhibitors of interleukin-1β converting enzyme 2689
Mjalli A. M. M. Chapman K. T. and MacCoss M.
Synthesis of a peptidyl 2,2-difluoro-4-phenylbutyl ketone and its evaluation as an inhibitor of interleukin-1β converting enzyme 2693
Mochizuki S. see Yanagisawa T. 1559
Moliterni J. see Mugrage B. 2099
Mondon M. see Gesson J.-P. 735
Monn J. A. Valli M. J. True R. A. Schoepp D. D. Leander J. D. and Lodge D.
Synthesis and pharmacological characterization of L-*trans*-4-tetrazolylproline (LY300020): a novel systemically-active AMPA receptor agonist 95
Monshizadegan H. see Das J. 1267
Monshizadegan H. see Das J. 1271
Monshizadegan H. see Hall S. E. 1263
Montana J. G. see Middleniss D. 2043
Montana J. G. see Middleniss D. 589
Montchamp J.-L. Piehler L. T. Tolbert T. J. and Frost J. W.
Designing inhibitors of dehydroquinate synthase: structural simplicity versus inhibitory potency 1403
Moon J. see Sawyer T. K. 819
Moon K. Y. see Nahm K. 2631
Moore K. W. Leeson P. D. Carling R. W. Tricklebank M. D. and Singh L.
Anticonvulsant activity of glycine-site NMDA antagonists—I. 2-Carboxyl prodrugs of 5,7-dichlorokynurenic acid 61
Moore K. W. see Leeson P. D. 71
Moore T. A. see Church K. M. 2623
Moore W. M. see Bertenshaw S. R. 1953
Moore W. R. see Wannamaker M. W. 1175
Moos W. H. see Pavia M. R. 387
Moran P. J. S. see Aleixo L. M. 1637
Moreland S. see Atwal K. S. 2797
Moreland S. see Kim K. S. 2667
Morgan A. R. see Huang L. 1751
Morgan A. R. see Woodburn K. 2017
Morgan A. R. see Xie G. 1565
Morgan B. see Gordon T. 915
Mori I. see Saika H. 2129
Mori M. and Oida S.
A simple and highly stereoselective route to a key intermediate carboxylic acid for the synthesis of 1β-methylcarbapenems 2389
Mori S. see Tanaka H. 1681
Morita S. see Otsubo K. 1633
Morton H. E. see Shiosaki K. 855
Moseley A. M. see Carling R. W. 65
Mosley R. T. see Castro J. L. 993
Mouna A. Ouazzani J. and Lenfant M.
Enantioselective acetylation of primary amines by *Cylindrocarpon radicicola* 681
Mouriño A. see Nilsson K. 1855
Moutiez M. see Tromelin A. 1971
Moyer M. P. Weber F. H. Canning P. C. Gross J. L. and Saint Fort R.
Investigation of side-chain SAR formulation and injection site toleration of pyrazolo[3,4-*f*]quinoline derivatives: a potent series of *in vivo* active immunostimulants 1379
Mrozik H. see Blizzard T. A. 2093
Mrozik H. see Meinke P. T. 2675

Mu Y. see Gibbs R. A. 281
Mueller R. see Franciskovich J. 765
Mugrage B. Moliterni J. Robinson L. Webb R. L. Shetty S. S. Lipson K. E. Chin M. H. Neale R. and Cioffi C. CGS 27830 A potent nonpeptide endothelin receptor antagonist 2099
Mui P. W. see Skiles J. W. 773
Mukhopadhyay S. N. see Ghoshal N. 329
Muller M. see Streith J. 2375
Mumford R. A. see Shah S. K. 2295
Mumper M. W. Aurenge C. and Hosmane R. S. A short convenient synthesis of 2'-deoxyshowdomycin 2847
Murakami K. see Kim S.-G. 1223
Murano M. see Kobayashi T. 1815
Muraoka M. see Kawakami H. 2821
Murata K. Kaneko S. and Kitazume T. Preparation and biological evaluation of γ-fluoromethyl-α-methylene-γ-butyrolactone and γ-butyrolactam 2685
Muroi H. see Kubo I. 1305
Murray W. V. Lalan P. Gill A. Addo M. F. Lewis J. M. Lee D. K. H. Wachter M. P. Rampulla R. and Underwood D. C. Substituted pyrrolidin-2-one biphenyltetrazoles as angiotensin II antagonists 369
Murray W. V. Lalan P. Gill A. Addo M. F. Lewis J. M. Lee D. K. H. Wachter M. P. Rampulla R. and Underwood D. C. Additions and Correction 785
Murray W. V. see Bandurco V. T. 375
Murray W. V. see Hsi J. D. 1523
Muthard D. A. see DiNinno F. 2187

Nabata H. see Ishizawa T. 1659
Nabata H. see Koga H. 1111
Nabata H. see Koga H. 1115
Nabata H. see Koga H. 2005
Nabata H. see Koga H. 625
Nabata H. see Sato H. 2627
Nachbar R. B. see de Laszlo S. E. 1299
Nadzan A. M. see Shiosaki K. 855
Nagaraj R. see Joseph M. 1025
Nagate T. see Kobori T. 2225
Nahm K. Kim W. S. and Moon K. Y. Quinolone compounds with carboxylic equivalents and semiempirical calculations on their tautomers 2631
Nahorski S. R. see Mills S. J. 1505
Nair H. K. and Quinn D. M. *m*-Alkyl α,α,α-trifluoroacetophenones: a new class of potent transition state analog inhibitors of acetylcholinesterase 2619
Nakanishi H. see Su T. 835
Nakashima H. see Kim S.-G. 1223
Nakatani K. see Ge Y. 1085
Nakatsuka T. see Tanaka R. 2299
Namane A. see Bay S. 2515
Naples L. see Afonso A. 2177
Nara H. see Matsuda A. 2751
Narayanan B. A. see Hamilton G. S. 27
Nash S. A. see Chandrakumar N. S. 309
Neale R. see Mugrage B. 2099
Neau P. see Lamotte H. 2587
Neises B. see Schirlin D. 253
Neliat G. see Emonds-Alt X. 925
Newaz S. N. see Banik B. K. 2363
Newman-Tarr T. see Holt D. A. 1977
Ng F. M. see Thompson P. E. 1625
Nguyen-Ba N. see Belleau B. 1723
Nguyen-Ba N. see Siddiqui M. A. 1543
Nicholls S. R. see McGuigan C. 1207
Nichols A. see Cheng H.-Y. 1179
Nickson C. see McGuigan C. 1207
Nicolaou K. C. see Maligres P. E. 1051
Nielsen B. Fisker H. Ebert B. Madsen U. Curtis D. R. Krogsgaard-Larsen P. and Hansen J. J. Enzymatic resolution of AMPA by use of α-chymotrypsin 107
Nielsen E. Ø. see Hays S. J. 77
Nielsen E. Ø. see Wätjen F. 105
Nikolakakis A. see Zamir L. O. 1441
Nilsson K. Vallés M. J. Castedo L. Mouriño A. Halkes S. J. and van de Velde J. P. Synthesis and biological evaluation of 18-substituted analogs of 1α,25-dihydroxyvitamin D_3 1855
Nishi K. see Imuta M. 2199
Nishii Y. see Kobayashi T. 1815
Niu C. see Wasserman H. H. 2437
Nobbs M. S. see Barraclough P. 509
Nogueras M. Sánchez A. Melguizo M. Quijano Mª L. and Melgarejo M. Synthesis of 5-glycosylamino pyrimidines. A new class of compounds with potential anti-AIDS activity 601
Nolan W. see Higginbottom M. 841
Nollstadt K. see Balkovec J. M. 2039
Nordblom G. D. see Hodges J. C. 905
Norman A. W. see Norman T. C. 1785
Norman P. see Abram T. S. 1517
Norman T. C. and Norman A. W. Consideration of chemical mechanisms for the nonphotochemical production of vitamin D_3 in biological systems 1785
Norton M. B. see Reitz D. B. 1055
Numata K. see Kobori T. 2225
Nunn D. S. see Pirrung M. C. 2095
Nyce P. L. see McDonald I. A. 1717
Nyilas A. Agrawal S. and Zamecnik P. Solid phase synthesis of oligonucleotides carrying puromycin at 3'-terminal 1371

O'Connor S. P. see Meinke P. T. 2675
O'Connor T. J. see McGuigan C. 1207
O'Hagan D. see Dasaradhi L. 1655
O'Malley P. J. see Smith E. C. R. 81
O'Toole J. see Higginbottom M. 841
O'Toole J. C. see Araki K. 2457
Oberti R. see Franceschi G. 2333
Odarjuk J. see Schmidt M. 441
Ogura K. see Ohnuma S. 2733
Oh H.-J. see Holt D. A. 1735
Oh S. H. see Kim H.-S. 1339
Ohemeng K. A. Schwender C. F. Fu K. P. and Barrett J. F. DNA Gyrase inhibitory and antibacterial activity of some flavones—I 225
Ohfune Y. Shimamoto K. Ishida M. and Shinozaki H. Synthesis of L-2-(2,3-dicarboxycyclopropyl)glycines. Novel conformationally restricted glutamate analogues 15
Ohnmacht C. J. see Frank C. A. 2725
Ohnmacht C. J. see Grant T. 2723

Ohnuma S. Koyama T. and Ogura K.
Solanesyl diphosphate synthase reaction with artificial substrates. Formation of *R* and *S*-enantiomers of 4- and 8-methyl derivatives of geranylgeranyl diphosphate 2733
Ohta M. see Ishizawa T. 1659
Ohta M. see Koga H. 625
Ohtsuka E. see Matsuda A. 2751
Oida S. see Mori M. 2389
Ojima I. Zucco M. Duclos O. Kuduk S. D. Sun C. M. and Park Y. H.
N-Acyl-3-hydroxy-β-lactams as key intermediates for taxotère and its analogs 2479
Okamura W. H. see Midland M. M. 1799
Okano T. see Kobayashi T. 1815
Oldham A. A. see Gibson K. H. 1019
Oldham A. A. see Allott C. P. 899
Olins G. M. see Reitz D. B. 1055
Ona H. see Imuta M. 2199
Ong C. W. Yen F. W. Chou Y. M. and Chen Y. K. C. C. F.
Biselectrostatic interaction with DNA as potential anti-tumor agents: novel 2,11-diamino-5,8-dithiaundecane derivatives 607
Ono A. see Dan A. 615
Ono A. see Matsuda A. 2751
Ono K. see Kawakami H. 2821
Oon S.-M. see Doyle M. P. 2409
Organ H. M. Holmes M. A. Pisano J. M. Staruch M. J. Wyvratt M. J. Dumont F. J. and Sinclair P. J.
Novel derivatives at the C21 position of the FK-506 macrocycle 657
Ornstein P. L. Arnold M. B. Augenstein N. K. Deeter J. B. Leander J. D. Lodge D. Calligaro D. O. and Schoepp D. D.
Unusual stereochemical preferences of decahydroisoquinoline-3-carboxylic acid competitive NMDA antagonists 2067
Ornstein P. L. Arnold M. B. Evrard D. Leander J. D. Lodge D. and Schoepp D. D.
Tetrazole amino acids as competitive NMDA antagonists 43
Orr D. C. see Holmes D. S. 503
Ortegon M. E. see Maryanoff B. E. 2653
Ortwine D. F. see Malone T. C. 49
Osguthorpe D. J. see Dutta A. S. 943
Oshiro G. see Soll R. M. 757
Ostlind D. A. see Meinke P. T. 2675
Otsubo K. Morita S. and Uchida M.
Synthesis of *N*-acetylthemiaminal metabolites of OPC-21268, vasopressin V1 receptor antagonist 1633
Ouazzani J. see Mouna A. 681
Owen S. see Swain C. J. 1703
Owen S. N. see Seward E. M. 1361
Owen T. see Stein G. S. 1885
Owens D. A. see Lawson J. E. 561

Padia J. K. Bolton G. L. Hill D. Horwell D. C. Roth B. D. and Trivedi B. K.
Synthesis and SAR study of novel CCK-B antagonists 2805
Padilla L. M. see Dubowchik G. M. 2843
Padmapriya A. A. and Agrawal S.
Synthesis of oligodeoxynucleoside methylphosphonothioates 761
Page M. I. see Laws A. P. 2317
Painter G. R. see Choi W.-B. 693
Painter G. R. see Wilson L. J. 169
Palmer E. see Middlemiss D. 2043
Palmer E. see Middlemiss D. 589
Palmer M. J. see James K. 825
Palomo C. Aizpurua J. M. Galarza R. Iturburu M. and Legido M.
The cycloaddition of monoalkylketenes to 2-oxoalkanoic ester-derived imines: a concise stereoselective approach to α,β-disubstituted aspartates and 3,4-dialkylsubstituted β-lactams 2461
Palomo M. A. see Reitz D. B. 1055
Pals A. see Parve O. 357
Pals A. see Parve O. 359
Panchal T. A. see Dowle M. D. 2047
Panchal T. A. see Middlemiss D. 2043
Panchal T. A. see Middlemiss D. 589
Pandey R. K. Jagerovic N. Ryan J. M. Dougherty T. J. and Smith K. M.
Efficient syntheses of new classes of regiochemically pure benzoporphyrin derivatives 2615
Pandeya S. N. see Srivastava K. 547
Panek J. S. see Beresis R. 1609
Pansegrau P. D. see Corey S. D. 2857
Pansegrau P. D. see Miller M. J. 1435
Pantano M. see Formaggio F. 953
Panunzio M. see Bandini E. 2347
Papageorgiou C. Florineth A. French R. Haltiner R. and Borer X.
Derivatives of cyclosporin at position 2 as probes for cyclophilin 2559
Park C. H. see Soll R. M. 757
Park H. see Georg G. I. 2467
Park Y. H. see Ojima I. 2479
Parmar V. S. Prasad A. K. Sharma N. K. Bisht K. S. Pati H. N. and Taneja P.
Regioselective enzyme-catalyzed deacetylation of benzyl phenyl ketone peracetates in organic solvents 585
Parmegiani R. see Cooper A. B. 1079
Parratt M. J. see Jennings L. J. 2611
Parrick J. Porasa M. Davies L. K. Dennis M. F. Patel K. B. Stratford M. R. L. and Wardman P.
Targeting radiosensitizers to DNA by minor groove binding: nitroarenes based on netropsin and distamycin 1697
Parrilla A. see Durán I. 2593
Parve O. Pals A. Kadarpik V. Lahe L. Lille U. Sikk P. Lõokene A. and Välimäe T.
Enantioselective preparation of novel bicyclo[3.2.0]heptane derivatives using ester hydrolysis catalyzed by Novo Lipolase™ 359
Parve O. Pals A. Kadarpik V. Lille U. Sikk P. Lõokene A. and Välimäe T.
High-purity porcine pancreatic lipase: novel effects in catalyzing hydrolysis of esters derived from bicyclo[3.2.0]hept-2-en-6-ols 357
Pasau P. see Krief A. 365
Pass M. see Dowle M. D. 2047
Pass M. see Middlemiss D. 589
Patch R. J. see Hamilton G. S. 27
Patchett A. A. see de Laszlo S. E. 1299
Patel B. see Holmes D. S. 503
Patel J. see Bare T. M. 55
Patel J. B. see Bare T. M. 55
Patel K. B. see Parrick J. 1697
Patel S. see Chambers M. S. 1919
Paternoster I. L. see Borthwick A. D. 2577
Paternoster I. L. see Holmes D. S. 503

Pati H. N. see Parmar V. S. 585
Paton J. M. S. see Middlemiss D. 2043
Paton J. M. S. see Middlemiss D. 589
Pattabhi V. see Jayakumar R. 153
Paul P. K. C. see Dutta A. S. 943
Pavia A. A. see Maurizis J. C. 161
Pavia A. A. see Pucci B. 1003
Pavia M. R. Sawyer T. K. and Moos W. H. INTRODUCTION: The generation of molecular diversity 387
Pawar S. M. see Jain R. K. 1333
Payne J. J. see Giblin G. M. P. 2605
Pearce R. J. see Allott C. P. 899
Pearson M. J. see Kaura A. C. 2183
Pedroso E. see Bardella F. 2793
Peet N. P. see Angelastro M. R. 525
Peiris S. M. see Swayze E. E. 543
Peishoff C. E. see Samanen J. M. 909
Pelyvás I. F. see Sztaricskai F. 235
Pennington P. A. see Wikel J. H. 1157
Pérez-Castells J. see Alcaide B. 2369
Peri S. P. see Casteel D. A. 1707
Périgaud C. Gosselin G. Lefebvre I. Girardet J.-L. Benzaria S. Barber I. and Imbach J.-L. Rational design for cytosolic delivery of nucleoside monophosphates: 'SATE' and 'DTE' as enzyme-labile transient phosphate protecting groups 2521
Peris W. see Makovec F. 861
Perni R. B. see Wentland M. P. 1711
Perrone E. see Alpegiani M. 2259
Perrone E. see Cabri W. 2255
Perrone E. see Jabès D. 2165
Perrone E. see Rizzo V. 2265
Perrotta E. see Altamura M. 2159
Persson J. see Andersson C.-M. 2553
Pestellini V. see Altamura M. 2159
Petkov D. D. see Dineva M. A. 2781
Petraitis J. J. see Wright S. W. 2875
Petrillo E. W. see Poss M. A. 2739
Petrin J. see McCombie S. W. 1537
Pettibone D. J. see Salituro G. M. 337
Pettit G. R. Tan R. Williams M. D. Tackett L. Schmidt J. M. Cerny R. L. and Hooper J. N. A. Isolation and structure of phakellistatin 2 from the Eastern Indian Ocean marine sponge *Phakellia carteri* 2869
Pfaendler H. R. Weisner F. and Metzger K. Synthesis and antibacterial activity of (1'*R* 5*R*,6*R*)-2-*tert*-butyl-6-(1'-hydroxyethyl) oxapenem-3-carboxylic acid 2211
Phadke A. S. see Woodburn K. 2017
Phillion D. P. see Knowles W. S. 2863
Piehler L. T. see Montchamp J.-L. 1403
Pierce J. see Hodge C. N. 1605
Pike A. J. see Ternansky R. J. 2237
Pilling G. M. see Wentland M. P. 1711
Pinto I. L. Buckle D. R. Readshaw S. A. and Smith D. G. The selective inhibition of phosphodiesterase IV by benzopyran deriv-atives of rolipram 1743
Pinto J. E. B. P. see Weaver L. M. 1421
Piot O. see Mignani S. 1913
Piper D. C. see Bolton D. 1941
Pirrung M. C. Nunn D. S. McPhail A. T. and Mitchell R. E. Synthesis and absolute configuration of hydroxythreonine, a biosynthetic precursor of rhizobitoxine in *Pseudomonas* 2095
Pisano J. M. see Organ H. M. 657
Piskorz C. F. see Jain R. K. 1333
Pitlik J. Gunda T. E. Batta G. and Jeko J. Stereoselective formation of tricyclic cephalosporins in reactions of cephem phosphorus ylides and ketoaldehydes 2451
Piwinski J. J. see Wong J. K. 1073
Plaxton W. C. see Fischer R. S. 1415
Pletsch A. see Klar U. 199
Plevyak S. P. see Chiang Y.-C. P. 2029
Plumet J. see Midland M. M. 1799
Plummer M. Hamby J. M. Hingorani G. Batley B. L. and Rapundalo S. T. Peptidomimetic inhibitors of renin incorporating topographically modified isosteres spanning the $P_1(\rightarrow P_3)$-P_1' sites 2119
Podona T. see Besson T. 1935
Poindexter G. S. Foley M. A. Macdonald J. E. Sarmiento J. G. Bryson C. Goggins G. D. Cavanagh R. L. and Buyniski J. P. Isosteric replacement in a series of β-substituted monophosphonate calcium antagonists 2817
Poindexter G. S. see Lawson J. E. 561
Ponzini F. see Annunziata R. 2397
Poorman R. A. see Sawyer T. K. 819
Porreca F. see Hristova-Kazmierski M. K. 831
Porssa M. see Parrick J. 1697
Posner G. H. Guyton K. Z. Kensler T. W. Barsony J. Lieberman M. E. Reddy G. S. Clark J. W. Wankadiya K. F. and Tserng K.-Y. 1-(Hydroxyalkyl)-25-hydroxyvitamin D_3 analogs of calcitriol—II. Preliminary biological evaluation 1835
Posner G. H. and Dai H. 1-(Hydroxyalkyl)-25-hydroxyvitamin D_3 analogs of calcitriol—I. Synthesis 1829
Poss M. A. Reid J. A. Free C. A. Rogers W. L. Weber H. Ryono D. E. Dejneka T. DeForrest J. M. Waldron T. L. Brittain R. J. Weller H. N. Cimarusti M. P. and Petrillo E. W. Diol sulfonamides: a potent and novel class of inhibitors of human renin 2739
Post-Munson D. see Epperson J. R. 2801
Potier P. see Dekhane M. 2831
Potter B. V. L. see Howarth N. M. 313
Potter B. V. L. see Mills S. J. 1505
Potter B. V. L. see Mills S. J. 2599
Pottorf R. S. see Cain G. A. 1767
Pottorf R. S. see Cain G. A. 2055
Pottorf R. S. see Christos T. E. 1035
Poulsen G. A. see Madsen U. 1649
Powis G. see Kozikowski A. P. 1323
Prajapati D. and Sandhu J. S. A new and convenient method for the preparation of β-lactams and unsaturated amides using N-[[(chlorosulfinyl)oxy]methylene]-N-methylmethanaminium chloride 2419

Prakash T. P. and Ganesh K. N.
8-Amino(2-aminoethyl)-2'-deoxyadenosine incorporation into DNA by solid phase synthesis 689
Prasad A. K. see Parmar V. S. 585
Prasad C. V. C. see Caulfield T. J. 2771
Prashad M.
Synthesis and squalene synthetase inhibitory activity of tripotassium 1-methyl-1-[(*N*-benzyl-*N*-farnesyl)aminoethylphosphinato]ethylphosphonate as a tethered analog of *N*-benzyl-*N*-farnesylamine–inorganic pyrophosphate ion pair 2051
Pratap R. Gulati D. Bhakuni D. S. and George C. X.
An unusual oxetane nucleoside as a potent antiviral agent 1061
Press J. B. see Sanfilippo P. J. 1385
Prestwich G. D. see Anstead G. M. 1319
Price M. see Whittaker M. 1493
Priestley T. see Leeson P. D. 71
Primeau J. see Soll R. M. 757
Pritchard J. M. see Smith P. W. 931
Pritchard M. C. see Bourne G. T. 889
Pritchard M. C. see Campbell M. M. 667
Pritchard M. C. see Eden J. M. 989
Pritchard M. C. see Hill D. 885
Probert, Jr A. W. see Malone T. C. 49
Prochniak M. A. see Chenard B. L. 1991
Prochniak M. A. see Chenard B. L. 91
Procopiou P. A. Bailey E. J. Hutson J. L. Kirk B. E. Sharratt P. J. Spooner S. J. and Watson N. S.
The squalestatins: novel inhibitors of squalene synthase. The optimal C1 chain-length requirements 2527
Procopiou P. A. see Giblin G. M. P. 2605
Procopiou P. A. see Watson N. S. 2541
Proietto V. see Emonds-Alt X. 925
Prousa R. see Schönecker B. 1849
Prouty C. P. see Caulfield T. J. 2771
Pruess D. L. see Dax S. L. 209
Pucci B. Guedj C. and Pavia A. A.
Biocompatible non-ionic surfactants for biomedical utilization: double-tailed hydrocarbon and/or fluorocarbon synthetic glycolipids 1003
Pucci B. see Maurizis J. C. 161
Pudzianowski A. T. see Biller S. A. 595
Pugsley T. A. see Jaén J. C. 639
Pugsley T. A. see Wustrow D. J. 277
Pullan L. M. see Bare T. M. 55
Purohit A. see Howarth N. M. 313

Qian C. see Li T. 2759
Qian L. see Kim K. S. 2667
Quagliato C. S. see de Laszlo S. E. 1299
Quagliato C. S. see Allen E. E. 1293
Quijano Mª L. see Nogueras M. 601
Quinn D. M. see Nair H. K. 2619
Quinn R. J. Taylor C. Suganuma M. and Fujiki H.
The conserved acid binding domain model of inhibitors of protein phosphatases 1 and 2A: molecular modelling aspects 1029

Rafferty M. see Chandrakumar N. S. 309
Rahman S. S. see Markwell R. E. 2537
Raissian M. see Siddiqi S. M. 663
Rajagopalan J. S. and Jaffe E. K.
Microbial production and NMR characterization of [2,6,9-^{13}C]chorismate and [1,3,5,8-^{13}C]chorismate 1453
Rajdev S. see Reynolds I. J. 85
Rajur S. B. see Mehta V. D. 785
Rake J. see Wentland M. P. 1711
Ramjee M. K. Coggins J. R. Hawkes T. R. Lowe D. J. and Thorneley R. N. F.
The stoichiometry of binding of flavin mononucleotide (FMN) hydroquinone to *Escherichia coli* chorismate synthase 1409
Rampulla R. see Murray W. V. 369
Rampulla R. see Murray W. V. 785
Randall P. see Barraclough P. 509
Rao B. K. see Georg G. I. 1345
Rao C. see Sawyer T. K. 819
Rapundalo S. see Hamilton H. 813
Rapundalo S. T. see Plummer M. 2119
Rasmussen T. B. see Madsen U. 1649
Rataud J. see Jimonet P. 983

Ratcliffe G. S. see Higginbottom M. 841
Ratcliffe G. S. see Horwell D. C. 799
Ratcliffe R. W. see Wilkening R. R. 1287
Rathjen D. A. and Aston R.
Selective enhancement of tumour necrosis factor activity: mapping regions with monoclonal antibodies 457
Ratovelomanana V. see Tellier F. 1629
Ravikumar V. T. Sasmor H. and Cole D. L.
Use of 2-diphenylmethylsilylethyl (DPSE) protecting group in oligo-nucleotide synthesis via phosphoramidite approach 2637
Readshaw S. A. see Pinto I. L. 1743
Ream J. E. see Knowles W. S. 2863
Ream J. E. see Miller M. J. 1435
Reddy B. S. P. see Kamal A. 743
Reddy G. P. see Clark J. W. 1873
Reddy G. S. Clark J. W. Tserng K.-Y. Uskokovic M. R. and McLane J. A.
Metabolism of 1 25$(OH)_2$16-ene D_3 in kidney: influence of structural modification of D-ring on side chain metabolism 1879
Reddy G. S. see Clark J. W. 1873
Reddy G. S. see Posner G. H. 1835
Reddy J. P. see Engler T. A. 1229
Reddy N. L. Fischer J. B. Burke-Howie K. J. Barmettler P. Rhodes M. R. Weber E. and Keana J. F. W.
N,N'-Disubstituted acetamidines as high affinity sigma receptor ligands 2113
Reed M. J. see Howarth N. M. 313
Rees D. C. see Henry J. A. 949
Rees D. C. see Higginbottom M. 841
Rees D. C. see Horwell D. C. 799
Reichard G. A. see Corey E. J. 2635
Reichenbächer M. see Schönecker B. 1849
Reid A. C. see Allott C. P. 899
Reid J. A. see Das J. 1267
Reid J. A. see Das J. 1271
Reid J. A. see Poss M. A. 2739
Reid R. J. see Barbachyn M. R. 671
Reider P. J. see Madar A.-M. 2393
Reilly A. Coggins J. R. and Kleanthous C.

Hybrid formation in the shikimate pathway enzyme dehydroquinase 1429
Reinhard E. J. see Reitz D. B. 1055
Reitz D. B. Garland D. J. Norton M. B. Collins J. T. Reinhard E. J. Manning R. E. Olins G. M. Chen S. T. Palomo M. A. McMahon E. G. and Koehler K. F. N_1-Sterically hindered 2*H*-imidazol-2-one angiotensin II receptor anta-gonists: the conversion of surmountable antagonists to insurmountable antagonists 1055
Rémy J. M. see Schirlin D. 253
Resul B. see Liljebris C. 241
Reuman M. see Wentland M. P. 1711
Revel L. see Makovec F. 861
Revesz L. see Bell P. 1007
Rew D. J. see Chiang Y.-C. P. 2029
Reynolds E. E. see Doherty A. M. 497
Reynolds I. J. Rothermund K. D. and Rajdev S. Interaction of rigid polyamine analogues with the NMDA receptor complex from rat brain 85
Rhein D. A. see Davidson S. K. 2729
Rhodes M. R. see Reddy N. L. 2113
Rich D. H. see García-Echeverría C. 1601
Rich L. C. see Biller S. A. 595
Richter K. E. G. see Chenard B. L. 1991
Ridgill M. P. see Leeson P. D. 299
Riendeau D. see Thérien M. 2063
Rieser M. J. see Fang X. 1153
Ripoche P. see Lamotte H. 2587
Riscoe M. K. see Winter R. W. 2079
Rittle K. E. see Evans B. E. 867
Rivero R. A. Chakravarty P. K. Chen R. Greenlee W. J. Rosegay A. and Simpson R. The synthesis of [^{3}H]-Losartan, [^{3}H]-L-158,641 and [^{3}H]-L-158,809 557
Rivero R. A. Kevin N. J. and Allen E. E. New potent angiotensin II receptor antagonists containing phenylthiophenes and phenylfurans in place of the biphenyl moiety 1119
Rizzi J. P. see Lowe, III J. A. 921
Rizzo V. Borghi D. Sacchi N. Alpegiani M. and Perrone E. Studies on cephem sulfones as mechanism-based inactivators of human leukocyte elastase—IV. Reactions ensuing from enzymatic β-lactam cleavage 2265
Rizzo V. see Alpegiani M. 2259
Rizzo V. see Franceschi G. 2333
Roberti M. see Kozikowski A. P. 1327
Roberts D. A. see Allott C. P. 899
Roberts E. see Higginbottom M. 841
Roberts E. see Higginbottom M. 881
Robertson M. J. see Dowle M. D. 2047
Robertson M. J. see Middlemiss D. 2043
Robertson M. J. see Middlemiss D. 589
Robichaud L. J. see Hays S. J. 77
Robinson L. see Mugrage B. 2099
Rodrigues J. A. R. see Aleixo L. M. 1637
Rodriguez M. see Rolland M. 851
Rodriques K. see Dellaria, Jr J. F. 305
Rogers R. S. see Bertenshaw S. R. 1953
Rogers W. L. see Poss M. A. 2739
Rolland M. Lignon M.-F. Galas M.-C. Bernad N. Rodriguez M. Fulcrand P. and Martinez J. On the significance of the C-terminal primary amide in cholecystokinin 851
Roman C. R. see Sofia M. J. 1147
Roques B. P. Corringer P.-J. Derrien M. Daugé V. and Durieux C. Structure-based design and pharmacological properties of potent selective and systemically active CCK-B peptidomimetics 847
Rose W. C. see Ueda Y. 1761
Rosegay A. see Rivero R. A. 557
Rösel J. see Fässler A. 2837
Rosenthal A. S. see Skiles J. W. 773
Rosentreter U. see Abram T. S. 1517
Rosinski K. see McCombie S. W. 1537
Ross B. C. see Dowle M. D. 2047
Ross B. C. see Middlemiss D. 2043
Ross B. C. see Middlemiss D. 589
Rossi R. see Jabès D. 2165
Rossman P. L. see Dax S. L. 209
Roth B. D. see Padia J. K. 2805
Rothermund K. D. see Reynolds I. J. 85
Rousseau B. see Lamotte H. 2587
Rovati L. C. see Makovec F. 861
Rowden J. Y. see Colvin E. W. 2405
Rowe C. J. see Lewis M. L. 1189
Rowe C. J. see Lewis M. L. 1193
Rowe C. J. see Lewis M. L. 1197
Rowley M. see Leeson P. D. 299
Rowley M. see Leeson P. D. 71
Roy P. see Guay D. 1125
Rozamus L. W. see Holt D. A 1735
Rudge D. A. see Allott C. P. 899
Rudolph C. see Kleinschroth J. 1959
Rusiecki V. K. and Warne S. A. Synthesis of N_α-Fmoc-N_ε-Nvoc-lysine and use in the preparation of selectively functionalized peptides 707
Russell K. Brown F. J. Warwick P. Forst J. Grant T. Howe B. Kau S. T. Li J. H. McLaren F. M. Shapiro H. S. and Trivedi S. A highly potent series of fluoroalkyl benzoxazine pyridine-N-oxide potassium channel openers 2727
Russell K. see Grant T. 2723
Russell S. T. see Allott C. P. 899
Russo A. see Soll R. M. 757
Ryan J. M. see Pandey R. K. 2615
Ryan M. see Hamilton H. 813
Ryono D. E. see Poss M. A. 2739

Sabin V. see Seward E. M. 1361
Sabin V. see Swain C. J. 1703
Sacchi N. see Rizzo V. 2265
Sadowski S. see Mills S. G. 2707
Sadowski S. see Seward E. M. 1361
Sadowski S. see Swain C. J. 1703
Safrany S. T. see Mills S. J. 1505
Saha A. K. see Caulfield T. J. 2771
Saha U. K. see Gurjar M. K. 697
Saika H. Früh Th. Iwasaki G. Koizumi S. Mori I. and Hayakawa K. Synthesis of (2*R*,3*R*)-, (2*S*,3*S*)-, (2*R*,3*S*)- and (2*S*,3*R*)-imidazole glycerol phosphates (IGP): substrates for IGP-dehydratase (IGPD) 2129

Saindane M. T. see Wentland M. P. 1711
Saint Fort R. see Moyer M. P. 1379
Saito I. see Matsugo S. 1671
Sakagami Y. see Fukushima Y. 1219
Sakodinskaya I. K. see Yatsimirsky A. K. 635
Saksena A. K. see Cooper A. B. 1079
Salituro G. M. Pettibone D. J. Clineschmidt B. V. Williamson J. M. and Zink D. L.
Potent, non-peptidic oxytocin receptor antagonists from a natural source 337
Sallin K. J. see Dellaria, Jr J. F. 305
Salmon S. E. see Lam K. S. 419
Salzmann T. N. see DiNinno F. 2187
Samanen J. M. Peishoff C. E. Keenan R. M. and Weinstock J.
Refinement of a molecular model of angiotensin II (AII) employed in the discovery of potent nonpeptide antagonists 909
Sammons R. D. see Miller M. J. 1435
Sánchez A. see Nogueras M. 601
Sánchez-Vigo B. see Alcaide B. 2369
Sandhu J. S. see Prajapati D. 2419
Sanfilippo P. J. McNally J. J. Press J. B. Falotico R. Giardino E. and Katz L. B.
Thiophene systems—XV. Synthesis and antihypertensive activity of 7-(substituted benzamido)-6-hydroxythieno[3,2-*b*]pyrans as new potassium channel activators 1385
Santos-Moore A. see Clark J. W. 1873
Sardaro M. P. see Caulfield T. J. 2771
Sarmiento J. G. see Lawson J. E. 561
Sarmiento J. G. see Poindexter G. S. 2817
Saroglou L. see Wood L. M. 1499
Sarshar S. see Corey E. J. 2635
Sasaki T. see Minakawa N. 183
Sasmor H. see Ravikumar V. T. 2637
Satani T. see Takabe K. 157
Sato D. see Fujisawa T. 2343
Sato H. Koga H. Ishizawa T. Makino T. Kuromaru K. Taka N. Takahashi T. Sato T. and Nabata H.
Vasorelaxant activity of 2-substituted 6-nitro-2*H*-1-benzopyran-4-carbothioamide K^+ channel openers 2627
Sato H. see Ishizawa T. 1659
Sato H. see Koga H. 1111
Sato H. see Koga H. 1115
Sato H. see Koga H. 2005
Sato H. see Koga H. 625
Sato K. see Kobayashi T. 1815
Sato M. Kahn M. Lin Z. Johnson M. E. and Hayes T. K.
Design and synthesis of hypertrehalosemic hormone mimetics 1277
Sato T. see Ishizawa T. 1659
Sato T. see Koga H. 1115
Sato T. see Sato H. 2627
Satoh K. see Inoue A. 345
Satta G. see Altamura M. 2159
Saulnier M. G. LeBoulluec K. L. McGee D. P. C. Long B. H. Crosswell A. R. and Vyas D. M.
Synthesis and biological activity of 3',4',5'-trihydroxy etoposide 1619
Saussy, Jr D. L. see Sawyer J. S. 1981
Saussy, Jr D. L. see Sawyer J. S. 1985
Saussy, Jr D. L. see Sofia M. J. 1147
Sauvé G. see Vaillancourt M. 1169
Sauve G. see Zacharie B. 619
Sawada H. see Takabe K. 157
Sawai H. see Shinozuka K. 2883
Sawhney S. N. and Sharma P. K.
Synthesis and anti-inflammatory activity of some 3-heterocyclyl-1,2-benzisothiazoles 1551
Sawyer J. S. Baldwin R. F. Froelich L. L. Saussy, Jr D. L. and Jackson W. T.
Synthesis and pharmacologic activity of hydroxyacetophenone-substituted benzophenone/xanthone leukotriene B_4 receptor antagonists 1981
Sawyer J. S. Baldwin R. F. Saussy, Jr D. L. Froelich L. L. and Jackson W. T.
Diaryl ether/carboxylic acid derivatives of LY255283: receptor antagonists of leukotriene B_4 1985
Sawyer T. K. Fisher J. F. Hester J. B. Smith C. W. Tomasselli A. G. Tarpley W. G. Burton P. S. Hui J. O. McQuade T. J. Conradi R. A. Bradford V. S. Liu L. Kinner J. H. Tustin J. Alexander D. L. Harrison A. W. Emmert D. E. Staples D. J. Maggiora L. L. Zhang Y. Z. Poorman R. A. Dunn B. M. Rao C. Scarborough P. E. Lowther W. T. Craik C. DeCamp D. Moon J. Howe W. J. and Heinrikson R. L.
Peptidomimetic inhibitors of human immunodeficiency virus protease (HIV-PR): design, enzyme binding and selectivity, antiviral efficacy, and cell permeability properties 819
Sawyer T. K. see Pavia M. R. 387
Saywell K. see Carling R. W. 65
Sbraci P. see Altamura M. 2159
Scalise O. see Corsano S. 2713
Scapicchi R. see Corsano S. 2713
Scarborough P. E. see Sawyer T. K. 819
Schaadt R. D. see Barbachyn M. R. 671
Schächtele C. see Kleinschroth J. 1959
Schaeper M. see Church K. M. 2623
Schairer W. C. see Caulfield T. J. 2771
Schatzman G. L. see Wannamaker M. W. 1175
Scheigetz J. see Thérien M. 2063
Schicho D. L. see Jaynes B. H. 1531
Schinazi R. F. see Choi W.-B. 693
Schinazi R. F. see Wilson L. J. 169
Schirlin D. Baltzer S. Van Dorsselaer V. Weber F. Weill C. Altenburger J. M. Neises B. Flynn G. Rémy J. M. and Tarnus C.
Short and unexpectedly potent difluorostatone type inhibitors of HIV-1 protease 253
Schlemmer K. H. see Abram T. S. 1517
Schlewer G. see Linget J. M. 1309
Schmid W. Avila L. Z. Williams K. W. and Whitesides G. M.
Synthesis of methyl α-sialosides N-substituted with large alkanoyl groups, and investigation of their inhibition of agglutination of erythrocytes by influenza A virus 747
Schmidt G. Schröck W. and Endermann R.
Synthesis and biological activity of tetracyclic carbapenems 2193
Schmidt J. M. see Pettit G. R. 2869
Schmidt M. Eichler J. Odarjuk J. Krause E. Beyermann M. and Bienert

M.
Multiple peptide synthesis using cellulose-based carriers: synthesis of substance P-diastereoisomers and their histamine-releasing activity 441
Schmidt R. R. and Frische K.
A new galactosyl transferase inhibitor 1747
Schmidt W. K. see Cain G. A. 1767
Schmidt W. K. see Cain G. A. 2055
Schmidt W. K. see Christos T. E. 1035
Schneider F. Fischer P. Ebner T. and Meese C. O.
Conformation of the CYP2D6 model substrate sparteine under physio-logical conditions 1667
Schneller S. W. see Siddiqi S. M. 663
Schoemaker H. E. see Formaggio F. 953
Schoepp D. D. see Monn J. A. 95
Schoepp D. D. see Ornstein P. L. 2067
Schoepp D. D. see Ornstein P. L. 43
Schönecker B. Prousa R. Reichenbächer M. Gliesing S. Kosan H. Droescher P. Hausschild U. and Thieroff-Ekerdt R.
Synthesis of 3β-acetoxy-1β,2β-epoxy-25-hydroxy-cholesta-5,7-diene and 2β,25-dihydroxyvitamin D_3 1849
Schorn T. S. see de Laszlo S. E. 1299
Schow S. R. and Tam S. W.
Novel sigma receptor ligands—I 215
Schow S. R. and Tam S. W.
Novel sigma receptor ligands—II 221
Schow S. R. see Babine R. E. 1589
Schow S. R. see Trova M. P. 1595
Schrier D. J. see Unangst P. C. 1729
Schröck W. see Schmidt G. 2193
Schroeder R. see Hamilton H. 813
Schultz P. G. see Skerker P. S. 285
Schultz R. see Miltz W. 1233
Schupsky J. J. see Maryanoff B. E. 2653
Schwender C. F. see Ohemeng K. A. 225
Scopes D. I. C. see Dowle M. D. 2047
Scopes D. I. C. see Middlemiss D. 2043
Scopes D. I. C. see Middlemiss D. 589
Searle M. S. see Gerhard U. 803
Sebestyén F. Dibó G. Kovács A. and Furka Á.
Chemical synthesis of peptide libraries 413
Seela F. and Winter H.
Oligodeoxyribonucleotides containing N^7-(2-deoxy-β-D-*erythro*-pentofuranosyl)adenine 273
Sentenac-Roumanou H. see Dekhane M. 2831
Sereno J. F. see Batcho A. D. 1821
Sergheraert C. see Tromelin A. 1971
Servi S. see Fuganti C. 2785
Seto Y. see Shinozuka K. 2883
Sewald N. see Lewis M. L. 1193
Seward E. M. Swain C. J. Merchant K. J. Owen S. N. Sabin V. Cascieri M. A. Sadowski S. Strader C. and Baker R.
Quinuclidine-based NK-1 antagonists—I. 3-Benzyloxy-1-azabicyclo[2.2.2]octanes 1361
Seward E. M. see Swain C. J. 1703
Shah G. P. see Barraclough P. 509
Shah P. see Middlemiss D. 589
Shah S. K. Finke P. E. Brause K. A. Chandler G. O. Ashe B. M. Weston H. Maycock A. L. Mumford R. A. and Doherty J. B.
Monocyclic β-lactam inhibitors of human leukocyte elastase. Stereospecific synthesis and activity of 3,4-disubstituted-2-azetidinones 2295
Shah S. K. see Thompson K. R. 2283
Shah S. K. see Thompson K. R. 2289
Shalaby I. A. see Chenard B. L. 91
Shalhoub V. see Stein G. S. 1885
Shan Y. Y. see Krief A. 365
Shank R. P. see Maryanoff B. E. 2653
Shankar B. B. see McCombie S. W. 1537
Shapiro E. S. see Afonso A. 2177
Shapiro H. S. see Grant T. 2723
Shapiro H. S. see Russell K. 2727
Sharma N. K. see Parmar V. S. 585
Sharma P. K. see Sawhney S. N. 1551
Sharma R. Marquez V. E. Milne G. W. A. Lewin N. E. and Blumberg P. M.
Conformationally constrained analogues of diacylglycerol—V. 2,5-Dideoxy-3-O-tetradecanoyl-D-galactono-1,4-lactone: a superior homologue of 3-O-tetradecanoyl-2-deoxy-L-ribonolactone with PK-C binding affinity 1993
Sharpe A. see Fletcher S. R. 141
Sharratt P. J. see Procopiou P. A. 2527
Sheardown M. J. see Knutsen L. J. S. 2661
Sheeka H. M. see McGuigan C. 1203
Sheffer-Dee-Noor S. Belakhov V. and Baasov T.
Insight into the catalytic mechanism of KDO8P synthase. Synthesis and evaluation of the isosteric phosphonate mimic of the putative cyclic intermediate 1583
Sheffer-Dee-Noor S. and Baasov T.
A combined chemical–enzymatic synthesis of a new phosphoramidate analogue of phosphoenolpyruvate 1615
Sheldrick R. see Smith P. W. 931
Shen S. see Langlois M. 1555
Shen S. see Langlois M. 2035
Shen T. Y. see Li T. 2759
Sherk S. R. see Wright S. W. 2875
Sherman M. I. Bertelsen A. H. and Cook A. F.
Protein epitope targeting: oligonucleotide diversity and drug discovery 469
Shetty S. S. see Mugrage B. 2099
Shih C. Hu Y. Gossett L. S. Habeck L. L. Mendelsohn L. G. and Grindey G. B.
Synthesis and biological activity of 2-desamino and 4-deoxy analogs of 5,10-dideazatetrahydrofolic acid (DDATHF) 2657
Shimamoto K. see Ohfune Y. 15
Shimizu M. Yamazaki T. and Yamada S.
Fluorescence-labeling reaction of vitamin D metabolites and analogs with fluorescent 1,2,4-triazoline-3,5-dione (DMEQ-TAD) 1809
Shimizu M. see Fujisawa T. 2343
Shin H. see Yoo S. 553
Shingler A. H. see Giblin G. M. P. 2605
Shinozaki H. see Ohfune Y. 15
Shinozuka K. Seto Y. Kawata H. and Sawai H.
Bi-functional labelling of DNA with tris(2-aminoethyl)amine-

derived novel fluorescent agent 2883
Shiosaki K. Lin C. W. Leanna M. R. Morton H. E. Miller T. R. Witte D. Stashko M. and Nadzan A. M.
Toward developing peptidomimetics: successful replacement of backbone amide bonds in tetrapeptide-based CCK-A receptor agonists 855
Shneier A. Harris J. Kleanthous C. Coggins J. R. Hawkins A. R. and Abell C.
Evidence for opposite stereochemical courses for the reactions catalysed by type I and type II dehydroquinases 1399
Shoop W. L. see Meinke P. T. 2675
Shullenberger D. F. and Long E. C.
Design and synthesis of a DNA-cleaving metallopeptide 333
Shutske G. M. see Kapples K. J. 2789
Siddiqi S. M. Raissian M. Schneller S. W. Ikeda S. Snoeck R. Andrei G. Balzarini J. and De Clercq E.
(±)-7-Deazaaristeromycin lacking the hydroxymethyl substituent 663
Siddiqui M. A. Brown W. L. Nguyen-Ba N. Dixit D. M. Mansour T. S. Hooker E. Viner K. C. and Cameron J. M.
Antiviral optically pure dioxolane purine nucleoside analogues 1543
Siegl P. K. S. see de Laszlo S. E. 1299
Siegl P. K. S. see Mantlo N. B. 1693
Sierra M. A. see Alcaide B. 2369
Sikk P. see Parve O. 357
Sikk P. see Parve O. 359
Sikorski J. A. see Corey S. D. 2857
Sikorski J. A. see Knowles W. S. 2863
Sikorski J. A. see Miller M. J. 1435
Silbaugh S. A. see Sofia M. J. 1147
Silverman R. B. see Ding C. Z. 2077
Simoni D. see Baraldi P. G. 2511
Simpson R. see Rivero R. A. 557
Simpson W. J. and Hughes P. S.
Cooperative binding of potassium ions to *trans*-isohumulone in the presence of divalent and trivalent cations 769
Sinclair P. J. see Organ H. M. 657
Singh B. see Wentland M. P. 1711
Singh H. see Kumar S. 363
Singh J. see Gordon T. 915
Singh L. see Moore K. W. 61
Singh R. see Kumar S. 363
Sircar J. C. see Unangst P. C. 1729
Skerker P. S. Jacobs J. W. Clark D. S. and Schultz P. G.
Probing a catalytic antibody active site using spin-labelled haptens 285
Skiles J. W. Sorcek R. Jacober S. Miao C. Mui P. W. McNeil D. and Rosenthal A. S.
Elastase inhibitors containing conformationally restricted lactams as P_3-P_2 dipeptide replacements 773
Slater M. J. see Laws A. P. 2317
Slusarchyk D. A. see Biller S. A. 595
Smith A. J. see Chambers M. S. 1919
Smith C. see Giblin G. M. P. 2605
Smith C. W. see Sawyer T. K. 819
Smith D. G. see Pinto I. L. 1743
Smith D. L. see Fang X. 1153
Smith E. C. R. McQuaid L. A. Calligaro D. O. and O'Malley P. J.
Structure–activity relationships of a series of glycine antagonists related to 5,7-dichlorokynurenic acid and 3-(2-carboxy-6-chloroindol-3-yl)acetic acid 81
Smith H. see Bell P. 1007
Smith J. D. see Carling R. W. 65
Smith J. D. see Leeson P. D. 299
Smith K. M. see Pandey R. K. 2615
Smith M. W. see Zhao S. 2641
Smith P. W. McElroy A. B. Pritchard J. M. Deal M. J. Ewan G. B. Hagan R. M. Ireland S. J. Ball D. Beresford I. Sheldrick R. Jordan C. C. and Ward P.
Low molecular weight neurokinin NK_2 antagonists 931
Smith R. W. see Frank C. A. 2725
Smith S. A. see Bermudez J. 2571
Smith W. L. see Clark R. D. 1375
Snider R. M. see Lowe, III J. A. 921
Snoeck R. see Siddiqi S. M. 663
Sodeoka M. Larson C. J. Chen L. Lane W. S. and Verdine G. L.
Limited proteolysis and site-directed mutagenesis of the NF-κB p50 DNA-binding subunit 1095
Sodeoka M. Larson C. J. Chen L. LeClair K. P. and Verdine G. L.
A multifunctional plasmid for protein expression by ECPCR: over-production of the p50 subunit of NF-κB 1089
Sofia M. J. Floreancig P. Jackson W. T. Marder P. Saussy, Jr D. L. Silbaugh S. A. Cockerham S. L. Froelich L. L. Roman C. R. Stengel P. W. and Fleisch J. H.
Acid unit modifications of 1,2,4,5-substituted hydroxyacetophenones and the effect on *in vitro* and *in vivo* LTB_4 receptor antagonism 1147
Soll R. M. Kinney W. A. Primeau J. Garrick L. McCaully R. J. Colatsky T. Oshiro G. Park C. H. Hartupee D. White V. McCallum J. Russo A. Dinish J. and Wojdan A.
3-Hydroxy-3-cyclobutene-1,2-dione: application of a novel carboxylic acid bioisostere to an *in vivo* active non-tetrazole angiotensin II antagonist 757
Solomon W. see Zein N. 1351
Somfai P. see Tanner D. 2415
Sommer J. see Gmeiner P. 1477
Sonegawa M. see Yanagisawa T. 1559
Song R. see Fang X. 1153
Sorcek R. see Skiles J. W. 773
Sorenson R. J. see Unangst P. C. 1729
Soulier J. L. see Langlois M. 1555
Spavold Z. M. see Whittaker M. 1493
Spellmeyer D. C. Brown S. Stauber G. B. Geysen H. M. and Valerio R.
Endothelin receptor ligands. Replacement net approach to SAR determination of potent hexapeptides 519
Spellmeyer D. C. Brown S. Stauber G. B. Geysen H. M. and Valerio R.
Endothelin receptor ligands. Multiple D-amino acid replacement net approach 1253
Spencer R. W. see Faraci W. S. 2271
Spinazze P. see Yu K.-L. 535
Spooner S. J. see Giblin G. M. P. 2605

Spooner S. J. see Procopiou P. A. 2527
Springer R. H. see Mancharan M. 2765
Spunta G. see Bandini E. 2347
Spurling T. see Wilson L. J. 169
Srivastava K. and Pandeya S. N. Synthesis and anticonvulsant activity of 3-arylamino-4-aryl-5-(N-4-chlorophenylthiocarbamido)-1,2,4-thiadiazoles 547
St. Clair M. see Choi W.-B. 693
St. Clair M. see Wilson L. J. 169
Staeger M. A. see Maynard G. D. 753
Stamm N. B. see Wikel J. H. 1157
Stanfield R. L. see Trivedi B. K. 259
Stanga M. A. see Groutas W. C. 1163
Stanley M. S. see Bridges R. J. 115
Stansfield I. see Leeson P. D. 299
Staples D. J. see Sawyer T. K. 819
Starkey I. D. see Holmes D. S. 1485
Staruch M. J. see Organ H. M. 657
Stashko M. see Shiosaki K. 855
Stauber G. B. see Spellmeyer D. C. 1253
Stauber G. B. see Spellmeyer D. C. 519
Steeples I. P. see Watson N. S. 2541
Stein G. S. Lian J. B. Uskokovic M. Aronow M. Shalhoub V. Owen T. and Barone L. Effects of $1,25(OH)_2D_3$ and vitamin D analogs on developmental control of cell growth and tissue-specific gene expression during osteoblast differentiation 1885
Steinbaugh B. see Hamilton H. 813
Steinman M. see Hou D. 2171
Stemp G. see Burrell G. 999
Stengel P. W. see Sofia M. J. 1147
Stevanovic S. Wiesmüller K.-H. Metzger J. Beck-Sickinger A. G. and Jung G. Natural and synthetic peptide pools: characterization by sequencing and electrospray mass spectrometry 431
Stevenson G. I. see Leeson P. D. 299
Stewart B. see Hamilton H. 813
Stewart C. see Hamilton H. 813
Stirnimann R. see Miltz W. 1233
Stocks M. J. see Teague S. J. 1947
Stoeber T. L. see Trivedi B. K. 259
Stokker G. E. Synthesis of one of the major mouse metabolites of lovastatin and simvastatin 2755
Stone D. see Barraclough P. 509
Storer R. see Holmes D. S. 503
Storer R. see Holmes D. S. 1485
Strader C. see Seward E. M. 1361
Strader C. see Swain C. J. 1703
Strader C. D. see Mills S. G. 2707
Strappaghetti G. see Corsano S. 2713
Stratford M. R. L. see Parrick J. 1697
Street L. J. see Castro J. L. 993
Streith J. Craig C. Muller M. and Tschamber T. β-Lactam derivatives from 1-H-1,2-diazepines 2375
Stuart G. see Middlemiss D. 2043
Stuart G. see Middlemiss D. 589
Stuart P. G. see Dowle M. D. 2047
Stutzmann J.-M. see Jimonet P. 983
Su T. Nakanishi H. Xue L. Chen B. Tuladhar S. Johnson M. E. and Kahn M. Nonpeptide β-turn mimetics of enkephalin 835
Suckling C. J. and Zhu L.-M. Carbon–carbon bond formation mediated by papain chemically modified by thiazolium salts 531
Suganuma M. see Quinn R. J. 1029
Sugie A. see Kawakami H. 2821
Sugita K. see Kobori T. 2225
Sugo I. see Koga H. 1111
Sugo I. see Koga H. 2005
Sujatha K. see Lutgring R. 739
Suman-Chauhan N. see Hill D. 885
Sumida S. see Tanaka H. 2253
Summers J. B. see Davidsen S. K. 2729
Summersell R. J. see Bermudez J. 205
Sun C. M. see Ojima I. 2479
Sun L. see Bastow K. F. 1045
Sutherland J. D. Wilson E. J. and Wright M. C. Directed evolution of novel biosynthetic pathways: growth of an *Escherichia coli* proline auxotroph on Δ^1-pyrroline-2-carboxylic acid 1185
Sutherland J. D. see Lewis M. L. 1189
Sutherland J. D. see Lewis M. L. 1193
Sutherland J. D. see Lewis M. L. 1197
Swain C. J. Seward E. M. Sabin V. Owen S. Baker R. Cascieri M. A. Sadowski S. Strader C. and Ball R. G. Quinuclidine based NK-1 antagonists—II. Determination of the absolute stereochemical requirements 1703
Swain C. J. see Seward E. M. 1361
Swanson P. C. and Glick G. D. Chemical sequencing of disulfide-crosslinked oligodeoxyribonucleotides 2117
Swayze E. E. Peiris S. M. Kucera L. S. White E. L. Wise D. S. Drach J. C. and Townsend L. B. Synthesis of 1-(2-aminopropyl)benzimidazoles, structurally related to the TIBO derivative R82150, with activity against human immunodeficiency virus 543
Sweet R. W. see Jarvest R. L. 2851
Sziraky P. see Guy A. 1041
Szmuszkovicz J. see Zhao S. 2641
Sztaricskai F. Hornyák M. Komáromi I. Batta G. and Pelyvás I. F. Synthesis of non-reducing disaccharides. New analogues of trehalosamine constructed from acosamine and ristosamine 235
Sztaricskai F. see Gunda T. E. 2379

Tackett L. see Pettit G. R. 2869
Tagliani A. see Fuganti C. 2785
Taka N. see Ishizawa T. 1659
Taka N. see Koga H. 1115
Taka N. see Koga H. 2005
Taka N. see Sato H. 2627
Takabe K. Sawada H. Satani T. Yamada T. Katagiri T. and Yoda H. Chemoenzymatic synthesis of optically active α-tocopherol side chain 157
Takahashi H. and Isobe M. *Symplectoteuthis* bioluminescence—I. Structure and binding form of chromophore in photoprotein of a luminous squid 2647
Takahashi T. see Ishizawa T. 1659
Takahashi T. see Koga H. 1115
Takahashi T. see Koga H. 2005
Takahashi T. see Sato H. 2627
Takaku H. see Kim S.-G. 1223
Takeuchi A. see Kobayashi T. 1815

Tailey J. J. see Bertenshaw S. R. 1953
Tam L. L. see Chandrakumar N. S. 309
Tam S. W. see Cain G. A. 1767
Tam S. W. see Cain G. A. 2055
Tam S. W. see Christos T. E. 1035
Tam S. W. see Schow S. R. 215
Tam S. W. see Schow S. R. 221
Tan R. see Pettit G. R. 2869
Tanaka H. Baba M. Yamamoto T. Mori S. Walker R. T. De Clercq E. and Miyasaka T. Synthesis of a potential photoaffinity labelling reagent for HIV-1 reverse transcriptase 1681
Tanaka H. Kameyama Y. Sumida S. and Torii S. 2-Substituted penems, new candidates for cephalosporinase inhibitors 2253
Tanaka R. Nakatsuka T. and Ishiguro M. Novel conversion reaction of β-lactam to γ-lactam. Synthesis of γ-lactam analogs of penam and penem antibiotics 2299
Tandon J. S. see Chauhan P. M. S. 677
Taneja P. see Parmar V. S. 585
Tani T. see Katsumura S. 2703
Tanner D. and Somfai P. Palladium-catalyzed transformation of a chiral vinylaziridine to a β-lactam. An enantioselective route to the carbapenem (+)-PS-5 2415
Tapparelli C. see Kottirsch G. 1675
Tarnawa I. Berzsenyi P. Andrási F. Botka P. Hámori T. Ling I. and Körösi J. Structure–activity relationships of 2,3-benzodiazepine compounds with glutamate antagonistic action 99
Tarnus C. see Schirlin D. 253
Tarpley W. G. see Sawyer T. K. 819
Tartar A. see Tromelin A. 1971
Tatematsu H. see Bastow K. F. 1045
Taylor C. see Quinn R. J. 1029
Taylor C. P. see Bigge C. F. 39
Taylor C. P. see Hays S. J. 77
Taylor M. see Hamilton H. 813
Taylor W. A. see Abram T. S. 1517
Teague S. J. and Stocks M. J. The affinity of the excised binding domain of FK-506 for the immunophilin FKBP12 1947
Teall M. see Fletcher S. R. 141
Tellier F. Hammoud A. Ratovelomanana V. Linstrumelle G. and Descoins C. Synthesis of a biologically active chlorinated analog of (*E E*)-8,10-dodecadienol (codlemone) 1629
Teng M. Gasparski C. M. Williams M. A. and Miller M. J. A combined electrophilic diazo and nucleophilic azide transfer reaction for the efficient conversion of an *N*-hydroxy-β-lactam to a carbacephem precursor 2431
Ternansky R, J. and Jordan C. L. The ring closure of substituted azetidinones: a new route to [4.2.0] fused beta-lactams 2443
Ternansky R. J. and Pike A. J. 3-Phosphono-1-carba-1-dethiacephalosporins as antibacterial agents 2237
Terry B. see Kim C. U. 1571
Teutsch G. see Aszodi J. 2231
Teutsch G. see Klich M. 2429
Theodorou M. E. see Fischer R. S. 1415
Thérien M. Fitzsimmons B. J. Scheigetz J. Macdonald D. Choo L. Y. Guay J. Falgueyret J. P. and Riendeau D. Justicidin E: a new leukotriene biosynthesis inhibitor 2063
Thieroff-Ekerdt R. see Schönecker B. 1849
Thomas D. R. see Bolton D. 1941
Thompson A. S. see Madar A.-M. 2393
Thompson K. R. Finke P. E. Shah S. K. Ashe B. M. Dahlgren M. E. Dellea P. S. Fletcher D. S. Hand K. M. Maycock A. L. and Doherty J. B. Inhibition of human leukocyte elastase—VII. Inhibition by 6-substituted penicillin amides 2289
Thompson K. R. Finke P. E. Shah S. K. Ashe B. M. Dahlgren M. E. Maycock A. L. and Doherty J. B. Inhibition of human leukocyte elastase—VI. Inhibition by 6-substituted penicillin esters 2283
Thompson M. see Bolton D. 1941
Thompson P. E. Lim N. Wijaya E. Ng F. M. and Hearn M. T. W. Hypoglycaemic activity of an analogue of human Growth Hormone [6-13] incorporating a D-Ala–Pro dipeptide unit 1625
Thompson T. M. see Whittaker M. 1493
Thompson T. M. see Wood L. M. 1499
Thomsen C. see Knutsen L. J. S. 2661
Thomson M. J. see Bermudez J. 2571
Thornberry N. A. see Mjalli A. M. M. 2689
Thorneley R. N. F. see Ramjee M. K. 1409
Thurston D. E. see Kamal A. 743
Tidwell R. R. see Donkor I. O. 1137
Timmermans P. B. M. W. M. see Carini D. J. 895
Timmis D. J. see Wood L. M. 1499
Tino J. A. see Vite G. D. 1211
Tintelnot-Blomley M. see Fässler A. 2837
Tivel K. L. see Manoharan M. 2765
Tolbert T. J. see Montchamp J.-L. 1403
Tomasselli A. G. see Sawyer T. K. 819
Tomaszek, Jr T. A. see Chenera B. 2717
Tomiyama T. see Yanagisawa T. 1559
Tomiyama T. see Yokota M. 1687
Tommasini I. see Colvin E. W. 2405
Tong L. Cardozo M. Jones P.-J. and Adams J. Preliminary structural analysis of the mutations selected by non-nucleoside inhibitors of HIV-1 reverse transcriptase 721
Toniolo C. see Formaggio F. 953
Toops D. S. see Barbachyn M. R. 671
Torii S. see Tanaka H. 2253
Toske S. G. see White J. D. 2383
Townsend C. A. see Janc J. W. 2313
Townsend C. A. see McGuire S. M. 653
Townsend L. B. see Swayze E. E. 543
Trainor D. A. see Frank C. A. 2725
Tranquillini E. see Dowle M. D. 2047
Travers A. see Dowle M. D. 2047
Travers A. see Middlemiss D. 2043
Tricklebank M. D. see Carling R. W. 65
Tricklebank M. D. see Moore K. W. 61
Trivedi B. K. Stoeber T. L. Stanfield R. L. Essenburg A. D. Hamelehle K. L. and Krause B. R.

Substituted *N,N'*-diphenyl ureas as potent inhibitors of acyl-CoA: cholesterol acyltransferase (ACAT) 259
Trivedi B. K. see Padia J. K. 2805
Trivedi S. see Frank C. A. 2725
Trivedi S. see Grant T. 2723
Trivedi S. see Russell K. 2727
Tromelin A. Moutiez M. Meziane-Cherif D. Aumercier M. Tartar A. and Sergheraert C. Synthesis of non reducible inhibitors for trypanothione reductase from *Trypanosoma cruzi* 1971
Trova M. P. Babine R. E. Byrn R. A. Casscles, Jr W. T. Hastings R. C. Hsu G. C. Jirousek M. R. Johnson B. D. Kerwar S. S. Schow S. R. Wissner A. Zhang N. and Wick M. M. Synthesis and biological evaluation of a series of HIV-1 protease inhibitors 1595
True R. A. see Monn J. A. 95
Truneh A. see Jarvest R. L. 2851
Tschamber T. see Streith J. 2375
Tserng K.-Y. see Clark J. W. 1873
Tserng K.-Y. see Posner G. H. 1835
Tserng K.-Y. see Reddy G. S. 1879
Tsugawa N. see Kobayashi T. 1815
Tu C.-C. see Chen S.-T. 1643
Tu C.-C. see Chen S.-T. 539
Tückmantel W. see Kozikowski A. P. 1323
Tudhope S. R. see Abram T. S. 1517
Tuladhar S. see Su T. 835
Tulchinsky M. L. see Wilson S. R. 1805
Tulshian D. B. and Bercovici A. Synthesis of a catechol metabolite of dilevalol 2073
Tun M. M. see Zein N. 1351
Tuomari A. V. see Ahmad S. 1215
Tuomari A. V. see Vite G. D. 1211
Tustin J. see Sawyer T. K. 819

Uchibori S. see Yokota M. 1687
Uchida M. see Otsubo K. 1633
Ueda Y. Mikkilineni A. B. Knipe J. O. Rose W. C. Casazza A. M. and Vyas D. M. Novel water soluble phosphate prodrugs of Taxol® possessing *in vivo* antitumor activity 1761
Ueyama N. see Yanagisawa T. 1559
Unangst P. C. Connor D. T. Cetenko W. A. Sorenson R. J. Sircar J. C. Wright C. D. Schrier D. J. and Dyer R. D. Oxazole, thiazole, and imidazole derivatives of 2,6-di-*tert*-butylphenol as dual 5-lipoxygenase and cyclooxygenase inhibitors 1729
Underwood D. C. see Bandurco V. T. 375
Underwood D. C. see Murray W. V. 369
Underwood D. C.see Murray W. V. 785
Upson D. A. see Caulfield T. J. 2771
Upton N. see Bolton D. 1941
Uretsky N. J. see Markovich K. M. 1241
Uskokovic M. see Goff J. P. 1825
Uskokovic M. see Stein G. S. 1885
Uskokovic M. R. see Batcho A. D. 1821
Uskokovic M. R. see Clark J. W. 1873
Uskokovic M. R. see Reddy G. S. 1879
Utecht R. E. see Chang S.-C. 555
Uyeo S. see Imuta M. 2199

Vaillancourt M. Vanasse B. Cohen E. and Sauvé G. Difunctional enols of N-protected amino acids as low molecular weight and novel inhibitors of HIV-1 protease 1169
Valerio R. see Spellmeyer D. C. 1253
Valerio R. see Spellmeyer D. C. 519
Välimäe T. see Parve O. 357
Välimäe T. see Parve O. 359
Vallés M. J. see Nilsson K. 1855
Valli M. J. see Monn J. A. 95
Van Aerschot A. Verheggen I. and Herdewijin P. Synthesis of nucleoside analogues with a 1,5-anhydrohexitol moiety 1013
Van Aerschot A. see Vandendriessche F. 193
Vanasse B. see Vaillancourt M. 1169
Van Baelen H. see Zhao X. 1863
Van Baelen H. see Allewaert K. 1859
Van Broeck D. see Emonds-Alt X. 925
Vandendriessche F. Voortmans M. Hoogmartens J. Van Aerschot A. and Herdewijn P. Synthesis of novel *N*-substituted guanidine linked nucleoside dimers and their incorporation into oligonucleotides 193
van der Heide F. R. see Doyle M. P. 2409
Vander Velde D. see Georg G. I. 1349
Vander Velde D. G. see Georg G. I. 1345
van de Velde J. P. see Nilsson K. 1855
Vandewalle M. see Allewaert K. 1859
Vandewalle M. see Zhao X. 1863
Van Dorsselaer V. see Schirlin D. 253
van Koten G. see Jastrzebski J. T. B. H. 2351
Van Sickle W. A. see Wannamaker M. W. 1175
Varma N. see Chauhan P. M. S. 677
Vartanian M. G. see Bigge C. F. 39
Vartanian M. G. see Hays S. J. 77
Vaught J. L. see Maryanoff B. E. 2653
Veber D. F. see Bock M. G. 871
Venkataraman R. see Groutas W. C. 1163
Venkataraman R. see Groutas W. C. 2745
Verdine G. L. see Sodeoka M. 1089
Verdine G. L. see Sodeoka M. 1095
Verheggen I. see Van Aerschot A. 1013
Verhoeven T. R. see Madar A.-M. 2393
Vigevani A. see Franceschi G. 2333
Vilain P. see Emonds-Alt X. 925
Vine S. J. see Barraclough P. 509
Viner K. C. see Siddiqui M. A. 1543
Visentin G. see Cabri W. 2255
Visentin G. see Jabès D. 2165
Vite G. D. Tino J. A. Zahler R. Goodfellow V. Tuomari A. V. McGeever-Rubin B. and Field A. K. Differences in antiviral activities for isomers of a fluorinated cyclobutane nucleoside analog 1211
Vite G. D. see Ahmad S. 1215
Volkmann R. A. see Faraci W. S. 2271
von Daehne W. Hoffmeyer L. and Keiding J. Rearrangement of unsymmetrical azetidinone disulfides to 2β-(heterocyclylthiomethyl)penams, a synthetic approach to new β-lactamase inhibitors 2247

VonVoigtlander P. F. see Zhao S. 2641
Voortmans M. see Vandendriessche F. 193
Vyas D. see Kant J. 2471
Vyas D. M. Wong H. Crosswell A. R. Casazza A. M. Knipe J. O. Mamber S. W. and Doyle T. W. Synthesis and antitumor evaluation of water soluble taxol phosphates 1357
Vyas D. M. see Saulnier M. G. 1619
Vyas D. M. see Ueda Y. 1761
Vyas D. M. see Zein N. 1351

Wachter M. P. see Bandurco V. T. 375
Wachter M. P. see Murray W. V. 369
Wachter M. P. see Murray W. V. 785
Waddell S. T. and Blizzard T. A. Semisynthesis of linear fragments corresponding to the eastern portion of azalide antibiotics 1757
Waid P. P. see Wannamaker M. W. 1175
Waldron T. L. see Kim K. S. 2667
Waldron T. L. see Poss M. A. 2739
Walford S. P. see Campbell M. M. 667
Walker D. G. see Dowle M. D. 2047
Walker M. C. see Corey S. D. 2857
Walker R. T. see Tanaka H. 1681
Wallace L. J. see Markovich K. M. 1241
Wang F. see Gibbs R. A. 281
Wang J. Bray A. M. DiPasquale A. J. Maeji N. J. and Geysen H. M. Application of the multipin peptide synthesis technique for peptide receptor binding studies: substance P as a model system 447
Wang J. DiPasquale A. J. Bray A. M. Maeji N. J. and Geysen H. M. Study of stereo-requirements of substance P binding to NK1 receptors using analogues with systematic D-amino acid replacements 451
Wang K.-T. see Chen S.-T. 1643
Wang K.-T. see Chen S.-T. 539
Wang K.-T. see Chen S.-T. 727
Wang K.-T. see Hsiao K.-F. 2125
Wankadiya K. F. see Clark J. W. 1873
Wankadiya K. F. see Posner G. H. 1835
Wannamaker M. W. Waid P. P. Moore W. R. Schatzman G. L. Van Sickle W. A. and Wilson P. K. Inhibition of 2,3-oxidosqualene cyclase by *N*-alkylpiperidines 1175
Ward P. see Andrews D. M. 2533
Ward P. see Smith P. W. 931
Ward R. W. see Markwell R. E. 2537
Ward S. see Gordon T. 915
Wardman P. see Parrick J. 1697
Warne S. A. see Rusiecki V. K. 707
Warwick P. see Russell K. 2727
Wasserman H. H. and Niu C. The chemistry of vicinal tricarbonyls. Synthesis of 3,4,7-trisubstituted carbacephams 2437
Watanabe H. see Kubodera N. 1869
Wates P. J. see Hodgson S. T. 2565
Wathen S. P. and Czarnik A. W. Cu(II)-Catalysis in the reduction of *N O*-dibenzoylhydroxylamine by a tertiary amine 1245
Wätjen F. Nielsen E. Ø. Drejer J. and Jensen L. H. Isatin oximes—a novel series of bioavailable non-NMDA antagonists 105
Watson N. S. Bell R. Chan C. Cox B. Hutson J. L. Keeling S. E. Kirk B. E. Procopiou P. A. Steeples I. P. and Widdowson J. The squalestatins: potent inhibitors of squalene synthase. The role of the tricarboxylic acid moiety 2541
Watson N. S. see Procopiou P. A. 2527
Watson S. P. see Middlemiss D. 589
Watson S. P. see Middlemiss D. 2043
Watt A. P. see Chambers M. S. 1919
Weaver L. M. Pinto J. E. B. P. and Herrmann K. M. Expression of potato DAHP synthase in *Escherichia coli* 1421
Weaver, III J. D. see Wentland M. P. 1711
Webb M. L. see Das J. 1267
Webb M. L. see Das J. 1271
Webb M. L. see Hall S. E. 1263
Webb R. L. see Mugrage B. 2099
Weber E. see Gee K. R. 251
Weber E. see Reddy N. L. 2113
Weber F. see Schirlin D. 253
Weber F. H. see Moyer M. P. 1379
Weber H. see Poss M. A. 2739
Wei C.-C. see Dax S. L. 209
Weill C. see Schirlin D. 253
Weinhardt K. K. see Clark R. D. 1375
Weinstein J. see Afonso A. 2177
Weinstock J. see Samanen J. M. 909
Weisner F. see Pfaendler H. R. 2211
Welch J. T. see Araki K. 2457
Weller H. N. see Poss M. A. 2739
Wentland M. P. Lesher G. Y. Reuman M. Pilling G. M. Saindane M. T. Perni R. B. Eissenstat M. A. Weaver, III J. D. Singh B. Rake J. and Coughlin S. A. Relationship of structure of bridged (2,6-dimethyl-4-pyridinyl)quinolones to mammalian topoisomerase II inhibition 1711
Wermuth C. G. see Linget J. M. 1309
Werner K. M. see Hecker S. J. 289
Werner K. M. see Hecker S. J. 295
Werner K. M. see Jaynes B. H. 1531
Weselcouch E. O. see Lawson J. E. 561
Weston H. see Finke P. E. 2277
Weston H. see Shah S. K. 2295
Westwick J. see Mills S. J. 2599
Wexler R. R. see Carini D. J. 895
Whang D. see Kim D. H. 263
White E. L. see Swayze E. E. 543
White J. D. and Toske S. G. Photochemically mediated ring contraction of pyrazolidin-3-ones to β-lactams 2383
White V. see Soll R. M. 757
Whitesides G. M. see Schmid W. 747
Whiting M. V. see Barraclough P. 509
Whittaker M. Thompson T. M. Spavold Z. M. Price M. Miller A. Galloway W. A. Fraser F. Floyd C. D. Drummond A. H. Davidson A. H. Bowles S. A. and Bebbington D. S. Cyclic ether acetal platelet activating factor (PAF) receptor antagonists—I. 3-Pyridyl derivatives 1493
Whittaker M. see Wood L. M. 1499
Whitten J. P. Baron B. M. and McDonald I. A. Competitive NMDA receptor antagonists: (*R*)-4-oxo-5-phosphononorvaline

structure–activity relationships 23
Whitten J. P. Cube R. V. Baron B. M. and McDonald I. A.
Competitive NMDA receptor antagonists: synthesis of β-ketophosphonate-substituted piperidine carboxylic acid derivatives 19
Wick M. M. see Babine R. E. 1589
Wick M. M. see Trova M. P. 1595
Widdowson J. see Watson N. S. 2541
Wiesmüller K.-H. see Stevanovic S. 431
Wijaya E. see Thompson P. E. 1625
Wikel J. H. Bemis K. G. Audia J. E. McQuaid L. A. Jones C. D. Pennington P. A. Lawhorn D. E. Hirsch K. R. and Stamm N. B.
QSAR Study of benzoquinolinones as inhibitors of human type 1 5-a-reductase 1157
Wikel J. H. and Dow E. R.
The use of neural networks for variable selection in QSAR 645
Wilcox R. A. see Mills S. J. 1505
Wild H. and Metzger K.-G.
Substituted 6-alkyloxapenems: potent β-lactamase inhibitors; synthesis and biological characterization 2205
Wilkening R. R. Ratcliffe R. W. Doss G. A. Bartizal K. F. Graham A. C. and Herbert C. M.
The synthesis of novel 8a-aza-8a-homoerythromycin derivatives via the Beckmann rearrangement of (9*Z*)-erythromycin A oxime 1287
Wilkerson W. W. DeLucca I. Galbraith W. Harris R. and Kerr J.
Anti-inflammatory β-benzeneethanamines—III 711
Wilkerson W. W. Galbraith W. DeLucca I. and Harris R. R.
Topical antiinflammatory dehydroabietylamine derivatives—IV 2087
Willetts J. see Ferkany J. W. 33
Williams B. J. see Leeson P. D. 71
Williams D. H. see Gerhard U. 803
Williams K. W. see Schmid W. 747
Williams M. A. see Teng M. 2431
Williams M. D. see Pettit G. R. 2869
Williams R. A. see Faraci W. S. 2271
Williamson J. M. see Salituro G. M. 337
Wilson E. J. see Lewis M. L. 1189
Wilson E. J. see Lewis M. L. 1193
Wilson E. J. see Lewis M. L. 1197
Wilson E. J. see Sutherland J. D. 1185
Wilson L. J. Choi W.-B. Spurling T. Liotta D. C. Schinazi R. F. Cannon D. Painter G. R. St. Clair M. and Furman P. A.
The synthesis and anti-HIV activity of pyrimidine dioxolanyl nucleosides 169
Wilson O. see McCombie S. W. 1537
Wilson P. K. see Wannamaker M. W. 1175
Wilson S. R. Tulchinsky M. L. and Wu Y.
Electrospray ionization mass spectrometry of vitamin D derivatives 1805
Wilson S. R. Zhao H. and Dewan J.
Chemistry of the new immunosuppressant KH-1060: new synthons and X-ray evidence for unique side-chain geometry 341
Winkler J. D. Hong B.-C. Bahador A. Kazanietz M. G. and Blumberg P. M.
Synthesis of ingenol analogs with affinity for protein kinase C 577
Winter H. see Seela F. 273
Winter R. W. Cornell K. A. Johnson L. L. and Riscoe M. K.
Synthesis and testing of substituted phenylthioribose analogs against *Klebsiella pneumoniae* 2079
Wise D. S. see Swayze E. E. 543
Wise L. D. see Jaén J. C. 639
Wise L. D. see Wustrow D. J. 277
Wissner A. see Trova M. P. 1595
Witte D. see Shiosaki K. 855
Wojdan A. see Soll R. M. 757
Wolos J. A. see Matthews D. P. 165
Wong A. see Cheng H.-Y. 1179
Wong E. H. F. see Clark R. D. 1375
Wong H. see Kant J. 2471
Wong H. see Vyas D. M. 1357
Wong J. K. Piwinski J. J. Green M. J. Ganguly A. K. Anthes J. C. and Billah M. M.
Dual antagonists of platelet activating factor and histamine—II. Pyridine ring substitution of *N*-acetyl-4-(8-chloro-5 6-dihydro-11*H*-benzo[5,6]cyclo-hepta[1,2-*b*]pyridin-11-ylidene)piperidines 1073
Wong P. C. see Carini D. J. 895
Wong Y.-S. see Hou D. 2171
Wood L. M. Whittaker M. Timmis D. J. Thompson T. M. Sarogiou L. Miller A. Davidson A. H. Christodoulou M. S. Cackett K. S. Bowles S. A. and Bebbington D. S.
Cyclic ether acetal platelet activating factor (PAF) receptor antagonists—II. Imidazo[4,5-c]pyridyl derivatives 1499
Wood R. see Gibson K. H. 1019
Woodburn J. R. see Dutta A. S. 943
Woodburn K. Phadke A. S. and Morgan A. R.
An *in vitro* study of boronated porphyrins for potential use in boron neutron capture therapy 2017
Woster P. M. see Guo J. Q. 147
Woster P. M. see Wu Y. Q. 2811
Wrasidlo W. see Maligres P. E. 1051
Wright C. D. see Kramer J. B. 2827
Wright C. D. see Unangst P. C. 1729
Wright M. C. see Lewis M. L. 1189
Wright M. C. see Lewis M. L. 1193
Wright M. C. see Lewis M. L. 1197
Wright M. C. see Sutherland J. D. 1185
Wright S. W. Petraitis J. J. Abelman M. M. Bostrom L. L. Corbett R. L. Green A. M. Kindt R. M. Sherk S. R. and Magolda R. L.
Inhibition of cartilage breakdown by isothiazolones 2875
Wu J.-P. see Bigge C. F. 39
Wu M. T. Ikeler T. J. Ashton W. T. Chang R. S. L. Lotti V. J. and Greenlee W. J.
Synthesis and structure–activity relationships of a novel series of non-peptide AT_2-selective angiotensin II receptor antagonists 2023
Wu M. T. see Mills S. G. 2707
Wu S.-H. see Hsiao K.-F. 2125
Wu Y. see Wilson S. R. 1805
Wu Y. Q. Lawrence T. Guo J. Q. and Woster P. M.
α-Cyano-substituted analogues of decarboxylated S-adenosylmethionine as

enzyme activated, irreversible inhibitors of S-adenosylmethionine decarboxylase 2811
Wu Y. Q. see Guo J. Q. 147
Wustrow D. J. Wise L. D. Pugsley T. A. Meltzer L. T. and Heffner T. G. 4-Aryltetrahydropyridines as selective σ ligands 277
Wyman P. A. see Bermudez J. 2571
Wyvratt M. J. see Organ H. M. 557

Xie G. Morgan A. R. and Lown J. W. Synthesis and DNA cleaving properties of hybrid molecules containing propargylic sulfones and minor groove binding lexitropsins 1565
Xue L. see Su T. 835

Yagi B. H. see Barbachyn M. R. 671
Yamada S. see Shimizu M. 1809
Yamada T. see Takabe K. 157
Yamaguchi K. see Ito S. 611
Yamamoto H. see Hattori K. 2337
Yamamoto N. see Kim S.-G. 1223
Yamamoto R. see Kobori T. 2225
Yamamoto T. see Ito S. 611
Yamamoto T. see Tanaka H. 1681
Yamamura H. I. see Boteju L. W. 2011
Yamamura H. I. see Hristova-Kazmierski M. K. 831
Yamazaki T. see Shimizu M. 1809
Yan Q. see Andres C. J. 565
Yanagisawa T. Ueyama N. Kawai T. Sonegawa M. Baba H. Mochizuki S. Kozakai K. and Tomiyama T. 4,5,6,7-Tetrahydro-8-oxo-cycloheptimidazoles: a new class of potent non-peptide angiotensin II receptor antagonists 1559
Yatsimirsky A. K. Bezsoudnova K. Yu. and Sakodinskaya I. K. Boric acid effect on the hydrolysis of 4-nitrophenyl 2,3-dihydroxybenzoate: mimic of borate inhibition of serine proteases 635
Yawman A. see Caulfield T. J. 2771
Ye Q.-M. see Georg G. I. 1345
Ye Q.-M. see Georg G. I. 1349
Yeadon M. see Hodgson S. T. 2565
Yen F. W. see Ong C. W. 607
Yen H.-K. see Holt D. A. 1735
Yeola S. see Choi W.-B. 693
Yoda H. see Takabe K. 157
Yoda K. see Miyauchi M. 2447
Yohannes D. see Boger D. L. 245
Yokota M. Imamaki K. Uchibori S. Kondo M. Kosakai K. and Tomiyama T. Role of sulfonamide moiety in non-prostanoid TXA_2 receptor antagonist KT2-962: modifications of this moiety and the resulting activities 1687
Yong Y. F. and Lipton M. A. The stereoselective synthesis of (*E*)-alkene dipeptide isosteres 2879
Yoo S. Kim S.-J. Shin H. and Hong K. W. Benzopyran sulfoxide derivatives as new potassium channel activator 553
Yoshida S. see Koga H. 1111
Yoshida S. see Koga H. 2005
Yoshimura Y. see Dan A. 615
Young D. see Bell P. 1007
Yu K.-L. Harte W. E. Spinazze P. Martin J. C. and Mansuri M. M. Synthesis of 1,3-diamino-2-hydroxypropane derivatives as pseudo-symmetric HIV protease inhibitors 535

Zacharie B. Martel R. Sauve G. and Belleau B. Chemoselective thioacylation of amino acids. Preparation of the four monothiothymopentin analogs and their biological activity 619
Zacharie B. see Belleau B. 1723
Zahler R. see Ahmad S. 1215
Zahler R. see Vite G. D. 1211
Zalewska T. see Boteju L. W. 2011
Zamboni R. J. see Guay D. 1125
Zamecnik P. see Nylas A. 1371
Zamir L. O. Nikolakakis A. Bonner C. A. and Jensen R. A. Evidence for enzymatic formation of isoprephenate from isochorismate 1441
Zarini F. see Jabès D. 2165
Zein N. Solomon W. Casazza A. M. Kadow J. F. Krishnan B. S. Tun M. M. Vyas D. M. and Doyle T. W. Protein damage caused by a synthetic enediyne core 1351
Zerwes H.-G. see Kottirsch G. 1675
Zhang N. see Babine R. E. 1589
Zhang N. see Trova M. P. 1595
Zhang Y. Z. see Sawyer T. K. 819
Zhao H. see Wilson S. R. 341
Zhao S. Freeman J. P. VonVoigtlander P. F. Smith M. W. and Szmuszkovicz J. Phenalene analogs of the kappa opiate agonist U-50,488 2641
Zhao X. De Clercq P. Vandewalle M. Allewaert K. Van Baelen H. and Bouillon R. Synthesis and biological evaluation of some 25,26-epoxy-1α,24-dihydroxy-vitamin D_3 analogues 1863
Zhao X. see Allewaert K. 1859
Zhou Q. see Chu G. 1343
Zhu L.-M. see Suckling C. J. 531
Zierhut W. see Miltz W. 1233
Zingaro G. J. see de Laszlo S. E. 1299
Zink D. L. see Salituro G. M. 337
Zucchi G. see Fuganti C. 2777
Zucco M. see Ojima I. 2479
Zuckermann R. N. see Kerr J. M. 463
Zurenko G. E. see Barbachyn M. R. 671
Zurenko G. E. see Brickner S. J. 2241

Announcing New and Newly Acquired Journals

Engineering

Control Engineering Practice

1995: Volume 3 (12 issues)

Publishes papers which illustrate the direct application of control theory and its supporting tools in all possible areas of automation. The journal is centred in engineering - especially mechanical, electrical and electronic, aerospace and chemical engineering, but also includes social effects, cultural aspects, project planning and system design and economic and management decisions.

Engineering Failure Analysis

1995: Volume 2 (4 issues)

Publishes original, high quality research papers, communications, and occasional review articles describing the analysis of engineering failures and related studies.

It provides essential reference material and critical feedback into design process thereby contributing to the prevention of engineering failures in the future.

Chemistry

Bioorganic & Medicinal Chemistry

A Tetrahedron Publication

1995: Volume 3 (12 issues)

Provides an international forum for the publication of full original research papers and critical reviews on molecular interactions in key biological targets such as receptors, channels, enzymes, nucleotides, lipids and saccharides. The aim of the journal is to promote a better understanding at the molecular level of life processes, and living organisms, as well as the interaction of chemical agents with these.

Physics

Studies in History and Philosophy of Modern Physics

Studies in History and Philosophy of Science, Part B

1995: Vol. 26B (3 issues)

SHPMP covers developments in physics from the mid nineteenth century to the present. The kind of theoretical physics which has come to dominate the exact sciences in the twentieth century. The journal is unrivalled in addressing this area in which much of the original and creative work in history and philosophy of science is currently being carried out. The editors particularly encourage articles of interest to scientists as well as specialists in history and philosophy.

PERGAMON

An imprint of Elsevier Science

Elsevier Science Ltd, The Boulevard, Langford Lane, Kidlington, Oxford, OX5 1GB, UK

Elsevier Science Inc., 660 White Plains Road, Tarrytown, NY 10591-5153, USA

Social & Behavioural Sciences

European Management Journal

1995: Volume 13 (4 issues)

Publishes leading-edge research from academics and senior industrialists throughout Europe and the United States enabling practitioners and management trainers to broaden their knowledge of the new operational environment.

International Business Review

1995: Volume 4 (4 issues)

This journal provides a forum for academics and professionals to share the latest developments and advances in knowledge and practice of international business. It aims to foster the exchange of ideas on a range of important international subjects and provide stimulus for research and the further development of international perspectives.

International Transactions in Operational Research

1995: Volume 2 (4 issues)

The primary purpose of this journal is to advance the understanding and practice of operational research on an international basis. The scope of the journal will include problems of an international nature (eg. fisheries management, environmental, global competitiveness).

Location Science

1995: Volume 3 (4 issues)

The primary focus of this journal is on research directed to extending and applying the theory and modeling of location decisions. The journal will also publish papers which address the underlying processes related to locational decisions, the determination of parameters associated with location problems, and issues of implementation.

Transportation Research Part C: Emerging Technologies

1995: Volume 3 (6 issues)

This journal is concerned with the impacts of new technology (including IVHS) on transportation system performance characteristics.

Environmental Science & Technology

Spill Science and Technology Bulletin

Sister Journal of *Marine Pollution Bulletin*

1995: Volume 2 (4 issues)

A new international, peer-reviewed journal on oil and chemical spill science and technology, focussing on the effects and control of discharges of oil, oil products and other hazardous substances. Both land and water spill issues will be addressed, and papers linking science and technology with policy and management matters will also be considered appropriate.

Free sample copies of these journals are/or will be available on publication, from your nearest Elsevier Science office

COR017p5

Save Money - Combined Subscription Available from Pergamon...

TETRAHEDRON - A combined subscription to all 5 Tetrahedron journals

(00876)
1994: 1994 (148 issues) Subscription price: **£6924.00 (US$10665.00)**

AIMS AND SCOPE
The Tetrahedron Family Package provides a complete reference source for all new and exciting developments in the field of organic, bioorganic and medicinal chemistry. This combined subscription comprises:
- *Bioorganic & Medicinal Chemistry*
- *Bioorganic & Medicinal Chemistry Letters*
- *Tetrahedron*
- *Tetrahedron: Asymmetry*
- *Tetrahedron Letters*

Those libraries which take the Tetrahedron Family Package will see an immediate benefit and saving. For individual contents listing and scope please see each individual journal's entry in this catalogue. Further ordering information is available from the Oxford Fulfilment Centre.

Pergamon

Pergamon is an imprint of Elsevier Science.
Sterling price quoted applies worldwide except in The Americas.
US dollar price quoted applies in The Americas only.
Prices include postage and insurance. Customers resident in the EU will be charged VAT (or the equivalent) at their own country's rate, unless a VAT (or equivalent) registration number is supplied. Elsevier Science VAT registration number in the UK: GB 490 6586 25 000.

Please send me more information about the combined subscription to **all five Tetrahedron journals** (00876)

Name _____ Position _____

Organisation _____ Department _____

Address _____

_____ Post/Zip Code _____

Return to: Elsevier Science Ltd, The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, UK
or Elsevier Science Inc., 660 White Plains Road, Tarrytown, NY 10591-5153, USA

BHA4

Receive Regular News of Elsevier 's Publications

Elsevier Science mails information on new and existing publications regularly.
If you would like to be added to the mailing list please send us your name and full mailing address, indicating your fields of interest:

ENGINEERING
Energy Sources & Technology, Civil & Structural Engineering, Mechanical Engineering, Electrical & Electronic Engineering, Systems & Control Engineering, Aeronautical & Aerospace Technology, Materials Technology, Chemical Engineering

LIFE SCIENCES & MEDICINE
Biological Sciences (including biochemistry & molecular biology), Agriculture, Veterinary Medicine, Immunology, Cancer Research, Pharmacology, Neuroscience, Vision Science, Clinical Medicine

PHYSICAL SCIENCES
Computer Science, Physics, Chemistry, Mathematics, Earth Science, Environmental Science, Materials Science, Space & Planetary Sciences

SOCIAL SCIENCE & HUMANITIES
Sociology, Women's Studies, Psychology, Education, Political Science, Geography, Economics, Management & Business, Linguistics, Information Science, Librarianship

Elsevier Science Ltd
The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, UK

Elsevier Science Inc.
660 White Plains Road, Tarrytown, NY 10591-5153, USA

COR017/P4

Printed in Great Britain by Nuffield Press Ltd.